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Pharmaceuticals together with salaries consume 60-80% of the health budgets of most counties in 
Kenya, therefore improving performance of the pharmaceutical commodity supply chain is one of 
the key activities aimed at improving health systems in Kenya. An efficient supply chain system 
reduces wastage and ensures availability of and accessibility to essential medicines, namely the 
right product in the right quality, in the right condition, at the right place, at the right time and at 
the right cost (the six rights of logistics). 
The purpose of this study was to evaluate the pharmaceutical commodities supply chain 
management challenges that health care workers of Busia County encounter while delivering 
services to the population and use the information to suggest improvements on the pharmaceutical 
supply chain performance. The study objectives were a) to determine how effective the Logistics 
Management Information System in Busia county is in serving her population needs b) to 
determine if funds allocated for procurement of medicines are efficiently utilized and c) to 
determine whether the staff using the pharmaceutical Logistics Management Information System 
and others in the supply management system are well trained on supply chain management and 
are of the right number. 
The study sites for this research were five facilities in each of the seven sub-counties in Busia 
County, whereby a sub-county hospital, a high volume health centre, a high volume and a low 
volume dispensary as well as one faith-based dispensary were targeted for this study. Main areas 
of research were the health facility pharmacy department, the comprehensive care clinic pharmacy, 
the pharmacy and county stores respectively.  
Cross-sectional descriptive study design was used. Instruments used were structured 
questionnaires, always, better and control analysis and also vital, essential and non-essential 
analysis respectively. The main findings were that most of the facilities experienced long lead time 
and delays in delivery of essential supplies, funds for procurement of medicines were well utilized 
but facility staffing levels were inadequate. The recommendations from this study are that, a) the 
county government should employ and train more health workers to support pharmaceutical 
commodity supply chain management b) the County Government should adopt efficient and 
effective supply chain management system, the Logistics Management Information System, so as 
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Definition of Key Terms 
Stock-outs: Situation where the demand of a product exceeds its supply due to the product not 
being available in the current inventory 
Lead time: Time that elapses between when items are ordered and when they are received from 
the supplier  
ABC Classification: A method of analysis for comparison and determination of medicines cost in 
an essential medicines list 






















CHAPTER ONE: INTRODUCTION 
1.1 Background 
Health is a fundamental right according to the Constitution of Kenya. The Constitution states that 
every Kenyan citizen has the right to the highest attainable standard of health and mandates the 
state to take policy, legislative, and other measures that include enforcement of laws and 
regulations and setting of standards so as to progressively achieve the realization of rights enclosed 
under Article 43, which include the right to health (The constitution of Kenya, 2010). 
The constitution also states that health is a devolved function and therefore assigned the role of 
delivering health services to the counties. Schedule 4 part 2 of the constitution on allocation of 
roles between National and County governments mandates the County Governments to provide 
and manage county health services which include ambulance services, county health pharmacies 
and facilities, and also primary health care promotion to all her citizens. The National Government 
on the other hand maintained the role of formulation of health policies and standards and 
management of both health workers internship program and national referral health facilities (The 
constitution of Kenya, 2010) 
A health system that functions well is one that is responsive to the expectations and needs of a 
population through promoting the health status of members of the community, protecting the 
population against financial repercussions of ill-health and enabling more access to people-
centered care for her population (World Health Organization, n.d.). In 2007 the World Health 
Organization came up with a health systems building blocks framework with the aim of defining 
what makes up health systems strengthening and what a health system is. The health system 
framework has six core components namely: quality service delivery, capable and adequate health 
workforce, reliable information system, access to medicines, vaccines and medical products, 
sustainable health financing and good leadership and governance (World Health Organization, 
2010). Good service delivery provides for quality health interventions that are safe and effective 
without wastage of resources, to the needy population whereas a capable health workforce is one 
that responds to the needs of the population and gives good health outcomes even with the little 
resources available to it. 
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A reliable health information system is one that allows for efficient collection of reliable data, 
analysis and use of information for decision making. Equitable access to vaccines, medicines and 
medical products that are of good quality, efficacious and affordable is made possible by a 
functioning health system.  A sustainable financing system is one that enables healthcare funding 
by enabling access to services and financial protection from catastrophic events and 
impoverishment to poor households. Leadership and governance ensure accountability and 
stewardship of health resources. Any activity that supports one or all of these pillars is called 
health systems strengthening (World Health Organization, 2007). 
The WHO health system pillars are interconnected and therefore cannot function well if the system 
lacks capabilities in certain areas. For instance, if one of the pillars for one reason or another is 
non-functional or is lacking, then the system will be non-responsive to the needs of the population 
since the system pillars either directly or indirectly affect each other as seen from a study done in 
Zambia (Mutale et al., 2013).  
The barrier to achieving good health outcomes in low-income countries is non-functional health 
systems (Mutale et al., 2013). In Kenya for example devolution of health services to county level 
was meant to bring services closer to the people and to improve efficiency in health service 
delivery. However, transfer of devolved health sector functions was done much faster than most 
counties were ready for due to the political context in Kenya at that time (B. Tsofa, 2016). 
Devolution was done at a time when county governments had not put up their own organizational 
structures in place and had not built capacity for those structures to manage their functions. This 
ended up causing major disruptions and challenges in the health sector service delivery (Benjamin 
Tsofa, Goodman, Gilson, & Molyneux, 2017) that resulted in non-functional health systems, 
challenges that are still being faced by counties to date. From a study done in the Philippines by 
Herrera & Roman (2010) the challenges faced by devolved health systems due to non-functional 
health systems are: detachment of national government from county health matters, inadequate 
health workforce, poor leadership, lack of accountability, ineffective commodity supply chain for 
medicines and medical supplies, brought about by widespread corruption, inadequate funding and 
inefficient information system.   
In general one of the major challenges faced at both national and county level is funding health 
care. The Kenyan budget for FY 2016/2017 allocated shillings Kes 60.3 billion for preventive and 
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curative health services to the health docket out of the whole Kes 2,264.8 billion country’s budget 
(The National Treasury, 2016). The 60.3 billion budgetary allocation for health amounts to only 
2.7% of the overall budget, which is nowhere near the Abuja declaration, where a target of 
allocating at least 15% of the country’s annual budget to improve the health sector was set by 
African Union countries in 2001 (WHO, 2011). The 2.7% allocation for the health sector means 
the health department is financially constrained and that it is also competing with other government 
priorities for resources. All in all the 2.7% health department allocation needs to be utilized 
efficiently. 
In the same FY 2016/2017, Busia County received Kes 6,069.8 million from the National 
Government of which Kes 1,716.7 million was allocated to the health sector (Busia County 
Treasury, 2016). The Kes 1,716.7 million accounts for only 3.5 % of her overall budget which just 
like the national budget is a very minimal allocation to a very vital sector like health. Most counties 
including Busia spend about 60-70% of their county budget on salaries and wages and purchase 
of medical products, leaving 30% to cater for other county needs like health service delivery as 
calculated from the FY 2016/2017 Busia County Budget. The county spent approximately 68% on 
salaries and wages and purchase of medicines. 
A functional health care system must have qualified personnel and must enable access to health 
services for her population. Access to health care including essential medicines is a fundamental 
right according to the Kenyan constitution. WHO defines essential medicines as “those medicines 
that satisfy the priority health care needs of the population and are therefore selected with 
consideration to their relevance to public health, evidence on efficacy and safety and comparative 
cost-effectiveness.”  
To improve access to health services there must be a functional  pharmaceutical supply chain 
which should within the context of a functioning health system provide medicines at all times in 
adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, 
and at a price an individual and the community can afford (World Health Organization). To realize 
this objective the pharmaceutical supply chain must be well funded so as to make it sustainable. 
Delivery of medicines at service delivery point is made possible through an efficient supply chain. 
Ram Ganeshan and Terry P. Harrison (1995) defined supply chain as a network of facilities and 
distribution options that perform the functions of procurement of materials, the transformation of 
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these materials into intermediate and finished products and the distribution of these finished 
products to customers. A typical pharmaceutical supply chain consists of manufacturing partners, 
warehouses, intermediaries, all hospital levels (Nilay Shah, 2004) and patients. 
Supply chain management is the integration of business processes in the provision of valuable 
products, services and information to customers and stakeholders through suppliers (Lambert et 
al. 2006). The Council of Supply Chain Management defines it as the planning and management 
of all activities involved in sourcing, procurement, manufacturing, and logistics (Wisner, Tan, 
Leong, 2012). It also includes linking and cooperation with suppliers, middlemen, third-party 
service providers, and consumers.  
1.1.1 The Pharmaceutical Management Framework 
A lot of emphasis on improving access to essential medicines is put on better pharmaceutical 
management through four basic functions: selection, procurement, distribution and use. Selection 
depends on prevalent disease burdens, treatment guidelines or protocols, health facility levels, 
knowledge and experience of health personnel and financial resources available. Procurement 
involves medicine quantification process, choice of appropriate procurement methods, tender 
management, setting up legal and binding agreements with suppliers and assuring the public of the 
good quality of pharmaceuticals Distribution includes clearance of customs at ports and airports, 
proper commodity inventory management and delivery of drugs to warehouses and to service 
delivery points. Use comprises diagnosing, prescribing, dispensing and rational medicine use by 
the patient (Management Science for Health, 2010). 
Each major function in the pharmaceutical management framework builds on the previous 
functions and logically leads to the next. A malfunction in one part of the framework will lead to 
collapse of the entire pharmaceutical management process, which would bring about a rise in the 
cost of medicines, commodity stock-outs in health facilities and increased patient suffering due to 
high cost they will have to incur in order to access healthcare (Management Science for Health, 
2012).  
The entire pharmaceutical management framework depends on the organization, sustainable 
funding, information and human resource management as its fundamental management support 
system. The framework also depends on policies, laws, and regulations which depend on strong 
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leadership and governance in order to build and strengthen public commitment to essential 
medicine supply by the government (Management Science for Health, 2010). 
1.1.2 The Pharmaceutical Logistics Cycle 
In terms of medicines, patients look for the right goods, in the right quantities, in the right 
condition, delivered to the right place, at the right time for the right cost (the six rights of 
logistics)(USAID, 2011). But to get the six rights right the logistics cycle has to be efficient.  
 
Source: Management Science for Health (2012)  
Figure 1: Pharmaceutical Logistics Cycle 
Logistics cycle is the correlation between the activities in a logistics system, which are: serving 
customers, product selection, quantification and procurement, inventory management, storage, and 
distribution. Other activities include Logistics management information systems (LMIS), pipeline 
monitoring, organization and staffing, budgeting, supervision, evaluation, quality monitoring, 
policy and adaptability of the system. The repetitive nature of activities in the cycle shows that 
various elements of the cycle are interdependent on each other (USAID, 2011).  
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Management support functions represented at the center of the cycle inform and influence the 
functioning of the rest of the elements around the cycle. LMIS collects data about medicines 
consumption and stocks available, information which is used for decision making for activities 
such as commodity resupply and redistribution for health facilities. (USAID, 2011). 
Quality monitoring ensures a systematic and functional logistics cycle in terms of quality of both 
product and work, the policy will involve government directives and approaches such as budgeting 
policies that would affect all elements of the logistics system. In terms of adaptability, logistics 
systems must be designed to be changeable and adjustable to constantly change circumstances 
such as financing policies by the government and donors, government regulations and logistic 
activities (USAID, 2011).  
Logistics management consists of organizing, implementing and managing the systematic and 
effective flow of raw materials, finished products, and information from point of origin to the 
consumption point with the aim of satisfying the customer. It includes both inbound (process of 
receiving, storing and distributing raw materials for use in production) and outbound (covers 
movement and storage of products and how related information flows from end of production line 
point to consumption point), transportation management, warehousing, order fulfilment, inventory 
management and third-party logistics providers (providers of outsourced logistics services).  
The pharmaceutical pipeline includes storage facilities (port facilities, warehouses, service 
delivery points) and transportation network connection (transport means) through which supplies 
move from manufacturer to the consumer. The pipeline consists of tanks (warehouses) that store 
and pipes (transportation links) that move the product to the home (service delivery point). 
Transportation means in remote areas may include boats, vehicles, animal driven carts, motorbikes 
and even bicycles (USAID, 2011). 
1.1.3 Logistics Management Information System (LMIS) 
The LMIS is a system that enables managers to locate any obstacles in the supply channel and 
ensure a continuous supply of medicines. It also enables commodity managers to collect and 
manage the information needed for making informed decisions concerning commodity 
management (Omo-Emmanuel & Chinedum, 2017), since the system tracks the flow of supplies 
and manages data on quantities of medicines or medical supplies available in an SDP at a particular 
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time, reports on quantities consumed as well as quantities of commodities needed for resupply and 
inventory losses due to expires and damages (USAID, 2011). 
The data managed through LMIS is also used at the national level for determining consumption 
levels, so as to enable facilitation of planning, allocation, an approximation of needed commodity 
quantities and procurement (Omo-Emmanuel & Chinedum, 2017) of needed commodities 
especially donor-funded ones.  
The Logistics Management Information System is a system that consists of reports and records. It 
is used to collect, organize and present needed information that is useful in not only making 
informed decisions by decision makers but will also lead to improved customer service. LMIS can 
be automated (computers, mobile phones, internet) or manual (Mutugi, 2014). An efficient LMIS 
minimizes chances of experiencing commodity stock outs and avoidable waste of resources that is 
brought about by breakages, theft, and expiration of medicines and medical products (USAID, 
2010). 
1.1.4 Human Resource for Health (HRH) 
For FY 2016/2017 Busia County spent Kes 340 million on the purchase of essential medical 
supplies for curative and preventive health services and Kes 833 million on human resource for 
health from her Ksh 6 Billion budget (Busia County Treasury, 2016). Medical products are 
expensive and they consume a lot of money (Management Science for Health, 2010) therefore 
developing the capacity for HRH to support health service delivery is very important. However in 
most countries, health workforce planning and management are hindered by incorrect data on HRH 
and as a result, unproductive policies for the sector are made, policies which do not back and even 
lack the capacity to manage the health workforce (World Health Organization, Western Pacific 
Region, 2006).  
Health workforce in different countries in the world differ in numbers due to factors like the 
region’s prevailing economic, social and political situation (World Health Organization, Western 
Pacific Region, 2006), imbalances in skill mix, migration of health workers from rural to urban 
areas and across borders and minimal production capacity (World Health Organization, 2010). 
Factors that influence migration of health personnel and as a result hamper health system 
performance include: workload that staff cannot manage with brought about by understaffing, 
safety of the staff, poor working environments, inadequate infrastructure and resources to perform 
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duties optimally, lack of career prospects, poor remuneration, difficult living conditions, lack of 
career prospects and inadequate training opportunities (Moosa et al., 2014). 
A 2013 WHO report estimated a global shortage of healthcare workers at 7.2 million with the 
possibility of increasing to 12.9 million by the year 2035 (Global Health Workforce Alliance, 
WHO, 2013). This portrays the critical need for employment of more healthcare workers so as to 
be able to gain an adequate coverage for essential health interventions for needy populations.  
The health workforce according to WHO can be defined as all people involved in actions whose 
primary purpose is to improve health. These human resources include clinical staff such as 
physicians, nurses, pharmacists, dentists as well as management and support staff, who are those 
who do not deliver services directly but are essential to the performance of health systems, such 
as managers and ambulance drivers (World Health Organization, 2010). 
The formulation of national policies in pursuit of HRH development objective requires sound 
information and evidence. However in Kenya this might not be possible because the report on 
training needs assessment of Kenyan health workforce, published in 2015 focused on medical 
officers and specialists, clinical officers and clinical officer specialists, nursing officers and nurse 
specialists but left out the Pharmacy and other departments that are crucial in health service 
delivery (Ministry of Health, 2015). Pharmacy department manages medical products and some 
vaccines, which forms part of the WHO health pillars. 
1.1.5. The Context of Busia County 
Busia County is one of the four counties that form western region. The county is divided into seven 
sub-counties namely: Bunyala, Matayos, Butula, Nambale, Samia, Teso North and Teso South. 
The county has a total of 115 health facilities, majority of which are sponsored by the county 
government, which it procures medicines and medical products for. Private and faith-based 
facilities represent 15% and 13% of the total health facilities in the county.  
Busia is one of the counties that has the largest number of donors who support many health 
activities on the ground (Busia County Health Profile, 2016). The county has 1098 health care 
workers, most of whom manage the supply chain at different facility levels (Ministry of Health, 
Busia County, 2017). At the county level, the County Pharmacist and the County chief nurse are 
in charge of coordinating supply chain management for both pharmaceuticals and non-
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pharmaceuticals respectively. At the sub-county level, it is done by the sub-county pharmacists 
and the nursing officer in charges as well as the supply chain officers and at levels 3 and 2 facilities 
the process is managed by nurses and pharmaceutical technologists.  
The current situation in Busia County is that most of the staff are not conversant with quantification 
process due to lack of training in that aspect. Quantification is done at county and sub-county 
levels but using old data and by making many assumptions and approximations since the exercise 
has only ever been done twice post-devolution, with support from partners. Centralized bulk 
procurement of medicines is done from, Mission for Essential Drugs and Supply (MEDS) and 
Kenya Medical Supply Authority (KEMSA) pre-qualified suppliers who were recommended by 
the central government. Procurement is also done from local suppliers (Health Sector Function 
Assignment and Competency Team (FACT), 2013), most of whom lack the capacity to meet the 
high volume of distribution for the county hospitals, leading to frequent drug stock-outs being 
experienced. Pipeline challenges that are experienced in the county are leakages, damages, 
pilferage of drugs and very long lead times.  Management of medicines and medical products is 
done by the pharmacy and nursing departments due to a shortage of pharmacy personnel in lower 
level facilities. Training on supply chain management are done on need the only basis and the 
training content is usually specific to various cadres. The training are always done with support 
from partners.  
1.2 Statement of the problem 
Devolution of health services mandated county governments to ensure that medicines and medical 
products are available in health facilities at all times and are affordable to their citizens. However, 
this has not been the case in Busia County. Inadequate funding for health care, lengthy 
procurement process for health commodities, commodity stock-outs in health facilities and lack of 
capacity to forecast, plan and determine county health care needs that is brought about by poor 
logistics management are some of the challenges that have been experienced by healthcare workers 
while trying to offer services to the population, challenges that have in fact affected supply chain 
performance.  
Inadequate funding has also led to inadequate staffing hence the lack of qualified workforce to 
handle the supply chain efficiently and effectively since the county is unable or unwilling to hire 
adequate pharmacy personnel to manage commodities and also to train them on up to date 
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information concerning pharmaceutical commodities. Medicines and medical products are a vital 
component of a functional health system because they save lives and promote the health of the 
population (Management Science for Health, 2012). They are costly due to the fact that they 
consume a large portion of the health budget and should, therefore, be handled with care to ensure 
the preservation of potency and efficacy by qualified personnel (Management Science for Health, 
2010). Lack of these molecules in health facilities would lead to devastating consequences to 
patients. It would compromise the quality of patient care, leading to poor health outcomes, 
catastrophic health expenditure due to patients experiencing high cost of health care (Le et al., 
2011) and even patient mortality. Inefficient supply chain management system would lead the 
County to continue experiencing losses such as expiry of medicines and medical products and be 
forced to spend more on procurement, so as to offer essential service to the population as mandated 
by the constitution.  
Based on the stated problem the study aimed at addressing the supply chain management 
challenges that healthcare workers in Busia County face while managing medicines and medical 
products, address human resource for health challenges concerning supply chain management so 
as to make necessary changes to the current management of inventory, changes that will lead to 
achieving efficiency. The study also aimed at making the information, human resource for health 
and medicines and technology pillars of the health system functional, which would, in turn, lead 
to improving performance of the pharmaceutical supply chain to meet the patients’ expectations.  
1.3 Research Objectives 
1.3.1 General Objective 
The study’s main objective was to assess pharmaceutical commodities supply chain management 
challenges that health care workers in Busia County encounter while delivering services to the 
population and use the information to suggest improvement on pharmaceutical supply chain 
performance.  
1.3.2 Specific Objective 
1. To determine the efficiency of the pharmaceutical Logistics Management Information System 
(LMIS) in Busia County in serving her population needs.  




3. To determine whether the staff managing the pharmaceutical supply chain system are well 
trained  and are of the right number.   
1.4 Research Questions 
1. Is the existing Logistics Management Information System efficient enough to serve the needs 
of Busia County? 
2. Are the county funds allocated for procurement of medicines efficiently used? 
3. Are the current staff who manage the supply chain adequately trained on supply chain 
management and of the right number?  
1.5 Justification of the study 
The significance of addressing the medicines and technology pillar was to enable Busia County 
address patient expectations in regards to the six rights of logistics by improving the performance 
of the pharmaceutical commodity supply chain. 
Funds allocated to the medicines and technology pillar had an impact on health outcomes, which 
can be linked to sustainable outcomes that are aligned with national health objectives and Health 
Sustainable Development Goal number three, on good health and well-being, through improved 










CHAPTER TWO: LITERATURE REVIEW 
2.1 Introduction 
This chapter presents a review of relevant literature on the supply chain management, logistics 
management information system, budgetary expenditure on medicines and healthcare workforce. 
It also presents both theoretical and conceptual frameworks upon which the research is based. 
2.2 Overview of the pharmaceutical supply chain 
The pharmaceutical supply chain is an important element of a health system that involves 
manufacturers, suppliers, third-party service providers, middlemen, patients, activities such as 
logistics and includes aspects like information systems and finance (Jaberidoost, Nikfar, 
Abdollahiasl, & Dinarvand, 2013), all with the aim of delivering medicines and medical products 
in the right quantity and right quality, at the right time and at the right cost to a customer (USAID, 
2011), so as to add value to all stakeholders.  
The medicine value chain is a crucial component of any health system performance. Effective 
management of diseases is made possible through the establishment of efficient procurement and 
robust supply chain management systems that ensure an adequate supply of essential medicines at 
all times and at affordable costs. A reliable logistics network will also enable access to essential 
medicines and allow monitoring of medicine use in order to better assess rational drug use and 
ensure sustainability of the pharmaceutical supply chain. This is important to any health system as 
it minimizes chances of stock outs, expiries, unnecessary waste and pilferage of medicines and 
medical products. It also ensures availability and access to essential medicines by the population 
at all times as shortage of these molecules will compromise quality patient care, leading to 
suffering of patients, development of microbial resistance strains that are difficult to treat and end 
up becoming a public health hazard, therefore a danger to the population as a whole and even death 
(Daniel, Tegegnework, Demissie, & Reithinger, 2012).  
Drug shortages may also lead to patients receiving the sub-standard quality of care and 
postponement of therapy or surgery (Kaiser, 2011; Rosoff, 2012). It will also lead to patients 
experiencing increased healthcare costs, medication errors, adverse outcomes, prescribing 
inaccuracies, missed dosages and reduced patient adherence to medication (Le et al., 2011), which 
will further worsen patient treatment outcomes.  
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Supply chain management, therefore, is the purposeful creation of value for stakeholders and 
customers through the incorporation of processes across the supply chain (Rossetti, Handfield, & 
Dooley, 2011). It involves organization and control of all activities involved in sourcing, acquiring, 
manufacturing and logistics activities (Wisner, Tan, Leong, 2012). 
2.3 Barriers to achieving effective hospital pharmaceutical supply chains 
Regulatory framework policies affecting the pharmaceutical industry directly affects the hospital 
pharmaceutical supply chain management. The supply chain is also affected by difficulty in 
forecasting commodity consumption of patients due to their health-seeking behavior and 
prescribing patterns of medicines by physicians. The buffer stock level is affected by uncertainties 
in demand by patients which results in stock-outs or expiries leading hospitals to incur high 
operational costs due to emergency purchases hospitals have to make in order to cater for their 
patients’ needs (Nilay Shah, 2004). 
In Sub Saharan Africa most local suppliers are unable to honor their procurement contractual 
obligations which include facilitation of local purchase orders of medicines and medical products 
and their delivery to SDPs. This greatly affects the availability of medicines in health facilities and 
thus the reliability of the supply chain (Arney, Yadav, Miller, & Wilkerson, 2014). There is also 
the aspect of non-flexible tendering process and government supply chain being too rigid that it 
affects the supply chain (Binanay et al., 2015). 
According to a study done in Nigeria poor leadership and governance of health system and 
uncoordinated value chain affect supply chain management. The supply chain is affected by poor 
procurement procedures that result in medicines stock outs, unregulated market prices for 
medicines and medical products, poor funding by the government as evidence in poor supply chain 
performance. Inefficiencies in supply chain management are also brought about by lack of vital 
consumption data or unreliable data concerning actual demand and supply of medicines and 
medical products, lack of qualified personnel to manage the supply chain processes, irrational 
prescribing by prescribers and also irrational drug use (Obuaku, 2014). 
Unreliable means of transportation of commodities to SDPs, the absence of well-founded data for 
supplies tracking and documentation, lack of straightforward protocols at every level of the supply 
chain system and poor storage facilities for medicines, medical products, and vaccines are all 
barriers to effective supply chain management (Biza et al., 2015). Some medicines and medical 
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products have to be imported and as a result, health facilities experience delays in delivery of 
essential supplies to their respective SDPs (Khozaim et al., 2014). 
2.4 The Logistics Management Information System (LMIS) 
According to Rushton, Croucher, & Baker (2014), LMIS refers to system of records and reports, 
either paper-based or electronic, which are used to aggregate, analyze, validate, and display 
logistics data. The primary goal of Logistics Management Information System is to ensure 
availability of quality health commodities at health facilities and community at large.  
There are various types of Information Management Systems used by different organizations 
across the world. Christiansen (2015) explains that the main types of Information Management 
Systems are Management Information System (MIS), Executive Information System (EIS), 
Decision Support Systems (DSS) and Enterprise Systems. Other Information Management System 
include office automation system, communication system and transaction processing system.  
Health care organizations are required to use standardized ways of exchanging logistic information 
with other systems and with specific authorizations hence the need for use of the Logistic 
Management Information Systems, which mostly depends on external information and standards 
to comply with medical regulations.  
2.4.1 Existing LMIS in the world 
A functional LMIS is one that is cost-effective, eliminates discrepancies in stock balances and 
gives valid and relevant information for tracking of supplies throughout the SC (Pinna, Carrus, & 
Marras, 2015) to enable informed decision making. 
The National Health Service in Italy rolled out an experiment involving the pharmacy department 
with the main objective being to rationalize the management of pharmaceuticals so as to limit 
clinical medication management risks and improve efficiency and effectiveness of SCMS. The 
idea was to centrally manage all drug-related activities by redesigning through computerized 
means the pharmaceutical logistics cycle activities: ordering, procurement, distribution and 
inventory management in order to contain costs (Pinna et al., 2015). 
Pakistan, on the other hand, adopted an electronic Contraceptive Logistic Management 
Information System (cLMIS) in 2010 to manage inventory (Hamid, Qureshi, & Bajwa, 2017) and 
provide relevant data on contraceptive consumption rates (Pakistan Logistics Information System). 
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In East Africa, Ethiopia uses an Integrated Pharmaceutical Logistics System (IPLS) so as to ensure 
ordering of medicines, distribution, and reporting in public health facilities (Mudzteba, 2014).  
Tanzania uses eLMIS for reporting and ordering of medicines and medical products from both 
facility level using paper-based system to the district and national levels where the system is 
computerized. eLMIS manages emergency orders in case of reports of commodity stock-outs in 
health facilities. They also use EPICOR9 for warehouse inventory management, CTC2 for tracking 
ART management and ILS gateway for some commodities whose reporting is done via SMS 
(Mjelva, 2017) 
2.4.2 LMIS in Kenya 
Initially, KEMSA owned the LMIS and made all decisions regarding commodity redistribution 
without any input from other parties but this was later revamped by the MOH to include other 
relevant stakeholders whose input was vital for the decision-making process. In Kenya the LMIS 
is used for inventory management of antiretroviral medicines, reproductive health medicines and 
medical products, medicines for Tuberculosis and Laboratory diagnostic testing kits for HIV/AIDS 
and Malaria. It is also used for essential medicine orders through KEMSA (USAID, 2007). The 
LMIS is used by (NASCOP) to track SCM of medicines and medical products to SDPs. It provides 
information on available stocks of medicines especially antiretrovirals and how the molecules are 
redistributed to health facilities in terms of quantities (NACC).  
Busia County just like the rest of the counties in Kenya uses the LMIS for both programs funded 
commodities and essential medicines orders. Orders are made to the pre-qualified supplier, 
KEMSA (Health Sector Function Assignment and Competency Team (FACT), 2013). Stock levels 
are tracked throughout the supply chain, quantities needed for resupply by each and every facility 
are computed, and also an approximation of commodity data for future requests is made possible 
by the LMIS (USAID, 2007).  
The current challenges with the LMIS in Busia County are lack of computers in lower level health 
facilities, which hinders LMIS performance.  In Busia County most staff who manage the supply 
chain in health facilities are computer illiterate, therefore cannot handle LMIS appropriately. There 
is incomplete and also delayed reporting on commodity consumption especially for donor-funded 
commodities which interfere with supply chain performance, as delivery and proper functioning 
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of LMIS is dependent on adequate, accurate and timely information flow throughout the logistics 
cycle.  
Most of the lower level facilities do not quantify their commodity needs before submitting their 
commodity requests. They give inaccurate information about their commodity needs, which in 
most cases has led to understocking and even overstocking of commodities in health facilities. 
Inaccurate information from health facilities also hinders decision-making at both county and 
national levels as data that is submitted cannot be processed and used for making important 
decisions on procurement and commodity redistribution. Due to this, commodity stock outs and 
losses that are brought about by the expiry of medicines have been experienced.  
Network connections in Busia County is a big challenge as lack of reliable internet connection in 
the region interferes with sending reports and making requests through LMIS as this requires an 
internet connection. There is knowledge gap brought about by lack of staff training on LMIS. For 
instance, only those in charge of managing the supply chain at Sub County and County levels are 
familiar with LMIS use. Also, staff training on making KEMSA orders using the LMIS was done 
for two people per Sub County. In case of staff turnover, the supply chain performance will be 
greatly affected.  
There is also a problem with LMIS orders not being honored by the departments concerned at the 
national level. Reports are made, sent and received but never checked by managers at the national 
level. Also, the “Push” system for donor-funded commodities is still in use by suppliers making 
SCM difficult for managers in SDPs. 
2.5. Pharmaceutical Expenditure on Medicines 
A vital part of health care expenditure is spending on medicines. A swift increase in medicines’ 
spending promotes health expenditure growth and thus broadens the significance of health in the 
economy (Belloni, Morgan, & Paris, 2016). Lu, Hernandez, Abegunde, & Edejer, (2011) stated 
that the global total pharmaceutical expenditure on medicines per individual was at $20.3 for low-
income countries and $71.9 for lower-middle income ones and that due to huge differences among 
income groups the upper-middle-income countries expenditure was at $152 per individual. 
According to the Kenya Health Sector Working Group Report on medium-term expenditure 
framework for the period 2017-18 to 2019-20 (September 2016), Ministry of Health allocation FY 
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2015/2016 increased by 25% with a health budget mean annual growth of 28% as compared to 
national health budget’s 20%.  
The National and County Health Budget Analysis FY 2016/17 done by the MOH states that for 
2016/2017 FY MOH was allocated Kes 60.9 billion out of the whole 1,505 billion national 
government’s budget. The allocation is equal to 3.7% down from 3.9% allocation for 2015/2016 
FY. This indicates a drop in government budgetary allocation to health and that we are drifting 
further away from the Abuja declaration’s 15% target on government spending on health. It also 
means that the national government’s allocation for health is inadequate. 
2.6 Pharmaceutical Commodity Supply Chain Management Costs 
Costs associated with Pharmaceutical supply chain can be classified as direct, indirect, fixed, 
variable, order and holding costs. Direct costs are those costs that are linked to a unit of product 
that is produced whereas indirect costs are those that are viewed as overhead costs like cost of 
lighting. Fixed costs are those that are considered as sunk costs while variable costs are those that 
change with a change in output level like the cost of labor. When ordering commodities from a 
supplier, the cost incurred will be referred to as order costs. Keeping commodities in storage will 
attract holding (carrying) costs (Wisner, Tan, Leong, 2012). 
Other costs will include transportation cost which are costs like distribution of medicines that are 
not included in the supplier’s contract (Management Science for Health, 2012). Transportation 
costs will also include labor costs for staff and fuel costs (Shretta et al., 2015). When emergency 
purchases are made, stock shortage costs, which are additional costs are met (Management Science 
for Health, 2012) by an institution. Procurement costs will be incurred during activities like 
development of tenders and forecasting (Shretta et al., 2015). 
The current challenges with budgetary allocation in Busia County are: that the leadership at the 
county health department are not strong enough to fight for more resource allocation for the health 
sector due to lack of commitment on their part and also reliable data to do so. Delays in the 
disbursement of funds by the national treasury lead to the county having to make adjustments, 
through cost-cutting measures, to the initial budgetary allocation. This leads to constrained 
resources at the county level, the main casualty being the health sector, which always ends up with 
very minimal allocation.  
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Political influence in budgetary allocation process by the county politicians affects the health 
sector as they are the ones who decide how much allocation will be given to various county 
departments. Since Busia like most counties gives health low priority against other county 
priorities like administrative costs and county investments, only 3.5% of the county budget goes 
to health as per the 2016/2017 county budget. This is a very minimal allocation to an important 
sector like health.  
There is also poor planning and lack of linkage between budgeting, planning and health sector 
priorities leading to minimal budgetary allocation by the county. Due to this, the county has been 
unsuccessful in attaining its health-related targets over the years. 
2.7 Pharmaceutical Drug Inventory Classifications 
For inventory management to be effective it must enable efficient resource use and enhance patient 
care by guaranteeing stock availability and minimizing chances of commodity stock outs (Santhi 
& Karthikeyan, 2016). To manage inventory one must acknowledge inventory classification 
methods (Kritchanchai & Meesamut, 2015), as they affect consumption rates and medicine 
expenditure (Santhi & Karthikeyan, 2016).  
Drug inventory is categorized into Always, Better and Control (ABC) and Vital, Essential and 
Non-essential (VEN), which is sometimes called VED – Vital, Essential and Desirable (Galka, 
2016). For the purpose of this paper, VEN nomenclature will be used. There is an option of 
combining the two analyses into ABC-VEN classifications (Nigah, Devnani, & Gupta, 2010). The 
classifications are based on hospital Annual Drug Expenditure (ADE). This is done so as to 
determine which drugs need strict, average or little managerial control that makes most effective 
resource use and minimize chances of stockouts (Mohamed & Ahmed, 2016). 
2.7.1 ABC Analysis 
Pareto ABC Analysis is a method used to manage inventory whose stock volume ranges in 
hundreds or more than that (Kritchanchai & Meesamut, 2015). It is a technique used to classify 
drug commodities according to their relative significance. It classifies drug commodities into three: 
category A, B and C. 70% of the cumulative cost are accounted for by the first 10-15% which 
make up category A of medicines. Category B is accounted for by 20-25% of commodities which 
make up 20% of the cumulative cost. Category c makeup 10% of the cumulative cost and is 
accounted for by 65-70% of health commodities (Anand, Ingle, Kishore, & Kumar, 2013). The 
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purpose of this method is to minimize complexities and by so doing enhance the effectiveness of 
inventory management (Kritchanchai & Meesamut, 2015). 
2.7.2 VEN Analysis 
In VEN analysis drug items are categorized into vital, essential and nonessential/desirable, based 
on their criticality (Kritchanchai & Meesamut, 2015).  
V stands for vital items. They are life-saving medicines, have serious withdrawal side effects, and 
are crucial therefore their unavailability will render a hospital non-functional. 
E stands for essential items. Their unavailability may not render a hospital non-functional but will 
definitely affect the quality of services being offered. 
N stands for non-essential items and their unavailability will not affect patients’ health. They are 
used to manage minor illnesses and their efficacy is questionable (Anand et al., 2013; Management 
Science for Health, 2012). 
Through VEN analysis, cost containment is made possible by reducing amounts of non-essential 
medicines and instead directing the restricted funds to Vital and essential medicines. It is also 
crucial in guaranteeing the availability of life-saving drugs (Lyombe, 2013). 
2.7.3 ABC-VEN Matrix 
ABC-VEN matrix categorizes medicines into nine sub-classes: AV, AE, AN, BV, BE, BN, CV, 
CE, and CN by combining ABC and VEN analyses respectively. It further subcategorizes the sub-
classes into three categories: I, II and III. Category I are vital items while II and III are less 
frequently ordered items. Category I contains items from AV, AE, AN, BV and CV subclasses. 
Category II contains items from BE, CE and BN subclasses whereas Category III contains items 
from the CN subclass (Kritchanchai & Meesamut, 2015). 
ABC-VEN matrix is used for prioritization of items and to minimize item lists, especially those 
that need strict managerial control (Anand et al., 2013), as seen from an analysis done at an Indian 
tertiary care hospital showed that only 322 of 1536 medicines needed hospital managerial control 
(Kumar & Chakravarty, 2015).This model makes an available vital category of drugs, stressing on 
the importance of stocking category B and C medicines and monitoring medicine use. This is 




2.8 Staff Training on Supply Chain Management and personnel staffing levels 
Focus on Human Resource has always been on community health workers, nurses and doctors, not 
on how to refine and support the supply chain (A. Brown et al., 2014). On this, the International 
Pharmacy Federation (FIP) through their Global Workforce Report in 2012 confirmed that it is 
necessary to have HR focus in SCM by connecting lack of access to medicines to a shortage of 
pharmacy staff (International Pharmaceutical Federation, 2012).  
Access to medicines is hindered by a shortage of trained pharmacy personnel especially in lower 
level health facilities (Lubinga et al., 2014). Resource-poor environments fail to see that to achieve 
effective supply chain management and better Supply chain performance, the human resource must 
be managed effectively (Brown et al., 2014). There is also need for investment in training of health 
workforce and use of their skills to achieve maximum productivity as stressed on by a WHO report 
in 2006 (The World Health Report 2006: Working Together for Health, 2006). 
Most staff, especially those that work in lower level facilities are not trained in SMC concepts and 
the few who are trained need to undergo training courses to improve their knowledge and skills on 
SMC. Constant transfers of skilled personnel especially those trained on SMC to other facilities 
also affects system performance (Hamid et al, 2017) since transferred staff in most cases do not 
implement their SMC training in their new facilities which further worsens the capacity of supply 
management in health facilities (A. N. Brown & Gilbert, 2014). 
Task shifting is used to enable access to treatment and to cope with human resource shortage 
(Baine & Kasangaki, 2014) in most health facilities. As a result of task shifting, the nursing cadre 
now handles medicines and medical products in lower level facilities, due to a shortage of 
pharmacy personnel in these health facilities. This shortage needs to be addressed since a WHO 
report already approximated a health workforce shortage of 7.2 million and forecasted that the 
figure would be expected to go up to 12.9 million by the year 2035 (Global Health Workforce 
Alliance, WHO, 2013). In Kenya, the MOH HIS Annual Report (2012) pointed out that the number 
of pharmaceutical personnel stood at 510 and that of nurses was 20371 respectively. In the same 
year another report, The Economic Survey (2012) stated that for every 100,000 population there 
were 20 doctors, 6 pharmacists, and 155 nurses.  All these cadres are vital as they are involved in 
the efficient management of the supply chain either directly or indirectly. 
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Human Resource Norms and Standard Guidelines For The Health Sector (2014) projected National 
HRH staffing needs as 13,141 for doctors, 38,515 for nurses and 3830 for pharmacy personnel 
(Ministry of Health, 2014b). Busia County staffing norm is much more constrained since it only 
has 23 doctors, 18 pharmacy personnel and 467 nurses (Busia County Treasury, 2016) that take 
care of Busia County’s 886,223 total population (County Government of Busia, 2016). The 
number of Busia County staff is inadequate as compared to the Economic Survey (2012) report on 
staffing norms. This study will seek to understand the competency gaps among pharmacy 
personnel in Busia County, especially in relation to Pharmaceutical Commodity SCM, and give 
recommendations on how these can be addressed. 
2.9 Managing supply chain challenges 
A more robust supply chain that is being managed by better-trained personnel is key to improving 
access to health care in poor resource settings (Lubinga et al, 2014). Concerning donor-funded 
commodities such as antiretroviral medicines, availability of efficient supply chain system will 
enable the country to develop and manage her own procurement process and distance itself from 
partner-enforced distribution model like in Rwanda (David J Ripin et al, 2014).  
To achieve efficiency hospitals should embrace technology and upgrade their current drug 
inventory system. Staff should also be trained on good inventory management practices so as to 
improve their skills (Oballah, Waiganjo, & Wachiuri, 2015) since through proper inventory 
management savings in total inventory cost can be made (Ilma Nurul Rachmsania, Mursyid Hasan 
Basri, 2012). 
It is necessary to adopt efficient and effective supply chain management system so as to minimize 
waste and inefficiency and to better health care standards (Elmuti, Khoury, Omran, & Abou-Zaid, 
2013). The government should also look into contractual obligations of suppliers and compel them 
to adhere to their obligations (Arney et al, 2014). 
For organization and effectiveness, supply chain interventions need the active participation of 
stakeholders, an efficient LMIS, good inventory management practices and political goodwill from 
the government (Mukasa, Ali, Farron, & Weerdt, 2017). Increasing funding for health care will 
allow for the much-needed capacity building supply chain training for staff, research and 
development of a more comprehensible LMIS and also enable sustainability of SCMS (Mukasa et 
al., 2017). Addressing human resource for health shortage will go a long way to improve supply 
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chain management processes and inventory management practices and will also enhance smooth 
flow of information within the SC, leading to improved access to essential medicines by the 
population and good health outcomes (Lubinga et al, 2014).  
On Annual Drug Expenditure, ABC analysis, which is based on monetary value and use is not a 
good measure for inventory management as some items that have low monetary value are vital and 
their importance can be disregarded simply because they are not category A (Wandalkar, Pandit, 
& Zite, 2013). Criticality of drugs is also important and should be put into consideration (Mohamed 
& Ahmed, 2016). Efficient and effective inventory management is achieved when ABC is used in 
combination with VEN analysis (Anand et al., 2013) as it is more cost-effective and minimalizes 
stock out incidences of vital medicines (Monton, Charoenchai, & Suksaeree, 2014). 
There is need to address human resource for health shortage as this will improve the flow of 
logistics information, enable good inventory management and efficiency of the supply chain 
management as a whole. It will, in turn, lead to good health outcomes brought about by improved 
access to medicines (Lubinga et al, 2014). In an effort to reduce staff shortage, the government 
should employ the unemployed health workers with an emphasis on the right skill mix (Baine & 
Kasangaki, 2014). 
2.10 Theoretical Framework for Supply Chain Management 
This literature focuses on underlying theoretical basis of efficient supply chains used in medical 
healthcare. The theories include - agency theory, Transaction Cost Economics Theory, 
Psychological Contract Theory, Information theory and Resource Dependency Theory. 
Agency theory focuses on the main principal actors within the medical healthcare systems, the 
agents involved in the supply chain and how informative decisions are made between the two 
parties involved in the supply chain system using the information available to them.  
Transaction Cost Economics Theory focusses on the resources used within the healthcare 
organization. Risk factors are the prime focus study in this theory, whereby, human resource risks 
will be evaluated and analyzed using information available. Opportunistic behavior among the risk 
factors will be worth investigating for cost reduction process (Kilubi, 2017).  Information theory 
focusses on heavily relied on information sharing within healthcare system within Busia County. 
Information plays important role in making right decisions that will foster changes within 
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healthcare system. There are so many information that are shared on daily basis that can provide 
meaning and informative insights. 
Psychological Contract Theory focusses on partnership and gaining trust between pharmaceutical 
suppliers and hospitals medical service providers. If the partnership is purely strong, provision of 
pharmaceutical services will be achieved at the right time, and decision making processes will be 
quick.  
 Resource Dependency Theory focusses on the availability of external resources. Pharmaceutical 
suppliers and hospitals should have strong links to fill the gap of failure of resources in the 
organization as those strong links are immediate solutions to enable presence of efficient and 
effective there is robustness in pharmaceutical supply chain system. 
2.10.1 Agency Theory 
This theory was used by Romona Byrne & Damien Power, 2014 to analyze how firms involved in 
the Supply Chain are directly involved with each other and information asymmetry between the 
parties involved. Agency theory applies to a situation in which an actor (principal) gives control 
of important activities and decision-making to another party known as the agent (Sajad Fayezi, 
Andrew O’Loughlin, & Ambika Zutshi, 2012) and the agent is required to act in a way that serves 
the principal’s interests and not his own.  
The theory focuses on contractual obligations and supposes that due to the information available, 
actors are able to make rational decisions but does not consider the fact that there might be 
information asymmetry between the parties involved which might limit their ability to make 
decisions (Sanderson, Lonsdale, Mannion, & Matharu, 2015). 
2.10.2 Transaction Cost Economics Theory 
The theory was proposed by Williamson in 1975 and stresses on managing risks associated with 
contracting through use of governance structures. The theory helps to interpret situations where 
outsourcing will most probably benefit an organization. It addresses bounded rationality and 
information asymmetry and also addresses opportunistic behavior (Gurung & Prater, 2017) of 
suppliers. Under this theory, informal governance mechanism may incorporate moral outlook with 
self-regulation (Schmoltzi & Wallenburg, 2012), or an integration of both methods for more 
effective when there is a high risk of opportunism (Li, Huang, Cheng, Zheng, & Ji, 2014). 
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Richey et al, 2012 stated that this theory shows how firms minimalize opportunistic behavior using 
governing mechanisms but extreme formal governance mechanism does not prevent opportunistic 
behavior and may influence buyer-supplier association negatively. Therefore the use of both 
formal and informal mechanism is advisable as it will improve performance due to the possibility 
of relational cooperation making up for the rigid contractual governance and improving trust (Li 
et al., 2014; Wuttke, Blome, & Henke, 2013). 
2.10.3 Information Theory 
For organizations that take part in SCM to perform optimally, they must interconnect, cooperate 
and share information (Sanders, Autry, & Gligor, 2011; Tokar, Aloysius, Waller, & Williams, 
2011). Information sharing is also crucial in ending supply disruptions through coordination and 
consolidation of the supply chain (Mohd Nishat Faisal, D.K. Banwet, & Ravi Shankar, 2007), so 
as to enable better forecasting. In this theory, organizations must acknowledge that uncertainties 
in the SC are brought about by mutual or reciprocal influence amongst themselves and also by 
functions that are carried out by supply chain players, functions that are interdependent in nature 
(Casey G. Cegielski, L. Allison Jones‐Farmer, Yun Wu, & Benjamin T. Hazen, 2012). Information 
theory mainly focuses on uncertainty and information quantities (Beckstead & Beckie, 2011).  
2.10.4 Psychological Contract Theory 
The theory gives an understanding of how the integration of the supply chain is defined by long-
term associations like strategic partnerships (Menon, 2012). The theory builds on trust that is 
reciprocated among supply chain players. The long-term relationship is characterized by mutual 
dependence, like pharmaceutical suppliers and hospitals, which results in achieving gains or 
success by both parties involved if managed well.  
2.10.5. Resource Dependency Theory 
This theory was initially proposed by Pfeffer and Salancik in 1978. The theory states that 
organizations change and must also come to terms with their external environment in order to 
acquire resources they need to sustain themselves.  
Adams et al, 2014 used this theory to analyze supply chain alliances. In this theory actors lacking 
resources enter into associations with those with the resources to get the resources that they need 
in order to survive. This is brought about by the varied distribution of resources and capabilities 
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across different organizations hence the need to create links in order to acquire crucial resources 
(Kim & Choi, 2015).   
2.11 Conceptual Framework 
The conceptual framework is represented in the diagram below which shows the correlation 
between the study variables. It is developed from the Pharmaceutical Logistics Cycle (Fig 2). The 
independent variables are the LMIS, budgeting for medicines, medical products and vaccines and 
also adequate and human resource for health, who manage the Supply Chain. When manipulated 
through interventions, the independent variables will have an effect on the dependent variables, 
which are efficient product selection, efficient quantification, and procurement process, efficient 
inventory management and patient satisfaction respectively. 
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CHAPTER THREE: RESEARCH METHODOLOGY 
3.1 Introduction 
The chapter describes research design, study population, data collection tools, data collection and 
data analysis. 
3.2 Research Design 
A cross-sectional descriptive study design was used. Direct observation method and a 
questionnaire (Annex 1) were used to record key competency gaps of staff who use LMIS 
optimally at their health facilities. Self-administered questionnaire (Annex 3) was used to get 
information from staff who manage hospital pharmaceutical supply chain at different facility levels 
and procurement records (Appendices 1-14) were used to determine the availability of medicines 
in the facilities. ABC, VEN and ABC-VEN analysis were done to calculate pharmaceutical Annual 
Drugs Expenditure (ADE) for sub county hospitals in  
Busia County. 
3.3 Sampling  
3.3.1 Study Sites – Busia County health facilities 
The study focused on staff who manage the pharmaceutical commodity supply chain: pharmacy 
and nursing department, since pharmacy personnel were not available in lower level facilities. The 
county store and five facilities per Sub-county were targeted for this study as shown in table 2 
below. 
Sub county Sub county 
Hospital 
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Table 1: Busia County Study Sites 
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3.3.2 Population and Sampling 
The study targeted health facility personnel tasked with the responsibility of managing the supply 
chain. The sampling method was purposive as it targeted specific staff who were involved in 
supply chain management (Tables 1 and 2 below) and also personnel at County level who were 


















in Busia County 
1 1 6 14 19 31 11 
Number of 
health facilities 
targeted for the 
study 
1 1 6 7 7 7 6 
Table 2: Busia County Health Facilities 
Total number of health personnel working in 
Busia County who manage the pharmaceutical 
supply chain 
519 
Number of health personnel  targeted for the 
study that works in Busia County 
50 
Table 3: Human Resource for Health in Busia County 
Inclusion criteria: personnel who handle supply chain management and have worked in a 
particular workstation or county level for more than a year and county personnel involved in 
decision making, procurement, and budgetary allocation. 
Exclusion Criteria: personnel who have not been holding their current position for more than a 
year and those who are not involved in supply chain management or decision making process both 
at the county and facility level. 
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3.4 Data Collection Methods 
To address RQ1 (Is the existing Logistics Management Information System sufficiently robust to 
serve the needs of Busia County?), direct observation method, as well as a questionnaire (Annex 
1) were used to check on the efficiency and use of LMIS system in sub-county hospitals.  
To address RQ2 (Are funds meant for procurement of medicines efficiently used?) Archival 
method was used to collect data. Study tools were ABC and VEN analysis (Appendices 1-14).  
To address RQ3 (Are the current staff who manage the pharmaceutical commodity supply chain 
adequately trained and of the right number), a questionnaire (Annex 3) was administered to the 
pharmacy and nursing personnel through research assistant in order to assess competency gaps 
among personnel in relation to pharmaceutical supply chain management and staffing norms of 
personnel managing the pharmaceutical commodity supply chain in Busia County 
3.5 Data Management 
For analysis of data for RQ1 and RQ3, quantitative data analysis was done using Statistical 
Package for Social Sciences (SPSS). Objectives 1 and 3 were critically analyzed and inferences 
made in relation to the research objectives. Descriptive statistics were presented in form of charts 
and tables. 
For ABC analysis, Annual Drugs Expenditure (ADE) for each drug in the essential medicines list 
were calculated from inventory records and then drugs were arranged in descending order with the 
medicines with high Annual Drugs Expenditure at the top and those with low Annual Drugs 
Expenditure at the bottom. Calculation of cumulative cost was then done which totaled up to 100% 
of the total pharmaceutical Annual Drugs Expenditure. Data was then plotted according to class A 
(those medicines that consume 70% of Annual Drugs Expenditure), B (those that consume 20% 
of ADE) and C (those medicines that consume 10% of Annual Drugs Expenditure) respectively.  
For VEN analysis VEN status of each drug was established using the hospital medicines and 
therapeutic committee decision. Annual Drugs Expenditure was calculated from inventory records, 
medicines were classified to their respective classes, total Annual Drugs Expenditure was 
calculated and their presentation made in form of tables. 
Cross-tabulation was done for ABC-VEN matrix analysis by categorizing medicines as I (those 
that are expensive, vital, and require managerial control) II (those that are essential and cost 
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averagely) and III (those medicines that are non-essential ones and cheap). MS Excel spreadsheets, 
ratios, percentages and frequency tables were used in quantitative data analysis.  
 3.6 External and Internal Validity 
For internal validity, results from data collected were attributed to the independent variable. ABC 
and VEN analysis, which are well-established methods were used together with validated records 
of Busia County medicines expenditure to analyze the sufficiency of budgetary allocation for 
health as well as if county funds allocated for health are well utilized. Data collection tools that 
were used in this study were standardized tools that had been used in a similar context. Busia 
County procurement records that were used for this study were those achieved through current 
procurement methods embraced by the county government, which had national government 
approval. The questionnaires that were being used for this study were pre-tested by giving them to 
my work colleagues for piloting phase before use in the study in my facility a week before the 
commencement of data collection.  
Healthcare workers that participated in the study were required to sign informed consent document 
(Annex 5), which had to be vetted and cleared by the Ethics Committee of Strathmore Business 
School. The consent was treated with confidentiality and used solely for its intended purpose which 










CHAPTER FOUR: RESULTS 
4.1 Introduction 
This chapter presents the findings based on the data collected using questionnaires and 
procurement records for medicines. Response rate by participants during this study was 100% as 
all the 50 participants answered all the questions from the questionnaires. 
4.2 Logistic Management Information System (LMIS) 
4.2.1 Cadre distribution of the interviewee 
The respondents were asked to indicate their cadres. The findings revealed that out of the 50 
respondents, 26 respondents (52%) were nurses, 15 respondents (30%) were pharmaceutical 
technologists, 8 respondents (16%) were pharmacist while 1 respondent (2%) was a clinical 
officer. This finding suggests that most of the healthcare employees in Busia County who manage 
the supply chain in health facilities are nurses as summarized in figure 4 below. 
 
Figure 3: Cadre of interviewee 
4.2.2 Supply chain management 
The respondents were asked to indicate the officer responsible for supply chain management in 
their respective facilities. From the findings, 21 respondents (42%) said that Nursing officer-in-
charge was responsible, 19 respondents (38%) said that Hospital/Sub County Pharmacist was 
responsible, 8 respondents (16%) said that Pharmaceutical Technologist was responsible while 2 












suggests that supply chain management is managed by Nursing officer-in-charge in most of the 
healthcare facilities in Busia County. 
  Frequency Percent 
 
Table 4: Supply chain 
management 







Others (specify) 2 4 
Total 50 100 
 













Do you regularly use 
Counter Issue and 
Requisition Forms to 
manage the supply chain? 
YES 92.00% 
NO 8.00% 
Do you regularly use Stock 
Control Cards to manage 
the supply chain? 
YES 100.00% 
NO 0.00% 
Do you regularly use Daily 
Activities Register to 
manage the supply chain? 
YES 94.00% 
NO 6.00% 
Do you regularly use the 
Antibiotic Register to 
manage the supply chain? 
YES 74.00% 
NO 26.00% 
Do you regularly use 
Insulin Register to manage 
the supply chain? 
YES 30.00% 
NO 70.00% 
Do you regularly use 
Register for Controlled 
Drug Substances to 




The respondents were asked to denote the documents used to manage supply chain management 
in their facilities on a regular basis. From the findings, counter issue and requisition forms were 
used by 92% of the respondents, stock control cards were used by 100% of the respondents, daily 
activities registers were used by 94% of the respondents. Antibiotic register was used by 74% of 
the respondents, insulin register by 30% of the respondents and register for controlled substances 
was used by 36% of the respondents, as summarized in Table 5 above. This finding suggests that 
insulin register and register for controlled substances are rarely used to manage the supply chain 
in healthcare facilities in Busia County. 
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4.2.3 LMIS forms 
 
Figure 4: LMIS forms use in ordering and commodity management 
The respondents were asked what LMIS forms they used for ordering and reporting on Commodity 
management. From figure 6 below, 90% of the respondents said they used country-specific LMIS 
forms while 10% used other forms namely Facility Consumption Data Recording and Reporting 
(FCDRR) forms and Facility (FMAPS). 
4.2.4 LMIS forms availability 
    Column N % 
 
Table 6: LMIS forms 
availability 
Are the LMIS forms always available 




Does the tool cover all the key areas 





orders and reports 
How often do you send Commodity 
orders to the County and National 
levels for appropriate action 
Monthly 14.00% 
Quarterly 86.00% 
How often do you send Commodity 
reports to the County and National 




Table 8: Timely 
submission of orders and 
reports 
Are your reports and orders submitted 
to the relevant departments on time 
YES 98.00% 
NO 2.00% 
Is the data you submit normally 










4.2.5 Duration of sending forms to the county and national level 
The participants were asked how often they sent the commodity orders and reports to the County 
and National levels for appropriate action. From the findings, 14% of the respondents said they 
sent commodity orders on a monthly basis to the national level for appropriate action while 86% 
said they sent commodity orders on a quarterly basis to the county level for appropriate action. In 
terms of sending reports, 98% of the respondents said they sent commodity reports on a monthly 
basis to the county for appropriate action while 2% said they sent commodity report quarterly to 
the national level for appropriate action. This is summarized in table 7 above. 
4.2.6 Timely submission of orders and reports 
The participants were asked if the reports and orders are submitted to the relevant departments on 
time and if the data submitted is normally accurate and complete. From the findings, 98% of the 
respondents said the reports and orders are submitted to the relevant departments on time and 94% 
said the data submitted is normally accurate and complete. This is summarized in table 8 above. 
4.2.7 Emergency order 
The participants were asked if they had placed an emergency order in the last two weeks. From 
the findings, 54% of the respondents said they had not placed an emergency in the last two weeks 
while 46% said they had placed an emergency order in the last two weeks. This is summarized in 
figure 6 below. 
 
Figure 5: Have you had to place an emergency order in the last two weeks 
23, 46%
27, 54%





4.2.8 Transport means 
The respondents were asked what transportation means were used to ferry commodities from the 
supplier directly to the facility. From the findings, 86% of the respondents said contracted 
companies were used, 8% of the respondents said facility utility vehicles were used for that 
exercise while 6% said motorcycles were used to ferry commodities from the supplier directly to 
the facility.  
The respondents were also asked about means of transportation they normally used to ferry 
commodities from the county or sub county store to the facility. From the findings, 24% of the 
respondents said contracted companies were used, 44% of the respondents said facility utility 
vehicles were used, 6% said private vehicle were used while 26% said motorcycles were used to 
ferry commodities from the county or sub county hospital store directly to the facility. This is 
summarized in table 9 below. 
  Count Column N % 
What transportation means is used 
to ferry commodities from the 




  Facility utility vehicle 4 8.0% 
  Motorcycle 3 6.0% 
What transportation means is used 
to ferry commodities from the 





  Facility utility vehicle 22 44.0% 
  Private vehicle 3 6.0% 
  Motorcycle 13 26.0% 
Table 9: Transport means 
4.2.9 Lead time 
The respondents were asked what their lead time was. From the findings, 34% of the respondents 
said their lead time was more than a three months, 28% of the respondents said their lead time was 
a quarter, 24% of the respondents said their lead time was a month, 8% of the respondents said 
their lead time was two months and 6% of the respondents said their lead time was two weeks as 




Figure 6: Lead time 
4.2.10 Facility infrastructure 
      Column N % 
Table 10: Facility 
infrastructure 
Is the facility connected to any 
form of electricity 
YES 94.00% 
  NO 6.00% 
Does the facility embrace 
electronic management tools for 
commodity management? 
YES 26.00% 
  NO 74.00% 
If yes on question 2 above, is the 
facility using current commodity 
management software? 
YES 17.80% 
  NO 82.20% 
Is the facility well connected to 
the internet? 
YES 22.00% 
  NO 78.00% 
  






How many Pharmacy staff in this 
facility handle the supply chain 
49 0.69 
How many Pharmaceutical 
technologists staff in this facility 
handle the supply chain 
49 0.71 
How many Nurses staff in this 
facility handle the supply chain 
49 1.61 
How many of the Pharmacists staff 
above are trained on LMIS use 
49 0.37 
How many of the Pharmaceutical 
technologists staff above are 
trained on LMIS use 
49 0.47 
How many of the Nurses staff 
above are trained on LMIS use 
49 0.53 
Valid N (list wise) 49   
 
The respondents were asked about the health facility infrastructure they work in. From the 











More than three months
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26% of the respondents said that the facilities embraced electronic management tools for 
commodity management, 17.8% of the respondents said that their facilities were using current 
commodity management software while 22% of the respondents said that their facilities were 
connected to internet. This is summarized in table 10 above. 
4.2.11 Supply chain staff 
The respondents were asked how many staff in the facility could handle supply chain and how 
many were trained on LMIS. From the findings, at least one pharmacist, one pharmaceutical 
technologist and two nurses could handle supply chain at any given time. Also, at least one 
pharmacist, one pharmaceutical technologist and two nurses in most of the facilities were trained 
on LMIS. This is summarized in table 11 above. 
4.2.12 Decision making 
The respondents were asked whether LMIS data collected from facilities aids them in decision-
making. From the findings, 60% of the respondents said that the LMIS data aided them in decision 
making as shown in figure 9 below. 
 
Figure 7: LMIS use in decision making 
30, 60%
20, 40%






Figure 8: How does the LMIS data aid in decision making 
Of the 60% who said yes, 50% said the LMIS data aided them in determining the resupply 
quantities of pharmaceutical commodities, 33% said the data aided in both quantification and 
redistribution of pharmaceutical commodities, 10% said the data aided them in monitoring 
commodity expiry dates, whereas 7% said the data aided them only in commodity redistribution 
as summarized in figure 10 above. 
4.2.13 Preferences  
The respondents were also asked to comment on their preferences of the electronic LMIS use as 
compared to the manual system or vice versa. From the findings, only 29 participants responded 
to this question with 44.8% saying that they preferred the electronic LMIS since it was more 
efficient and accurate and 27.6% said they prefer the electronic LMIS since it saves time. 17.2% 
said they preferred the electronic LMIS since it was easier to use and 10.3% preferred using the 
manual system since it was not affected by power blackouts hence found it to be more reliable than 






How does the LMIS data aid decision making
 Resupply quantities of
pharmaceutical commodities








  Frequency Cumulative Percent 
Table 12: Preferences 
Electronic LMIS since it 
is easier to use 
5 17.2 
Electronic LMIS since its 
more efficient and 
accurate 
13 62.1 
Electronic LMIS since its 
saves time 
8 89.7 
Manual system due to 
reliability in times of 
power blackouts 
3 100 
Total 29   
Table 13: LMIS use in facilities 
Is the software 




Does the current LMIS 
make the necessary 
adjustments and 
commodity requests 
when the need arises? 
YES 72.00% 
NO 28.00% 
Is the reporting timely? 
YES 88.00% 
NO 12.00% 
Are you able to teach 




Do you and your staff 
need additional training 
on LMIS use? 
YES 94.00% 
NO 6.00% 
In your opinion is the 
LMIS system versatile? 
YES 66.00% 
NO 34.00% 
4.2.14 LMIS use in the facilities 
The respondents were asked about the LMIS use in the facilities they worked in. From the findings, 
49% of the respondents said the LMIS software was appropriate for them and to their work, 72% 
of the respondents said the current LMIS could make the necessary adjustments and commodity 
requests when need arose. 88% of the respondents said the reporting using LMIS was timely while 
70% of the respondents said they are actually able to teach other staffs on LMIS use. However, 
94% of the respondents said they needed additional training on LMIS use whereas 66% of the 
respondents said the LMIS system was versatile. This is summarized in table 13 above. 
4.2.15 Reasons for Commodity Stock-outs 
The respondents were asked to state reasons for the commodity stock-outs in their respective 
facilities. From the findings, 16% of the respondents said long lead time was the reason for the 
stock outs, 12% of the respondents said poor commodity management, poor record keeping and 
also under ordering were the reasons for the commodity stock outs. 8% of the respondents said 
poor storage was the reason for the stock outs, 4% of the respondents said County bureaucracies 
were to blame, delays in: supply delivery to facilities and disbursement of funds by county. Also 
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supply chain failures, inadequate finances for procurement of pharmaceutical commodities, poor 
commodity consumption level, poor commodity quantification by facilities, use of push system 
for donor-funded commodities by the national government and health workers’ lengthy strikes 
were the other reasons for the commodity stock outs that the county health facilities experience 
from time to time as summarized in table 14 below.  
  Frequency Cumulative Percent 
 
Table 14: Reasons for 
commodity stock outs 
County bureaucracies 2 4 
Delay in supply 2 8 
Disbursement of funds by 
county 
2 12 
Failures 2 16 
Inadequate finances 2 20 
Long lead time 8 36 
Poor consumption level 2 40 
Poor management 6 52 
Poor quantification 2 56 
Poor record keeping 6 68 
Poor storage 4 76 
Push system 2 80 
Strikes 2 84 
Transport 2 88 
Under ordering 6 100 
Total 50   
Table 15: What could be 
done to manage commodity 
stock out situations in health 
facilities 
Avail transport 2 5.7 
Better coordination between 
procurement and distribution 
staff 
2 11.4 
Better record keeping 2 17.1 
Cost sharing 1 20 
Improve drug management 2 25.7 
Local purchases 2 31.4 
Managers to ensure prompt 
orders and delivery 
2 37.1 
Proper documentation 4 48.6 
Proper quantification 2 54.3 
Re-distribution 4 65.7 
Reduce lead time 8 88.6 
Reintroduction of user fee 2 94.3 
Supply promptly 2 100 
Total 35   
Table 16: Commodities 
resupply quantities 
determination 
Pharmacist based on 
consumption 
4 22.2 
In-charge user using previous 
quarter consumption 
2 33.3 
Pharmacist using Consumption 
*4-stock count 
8 77.8 
Pharmacist using population 
and treatment conditions 
4 100 




The respondents were asked to state what could be done to manage the pharmaceutical 
commodity stock out situations in their respective facilities. From the findings, 22.9% of the 
respondents said reducing the lead time will help manage stocks out situations, 11.4% said better 
record keeping in their facilities will help manage commodity stock outs. 11.4% said commodity 
re-distribution among facilities will help manage stocks as summarized in table 15 above. 
4.2.16 Resupply quantities determination 
The respondents were asked to state who, what and how commodity resupply quantities were 
determined in their respective facilities. From the findings, 44.4% of the respondents said the 
Pharmacist was the one responsible for determining commodity quantities that were needed for 
resupply. Resupply quantities were calculated using monthly commodity consumption levels 
*3months of stock plus a month of buffer stock. 22.2% of the respondents said the Pharmacist was 
responsible and that quantities of commodities needed for resupply were calculated based on 
commodity consumption levels of the facility. 22.2% of the respondents said that the Pharmacist 
was responsibly and that commodity resupply quantities were determined based on the population 
they served (workload) and their treatment conditions. 11.1% of the respondents said that the 
facility officer in-charge was responsible for making the orders and would use previous quarter 
consumption records to make commodity orders. This is summarized in table 16 above. 
4.3. Efficient use of county funds for procurement of medicines 
4.3.1.1 Busia County Referral Hospital 2015-2016 
 

































For the year 2015-2016, total quantities of 70,164 drugs were purchased by Busia County Referral 
Hospital that amounted to a total expenditure of Kes 5,247,759. On ABC analysis, 17.43% (n=19), 
35% (n=19) and 47.57% (n=48) drugs were found to be A, B and C category items. These items 
accounted for 74.92% (Kes. 3,931,650), 15.73% (Kes. 825,325) and 9.36% (Kes. 490,784) of ADE 
of the drug store as shown in the figure 11 above and Appendix 1 respectively.  
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 40.77% 53.64% 41 2815075 
E 7.17% 3.22% 9 169225 
N 52.06% 43.13% 36 2263459 
Table 17: VEN analysis of Busia County Referral Hospital 2015-2016 
On VEN analysis, 40.77% (n=41), 7.17% (n=9) and 52.06% (n=36) drugs were found to be V, E 
and N category items and accounted for 53.64% (Kes. 2,815,075), 3.22% (Kes. 169,225) and 
43.13% (Kes. 2,263,459) of ADE of the drug store as summarized in table 17 above. 














V AV 13 BV 10 CV 18 
E AE 1 BE 0 CE 8 
N AN 5 BN 9 CN 22 
Table 18: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 41.22% 86.35% 46 4531675 
II 31.35% 9.47% 17 496810 
III 27.43% 4.18% 23 219274 
Table 19: ABC-VEN matrix analysis 2015-2016 
From ABC-VEN matrix analysis in table 18 and table 19 above, there were 46 (41.22%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 17(31.35%) items in category II 
consisting of BE, BN and CE subgroups and 23 (27.43%) items in category III consisting of CN 
subgroup. These items accounted for 86.35% (Kes 4,531,675), 9.47% (Kes. 496,810) and 4.18% 
(Kes. 219,274) of ADE of the drugs respectively.  
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4.3.1.2.Busia County Referral Hospital 2016-2017 
 
Figure 10: ABC analysis of Busia County Referral Hospital 2016-2017 
For the year 2016-2017, total quantities of 279,537 drugs were purchased by Busia County Referral 
Hospital that amounted to a total expenditure of Kes 16,123,985. On ABC analysis, 20.5% (n=29), 
54.03% (n=33) and 25.47% (n=83) drugs were found to be A, B and C category items and these 
items accounted for 68.61% (Kes. 11,062,150), 15.73% (Kes. 3.474,175) and 10.15% (Kes. 
1,636,660) of ADE of the drug store as shown in the figure 12 above and Appendix 2.  
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 27.36% 42.11% 49 6789195 
E 0.56% 0.74% 6 119250 
N 72.08% 57.15% 90 9215540 
Table 20: VEN analysis of Busia County Referral Hospital 2016-2017 
On VEN analysis, 27.36% (n=49), 0.56% (n=6) and 72.08% (n=90) drugs were found to be items 
of V, E and N categories that amounted to 42.11% (Kes. 6,789,195), 0.74% (Kes. 119,250) and 
57.15% (Kes. 9,215,540) of ADE of the drug store as summarized in table 20. 
From ABC-VEN matrix analysis in table 21 and table 22 below, there were 63 (40.67%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 31(44.67%) items in category II 
consisting of BE, BN and CE subgroups and 51 (14.66%) items in category III consisting of CN 
subgroup. These items accounted for 76.34% (Kes 12,309,195), 16.51% (Kes. 2,661,365) and 



















































V AV 12 BV 8 CV 28 
E AE 0 BE 0 CE 6 
N AN 17 BN 25 CN 49 
Table 21: ABC-VEN matrix 2016-2017 
Category % Item % ADE No of items Total Value (KSH) 
I 40.67% 76.34% 63 12309195 
II 44.67% 16.51% 31 2661365 
III 14.66% 7.15% 51 1153425 
Table 22: ABC-VEN matrix analysis 2016-2017 
4.3.2.1 Khunyangu Sub county Hospital 2015-2016 
 
Figure 11: ABC analysis of Khunyangu Sub county Hospital 2015-2016 
For the year 2015-2016, total quantities of 86,697 drugs were purchased by Khunyangu Sub-County 
Hospital that amounted to a total expenditure of Kes 5,150,445. On ABC analysis, 20.49% (n=21), 
54.34% (n=28) and 25.17% (n=74) drugs were found to be A, B and C category items that 
amounted to 71.64% (Kes. 3,689,900), 18.51% (Kes. 953,595) and 9.84% (Kes. 506,950) of ADE 
of the drug store as shown in the figure 13 above and Appendix 3.  
On VEN analysis, 36.01% (n=44), 1.01% (n=5) and 62.98% (n=74) drugs were found to be V, E 
and N category items. These items accounted for 50.93% (Kes. 2,623,290), 3.89% (Kes. 200,445) 


































Category % Item % ADE No of items 
Total Value 
(KSH) 
V 36.01% 50.93% 44 2623290 
E 1.01% 3.89% 5 200445 
N 62.98% 45.17% 74 2326710 
Table 23: VEN analysis of Khunyangu Sub county Hospital 2015-2016 
From ABC-VEN matrix analysis in table 24 and table 25 below, there were 57 (45.04%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 21(33.70%) items in category II 
consisting of BE, BN and CE subgroups and 45 (21.26%) items in category III consisting of CN 
subgroup. These items accounted for 82.03% (Kes 4,224,790), 11.76% (Kes. 605,820) and 6.21% 
(Kes. 319,825) of ADE of the drugs respectively.  
  A   B   C   
  
Combined 
category No of items 
Combined 
category No of items 
Combined 
category No of items 
V AV 9 BV 9 CV 27 
E AE 1 BE 1 CE 2 
N AN 11 BN 18 CN 45 
Table 24: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 45.04% 82.03% 57 4224790 
II 33.70% 11.76% 21 605820 
III 21.26% 6.21% 45 319835 
Table 25: ABC-VEN matrix analysis 2015-2016 
4.3.2.2 Khunyangu Sub county Hospital 2016-2017 
For the year 2016-2017, a total quantity of 21,724drug was purchased by Khunyangu Sub-County 
Hospital that amounted to a total expenditure of Kes 1,731,254. On ABC analysis, 17.08% (n=15), 
47.45% (n=17) and 35.47% (n=44) drugs were found to be A, B and C category items that 
accounted for 67.58% (Kes. 1,170,000), 23.08% (Kes. 399,640) and 9.34% (Kes. 161,614) of ADE 




Figure 12: ABC analysis of Khunyangu Sub county Hospital 2016-2017 
On VEN analysis, 19.75% (n=37), 18.64% (n=8) and 61.6% (n=31) drugs were found to be V, E 
and N category items. These items accounted for 59.86% (Kes. 1,036,305), 9.67% (Kes. 167,400) 
and 30.47% (Kes. 527,549) of ADE of the drug store as summarized in table 26. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 19.75% 59.86% 37 1036305 
E 18.64% 9.67% 8 167400 
N 61.60% 30.47% 31 527549 
Table 26: VEN analysis of Khunyangu Sub county Hospital 2016-2017 
From ABC-VEN matrix analysis in table 27 and table 28 below, there were 42 (27.58%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 13(50.97%) items in category II 
consisting of BE, BN and CE subgroups and 21 (21.45%) items in category III consisting of CN 
subgroup. These items accounted for 81.72% (Kes 1,414,805), 14.02% (Kes. 242,700) and 4.26% 
(Kes. 73,749) of ADE of the drugs respectively.  
  A   B   C   
  
Combined 
category No of items 
Combined 
category No of items 
Combined 
category No of items 
V AV 10 BV 8 CV 19 
E AE 1 BE 3 CE 4 
N AN 4 BN 6 CN 21 

































Category % Item % ADE No of items 
Total Value 
(KSH) 
I 27.58% 81.72% 42 1414805 
II 50.97% 14.02% 13 242700 
III 21.45% 4.26% 21 73749 
Table 28: ABC-VEN matrix analysis 2016-2017 
4.3.3.1 Nambale Sub County Hospital 2015-2016 
For the year 2015-2016, total quantities of 69,345 drugs were purchased by Nambale Sub-County 
Hospital that amounted to a total expenditure of Kes 3,654,197. On ABC analysis, 19.43% (n=18), 
39.69% (n=22) and 40.88% (n=70) drugs were found to be A, B and C category items that 
accounted for 67.25% (Kes. 2,457,340), 23.16% (Kes. 896,160) and 9.6% (Kes. 350,697) of ADE 
of the drug store as shown in the figure 15 below and Appendix 5.  
 
Figure 13: ABC analysis of Nambale Sub county Hospital 2015-2016 
On VEN analysis, 28.36% (n=29), 2.45% (n=3) and 69.19% (n=78) drugs were found to be V, E 
and N category items. These items accounted for 24.07% (Kes. 879,704), 0.52% (Kes. 18,840) 
and 75.41% (Kes. 2,755,653) of ADE of the drug store as summarized in table 29. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 28.36% 24.07% 29 879704 
E 2.45% 0.52% 3 18840 
N 69.19% 75.41% 78 2755653 

































From ABC-VEN matrix analysis in table 30 and table 31 below, there were 41 (35.13%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 18(38.93%) items in category II 
consisting of BE, BN and CE subgroups and 51 (25.94%) items in category III consisting of CN 
subgroup. These items accounted for 77.15% (Kes 2,819,294), 16.45% (Kes. 601,170) and 6.4% 
(Kes. 233,733) of ADE of the drugs respectively.  














V AV 6 BV 7 CV 16 
E AE 0 BE 0 CE 3 
N AN 12 BN 15 CN 51 
Table 30: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 35.13% 77.15% 41 2819294 
II 38.93% 16.45% 18 601170 
III 25.94% 6.40% 51 233733 
Table 31: ABC-VEN matrix analysis 2015-2016 
4.3.3.2 Nambale Sub county Hospital 2016-2017 
 
Figure 14: ABC analysis of Nambale Sub county Hospital 2016-2017 
For the year 2016-2017, total quantities of 15,860 drugs were purchased by Nambale Sub-County 
Hospital that amounted to a total expenditure of Kes 1,326,579. On ABC analysis, 12.42% (n=12), 

































accounted for 70.92% (Kes. 940,800), 18.68% (Kes. 247,750) and 10.4% (Kes. 138,029) of ADE 
of the drug store as shown in the figure 16 above and Appendix 6.  
On VEN analysis, 31.08% (n=18), 1.01% (n=2) and 27.91% (n=28) drugs were found to be V, E 
and N category items. These items accounted for 43.37% (Kes. 575,300), 0.47% (Kes. 6,200) and 
56.17% (Kes. 745,079) of ADE of the drug store as summarized in table 32. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 31.08% 43.37% 18 575300 
E 1.01% 0.47% 2 6200 
N 67.91% 56.17% 38 745079 
Table 32: VEN analysis of Nambale Sub county Hospital 2016-2017 
From ABC-VEN matrix analysis in table 33 and table 34 below, there were 36 (78.83%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 8(11.38%) items in category II 
consisting of BE, BN and CE subgroups and 9.37 (14%) items in category III consisting of CN 
subgroup. These items accounted for 87.3% (Kes 1,158,100), 8.9% (Kes. 118,100) and 3.8% (Kes. 
50,379) of ADE of the drugs respectively.  














V AV 5 BV 8 CV 16 
E AE 0 BE 0 CE 2 
N AN 7 BN 6 CN 14 
Table 33: ABC-VEN matrix 2016-2017 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 78.83% 87.30% 36 1158100 
II 11.38% 8.90% 8 118100 
III 9.79% 3.80% 14 50379 
Table 34: ABC-VEN matrix analysis 2016-2017 
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4.3.4.1 Port Victoria Sub county Hospital 2015-2016 
 
Figure 15: ABC analysis of Port Victoria Sub county Hospital 2015-2016 
For the year 2015-2016, a total quantity of 158,847 drugs was purchased by Port Victoria Sub-
County Hospital that amounted to a total expenditure of Kes 8,521,268. On ABC analysis, 14.18% 
(n=23), 69.86% (n=38) and 15.95% (n=83) drugs were found to be A, B and C category items 
respectively that accounted for 64.23% (Kes. 5,473,550), 25.72% (Kes. 2,191,658) and 10.05% 
(Kes. 856,060) of ADE of the drug store as shown in the figure 17 above and Appendix 7.  
On VEN analysis, 22.53% (n=48), 0.67% (n=6) and 76.8% (n=90) drugs were found to be V, E 
and N category items. These items accounted for 37.25% (Kes. 3,174,050), 3.11% (Kes. 264,600) 
and 59.65% (Kes. 5,082,618) of ADE of the drug store as summarized in table 35. 
Category % Item % ADE No of items Total Value (KSH) 
V 22.53% 37.25% 48 3174050 
E 0.67% 3.11% 6 264600 
N 76.80% 59.65% 90 5082618 
Table 35: VEN analysis of Port Victoria Sub County Hospital 2015-2016 
From ABC-VEN matrix analysis in table 36 and table 37 below, there were 63 (28.46%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 31(58.1%) items in category II 
consisting of BE, BN and CE subgroups and 13.44 (13.44%) items in category III consisting of 
CN subgroup. These items accounted for 74.87% (Kes 6,379,800), 19.43% (Kes. 1,655,908) and 
















































V AV 8 BV 10 CV 30 
E AE 1 BE 2 CE 3 
N AN 14 BN 26 CN 50 
Table 36: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items Total Value (KSH) 
I 28.46% 74.87% 63 6379800 
II 58.10% 19.43% 31 1655908 
III 13.44% 5.70% 50 485560 
Table 37: ABC-VEN matrix analysis 2015-2016 
4.3.4.2 Port Victoria Sub county Hospital 2016-2017 
 
Figure 16: ABC analysis of Port Victoria Sub county Hospital 2016-2017 
For the year 2016-2017, total quantities of 31,244 drugs were purchased by Port Victoria Sub-
County Hospital that amounted to a total expenditure of Kes 2,243,423. On ABC analysis, 13.97% 
(n=17), 46.07% (n=16) and 39.97% (n=33) drugs were found to be A, B and C category items that 
accounted for 70.76% (Kes. 1,587,400), 20.56% (Kes. 461,194) and 8.68% (Kes. 194,829) of ADE 




































Category % Item % ADE No of items 
Total Value 
(KSH) 
V 44.04% 35.16% 32 788845 
E 6.29% 15.66% 8 351400 
N 49.67% 49.17% 26 1103178 
Table 38: VEN analysis of Port Victoria Sub county Hospital 2016-2017 
On VEN analysis, 44.04% (n=32), 6.29% (n=8) and 49.67% (n=26) drugs were found to be V, E 
and N category items. These items accounted for 35.16% (Kes. 788,845), 15.66% (Kes. 351,400) 
and 49.17% (Kes. 1,103,178) of ADE of the drug store as summarized in table 38. 
From ABC-VEN matrix analysis in table 39 and table 40 below, there were 41 (48.12%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 12(32.93%) items in category II 
consisting of BE, BN and CE subgroups and 13 (18.94%) items in category III consisting of CN 
subgroup. These items accounted for 83.34% (Kes 1,869,745), 12.71% (Kes. 285,094) and 3.95% 
(Kes. 88,584) of ADE of the drugs respectively.  
  A   B   C   
  
Combined 
category No of items 
Combined 
category No of items 
Combined 
category No of items 
V AV 7 BV 6 CV 19 
E AE 3 BE 3 CE 2 
N AN 7 BN 7 CN 12 
Table 39: ABC-VEN matrix 2016-2017 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 48.12% 83.34% 41 1869745 
II 32.93% 12.71% 12 285094 
III 18.94% 3.95% 13 88584 
Table 40: ABC-VEN matrix analysis 2016-2017 
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4.3.5.1 Sio Port Sub county Hospital 2015-2016 
 
Figure 17: ABC analysis of Sio Port Sub county Hospital 2015-2016 
For the year 2015-2016, total quantities of 37,702 drugs were purchased by Sio Port Sub-County 
Hospital that amounted to a total expenditure of Kes 2,735,027. On ABC analysis, 23.48% (n=16), 
30.27% (n=23) and 46.25% (n=68) drugs were found to be A, B and C category items that 
accounted for 70.7% (Kes. 1,933,600), 19.6% (Kes. 536,100) and 9.7% (Kes. 265,327) of ADE of 
the drug store as shown in the figure 19 and Appendix 9.  
On VEN analysis, 20.9% (n=41), 6.87% (n=3) and 72.23% (n=63) drugs were found to be V, E 
and N category items that accounted for 34.79% (Kes. 951,542), 1.94% (Kes. 53,040) and 63.27% 
(Kes. 1,730,445) of ADE of the drug store as summarized in table 41. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 20.90% 34.79% 41 951542 
E 6.87% 1.94% 3 53040 
N 72.23% 63.27% 63 1730445 
Table 41: VEN analysis of Sio Port Sub county Hospital 2015-2016 
From ABC-VEN matrix analysis in table 42 and table 43 below, there were 50 (28.36%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 16(29.24%) items in category II 
consisting of BE, BN and CE subgroups and 41 (42.4%) items in category III consisting of CN 
subgroup that accounted for 80.42% (Kes 2,199,422), 13.67% (Kes. 373,960) and 5.91% (Kes. 















































V AV 7 BV 8 CV 26 
E AE 0 BE 2 CE 1 
N AN 9 BN 13 CN 41 
Table 42: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 28.36% 80.42% 50 2199442 
II 29.24% 13.67% 16 373960 
III 42.40% 5.91% 41 161625 
Table 43: ABC-VEN matrix analysis 2015-2016 
4.3.5.2 Sio Port Sub County Hospital 2016-2017 
For the year 2016-2017, total quantities of 9,155 drugs were purchased by Sio Port Sub-County 
Hospital, amounting to a total expenditure of Kes 2,735,027. On ABC analysis, 15.29% (n=5), 
24.88% (n=7) and 59.83% (n=21) drugs were found to be A, B and C category items that accounted 
for 67.59% (Kes. 461,500), 24.62% (Kes. 168,100) and 7.79% (Kes. 53,175) of ADE of the drug 
store as shown in the figure 20 and Appendix 10. 
 





























Category % Item % ADE No of items 
Total Value 
(KSH) 
V 13.26% 37.74% 9 257660 
E 0.05% 0.03% 1 225 
N 86.68% 62.23% 23 424890 
Table 44: VEN analysis of Sio Port sub county Hospital 2016-2017 
On VEN analysis, 13.26% (n=9), 0.05% (n=1) and 86.68% (n=23) drugs were found to be V, E 
and N category items. These items accounted for 37.74% (Kes. 257,660), 0.03% (Kes. 225) and 
62.23% (Kes. 424,890) of ADE of the drug store as summarized in table 44. 














V AV 2 BV 1 CV 6 
E AE 0 BE 0 CE 1 
N AN 3 BN 6 CN 0 
Table 45: ABC-VEN matrix 2016-2017 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 17.06% 70.54% 11 481650 
II 24.39% 22.46% 7 153325 
III 58.55% 7.00% 15 47800 
Table 46: ABC-VEN matrix analysis 2016-2017 
From ABC-VEN matrix analysis in table 45 and table 46 below, there were 11 (17.06%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 7(24.39%) items in category II 
consisting of BE, BN and CE subgroups and 15 (58.55%) items in category III consisting of CN 
subgroup that accounted for 70.54% (Kes 2,481,650), 22.46% (Kes. 153,325) and 7% (Kes. 
47,800) of ADE of the drugs respectively.  
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4.3.6.1 Teso North Sub county Hospital 2015-2016 
 
Figure 19: ABC analysis of Teso North Sub county Hospital 2015-2016 
For the year 2015-2016, total quantities of 177,106 drugs were purchased by Teso North Sub-
County Hospital that amounted to a total expenditure of Kes 9,491,238. On ABC analysis, 13.55% 
(n=25), 74.15% (n=43) and 12.30% (n=81) drugs were found to be A, B and C category items that 
accounted for 61.19% (Kes. 5,807,300), 28.66% (Kes. 2,720,370) and 10.15% (Kes. 963,568) of 
ADE of the drug store as shown in the figure 21 and Appendix 11.  
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 44.22% 43.44% 50 4123210 
E 3.88% 2.08% 6 196948 
N 51.90% 54.48% 93 5171080 
Table 47: VEN analysis of Teso North Sub county Hospital 2015-2016 
On VEN analysis, 44.22% (n=50), 03.88% (n=6) and 51.9% (n=93) drugs were found to be V, E 
and N category items. These items accounted for 43.44% (Kes. 4,123,210), 2.08% (Kes. 196,948) 
and 51.9% (Kes. 5,171,080) of ADE of the drug store as summarized in table 47. 














V AV 11 BV 16 CV 22 
E AE 0 BE 3 CE 3 
N AN 14 BN 24 CN 56 

































Category % Item % ADE No of items 
Total Value 
(KSH) 
I 53.17% 76.05% 63 7218490 
II 38.23% 17.28% 30 1640128 
III 8.60% 6.67% 56 632620 
Table 49: ABC-VEN matrix analysis 2015-2016 
From ABC-VEN matrix analysis in table 48 and table 49 below, there were 63 (53.17%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 30 (38.23%) items in category II 
consisting of BE, BN and CE subgroups and 56 (8.60%) items in category III consisting of CN 
subgroup and accounted for 76.05% (Kes 7,218,490), 22.46% (Kes. 1,640,128) and 6.67% (Kes. 
632,620) of ADE of the drugs respectively.  
4.3.6.2 Teso North Sub county Hospital 2016-2017 
 
Figure 20: ABC analysis of Teso North Sub county Hospital 2016-2017 
For the year 2016-2017, total quantities of 29,297 drugs were purchased by Teso North Sub-County 
Hospital that amounted to a total expenditure of Kes 2,994,421. On ABC analysis, 18.65% (n=14), 
36.77% (n=18) and 44.4% (n=49) drugs were found to be A, B and C category items that accounted 
for 68.6% (Kes. 2,048,300), 22.25% (Kes. 666,380) and 31.6% (Kes. 946,121) of ADE of the drug 
store as shown in the figure 22 and Appendix 12.  
On VEN analysis, 36.57% (n=36), 7.75% (n=8) and 55.67% (n=37) drugs were found to be V, E 
and N category items. These items accounted for 65.68% (Kes. 1,966,850), 2.34% (Kes. 69,945) 

































Category % Item % ADE No of items 
Total Value 
(KSH) 
V 36.57% 65.68% 36 1966850 
E 7.75% 2.34% 8 69945 
N 55.67% 31.98% 37 957626 
Table 50: VEN analysis of Teso North Sub county Hospital 2016-2017 
From ABC-VEN matrix analysis in table 51 and table 52 below, there were 40 (46.15%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 18 (24.18%) items in category II 
consisting of BE, BN and CE subgroups and 23 (29.67%) items in category III consisting of CN 
subgroup. These items accounted for 82.57% (Kes 2,472,350), 12.51% (Kes. 374,525) and 4.93% 
(Kes. 147,546) of ADE of the drugs respectively.  














V AV 14 BV 8 CV 19 
E AE 0 BE 1 CE 7 
N AN 0 BN 9 CN 23 
Table 51: ABC-VEN matrix analysis 2016-2017 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 46.15% 82.57% 40 2472350 
II 24.18% 12.51% 18 374525 
III 29.67% 4.93% 23 147546 
Table 52: ABC-VEN matrix analysis 2016-2017 
4.3.7.1 Teso South Sub county Hospital 2015-2016 
 





























For the year 2015-2016, total quantities of 191,639 drugs were purchased by Teso South Sub-
County Hospital that amounted to a total expenditure of Kes 9,892,058. On ABC analysis, 13.89% 
(n=23), 55.92% (n=33) and 30.19% (n=78) drugs were found to be A, B and C category items 
respectively and accounted for 63.04% (Kes. 6,235,550), 26.57% (Kes. 2,628,078) and 10.4% 
(Kes. 1,028,430) of ADE of the drug store as shown in the figure 23 and Appendix 13.  
On VEN analysis, 42.61% (n=47), 1.43% (n=6) and 55.96% (n=81) drugs were found to be V, E 
and N category items. These items accounted for 30.14% (Kes. 2,981,835), 3.23% (Kes. 319,700) 
and 66.62% (Kes. 6,590,523) of ADE of the drug store as summarized in table 53. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 42.61% 30.14% 47 2981835 
E 1.43% 3.23% 6 319700 
N 55.96% 66.62% 81 6590523 
Table 53: VEN analysis of Teso South Sub county Hospital 2016-2016 
From ABC-VEN matrix analysis in table 54 and table 55 below, there were 62 (52.47%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 26 (39.11%) items in category II 
consisting of BE, BN and CE subgroups and 46 (8.42%) items in category III consisting of CN 
subgroup. These items accounted for 75.19% (Kes 7,437,885), 18.4% (Kes. 1,820,228) and 6.41% 
(Kes. 633,945) of ADE of the drugs respectively.  














V AV 7 BV 11 CV 29 
E AE 1 BE 1 CE 4 
N AN 15 BN 21 CN 45 
Table 54: ABC-VEN matrix 2015-2016 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 52.47% 75.19% 62 7437885 
II 39.11% 18.40% 26 1820228 
III 8.42% 6.41% 46 633945 
Table 55: ABC-VEN matrix analysis 2015-2016 
4.3.7.2 Teso South Sub county Hospital 2016-2017 
For the year 2015-2016, total quantities of 17,726 drugs were purchased by Teso South Sub-
County Hospital that amounted to a total expenditure of Kes 1,099,415. On ABC analysis, 17.43% 
(n=9), 16.89% (n=12) and 65.68% (n=22) drugs were found to be A, B and C category items that 
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accounted for 68.87% (Kes. 757,190), 21.34% (Kes. 234,636) and 9.79% (Kes. 107,589) of ADE 
of the drug store as shown in the figure 24 and Appendix 14.  
 
Figure 22: ABC analysis of Teso South Sub county Hospital 2016-2017 
On VEN analysis, 28.55% (n=21), 0.62% (n=2) and 70.83% (n=24) drugs were found to be V, E 
and N category items. These items accounted for 37.32% (Kes. 410,356), 1.17% (Kes. 12,900) 
and 61.5% (Kes. 676,159) of ADE of the drug store as summarized in table 56. 
Category % Item % ADE No of items 
Total Value 
(KSH) 
V 28.55% 37.32% 21 410356 
E 0.62% 1.17% 2 12900 
N 70.83% 61.50% 20 676159 
Table 56: VEN analysis of Teso South Sub county Hospital 2016-2017 
From ABC-VEN matrix analysis in table 57 and table 58 below, there were 27 (45.11%) items in 
category I consisting of AV, AE, AN, BV and CV subgroups, 6 (7.76%) items in category II 
consisting of BE, BN and CE subgroups and 10(47.13%) items in category III consisting of CN 
subgroup. These items accounted for 85.25% (Kes 937,296), 9.12% (Kes. 100,300) and 5.62% 


















































V AV 3 BV 7 CV 11 
E AE 0 BE 1 CE 1 
N AN 6 BN 4 CN 10 
Table 57: ABC-VEN matrix 2016-2017 
Category % Item % ADE No of items 
Total Value 
(KSH) 
I 45.11% 85.25% 27 937296 
II 7.76% 9.12% 6 100300 
III 47.13% 5.62% 10 61819 
Table 58: ABC-VEN matrix analysis 2016-2017 
4.4 Human Resource for Health for Pharmaceutical Supply Chain Management 
4.4.1 Officer, solely responsible for supply chain management 
 
 
Figure 23: Officer, solely responsible for supply chain management 
The respondents were asked to indicate the officer solely responsible for supply chain management 
in the facility. From the findings, 44% said that nurses were responsible, 42% said that pharmacists 
were responsible while 14% said that pharmaceutical technologists were responsible as shown in 
figure 25 above. 
4.4.2 Staff training on supply chain management  
The participants were asked to indicate the number of trained staff and the number of staff who 










after their administration. From the findings, at least 1 pharmacist, 1 pharmaceutical technologists, 
and 2 nurses were trained on inventory management practices. At least 1 pharmacist, 1 
pharmaceutical technologists and 1 nurse were trained on rational drug use as summarized on table 
59 below. 
    N Mean 
 
Table 59: Trained 
staff on supply chain 
management 
How many Pharmacists in the facility are trained on Inventory 
management practices 
50 1.16 
How many Pharmaceutical Technologists in the facility are trained on 
Inventory management practices 
50 1.12 
How many Nurses in the facility are trained on Inventory management 
practices 
50 1.48 
How many Pharmacists in the facility are trained on Rational drug use 50 1 
How many Pharmaceutical Technologists in the facility are trained on 
Rational drug use 
50 0.96 
How many Nurses in the facility are trained on Rational drug use 50 1 
How many Pharmacists in the facility are trained on Quantification 50 0.76 
How many Pharmaceutical Technologists in the facility are trained on 
Quantification 
50 0.88 
How many Nurses in the facility are trained on Quantification 50 0.92 
How many Pharmacists in the facility are trained on Forecasting 50 0.76 
How many Pharmaceutical Technologists in the facility are trained in 
Forecasting 
50 0.8 
How many Nurses in the facility are trained on Forecasting 50 0.92 
How many Pharmacists in the facility are trained in Supply chain planning 
and mapping 
50 0.16 
How many Pharmaceutical Technologists in the facility are trained in 
Supply chain planning and mapping 
50 0.08 
How many Nurses in the facility are trained in Supply chain planning and 
mapping 
50 0.16 
How many of the Pharmacists are able to report on sub-standard 
commodities as well as patient side effects from medicines after their 
administration? 
50 0.76 
How many of the Pharmaceutical Technologists are able to report on sub-
standard commodities as well as patient side effects from medicines after 
their administration? 
50 0.88 
How many of the Nurses are able to report on sub-standard commodities 
as well as patient side effects from medicines after their administration? 
50 1.68 




Are Yellow form reporting forms available at the facility? Pharmacists YES 76.00% 
  NO 24.00% 
Are Yellow form reporting forms available at the facility? Pharmaceutical 
Technologists 
YES 28.00% 
  NO 72.00% 
Are Yellow form reporting forms available at the facility? Nurses YES 44.00% 
  NO 56.00% 
Are Pink form reporting forms available at the facility? Pharmacists YES 16.00% 
  NO 84.00% 
Are Pink form reporting forms available at the facility? Pharmaceutical 
Technologists 
YES 16.00% 
  NO 84.00% 
Are Pink form reporting forms available at the facility? Nurses YES 4.00% 
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  NO 96.00% 
Are Alert card reporting forms available at the facility? Pharmacists YES 44.00% 
  NO 56.00% 
Are Alert card reporting forms available at the facility? Pharmaceutical 
Technologists 
YES 8.00% 
  NO 92.00% 
Are Alert card reporting forms available at the facility? Nurses YES 20.00% 
  NO 80.00% 
Table 61: SMC 
training 
Are SCM training conducted in the county done to your satisfaction? 
Pharmacists 
YES 44.00% 
  NO 56.00% 
Are SCM training conducted in the county done to your satisfaction? 
Pharmaceutical Technologists 
YES 16.00% 
  NO 84.00% 
Are SCM training conducted in the county done to your satisfaction? 
Nurses 
YES 8.00% 
  NO 92.00% 
 
From table 59 above, at least 1 pharmacist, 1 pharmaceutical technologists and 1 nurse were trained 
on pharmaceutical commodity quantification. At least 1 pharmacist, 1 pharmaceutical 
technologists and 1 nurse were trained on pharmaceutical commodity forecasting. At least 1 
pharmacist, 1 pharmaceutical technologists and 1 nurse were trained on supply chain planning and 
mapping and at least 1 pharmacist, 1 pharmaceutical technologists and 1 nurse were able to report 
on sub-standard commodities as well as patient side effects from medicines after their 
administration. 
4.4.3 Reporting forms 
The participants were asked whether pharmacovigilance reporting forms were available in the 
facilities. From the findings, 76% of pharmacists, 28% of pharmaceutical technologists and 72% 
of nurses said that Yellow forms were available at the facility. 84% of pharmacists, 84% of 
pharmaceutical technologists and 96% of nurses said that Pink forms was available at the facility 
and 56% of pharmacists, 8% of pharmaceutical technologists and 20% of nurses said that Alert 
cards were available at the facility. This is summarized in table 60 above 
4.4.4 SCM training 
The participants were also asked whether SCM training conducted in the county was done to their 
satisfaction. From the findings, 44% of pharmacists, 16% of pharmaceutical technologists and 8% 
of nurses said the SCM training were conducted in the county to their satisfaction as shown in 
table 61 above.  
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The participants were asked about their opinion on what needs to change on how SMC trainings 
were being conducted in the county. From the findings, 22% of the respondents said there was 
need more trainings on commodity management, 17% of the respondents said rotational training 
among the staff should be enforced, 17% of the respondents said that participation of lower-level 
officers should be included in the training, 11% of the respondents insisted on the inclusion of 
other cadres whereas 11% of the respondents said the training should be made more frequent as 
shown in figure 26 below. 
 
Figure 24: Opinion on what needs to change in SMC training 
4.4.5 Reference materials 
The respondents were asked about the reference materials in their facilities. From the findings, 
32% of the respondents said they had the Drug Formulary, 40% of the respondents said they had 
the Essential Medicines List, 40% of the respondents said they had the Standard Treatment 
Guidelines in their facilities. 56% of the respondents said they had all the Pharmacovigilance tools 
available in their facilities and 48% of the respondents said they had the Pediatric Treatment 











Opinion on what needs to change in 
SCM training
Include other cadres in SMC
trainings
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level facilities
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 Count Column N % 
Do you have the Drug Formulary reference materials 
you need to perform your departmental duties 
optimally? 
YES 16 32.0% 
NO 34 68.0% 
Do you have the Essential Medicines List reference 
materials you need to perform your departmental 
duties optimally? 
YES 20 40.0% 
NO 30 60.0% 
Do you have the Standard Treatment Guidelines 
reference materials you need to perform your 
departmental duties optimally? 
YES 20 40.0% 
NO 30 60.0% 
Do you have the Pharmacovigilance tools reference 
materials you need to perform your departmental 
duties optimally? 
YES 28 56.0% 
NO 22 44.0% 
Do you have the Pediatric treatment protocols 
reference materials you need to perform your 
departmental duties optimally? 
YES 24 48.0% 
NO 26 52.0% 
Table 62: Reference materials 
4.4.6 Standard Operating Procedures 
The respondents were asked whether the facilities had all the Standard Operating Procedures. From 
the findings, 80% of the respondents said they had Standard Operating Procedures for Good 
Storage Practices while 72% of the respondents said they had Standard Operating Procedures for 
Good Dispensing Practices. 72% of the respondents said they had Standard Operating Procedures 
for Good Inventory Management Practices. This is summarized in table 63 below. 
 Count Column N % 
Do you have Standard Operating Procedures for 
Good storage practices 
YES 40 80.0% 
NO 10 20.0% 
Do you have Standard Operating Procedures for 
Good dispensing practices 
YES 36 72.0% 
NO 14 28.0% 
Do you have Standard Operating Procedures for 
Good inventory management practices 
YES 36 72.0% 
NO 14 28.0% 
Table 63: Standard operating procedures 
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4.4.10 SCM activity 
The respondents were asked what activity of SCM they were particularly involved in. From the 
findings, 60% of the respondents said they were involved in commodity quantification while 24% 
of the respondents said they were involved in product selection. 8% of the respondents said they 
were involved in commodity procurement whereas 8% of the respondents said they were only 
involved in commodity distribution as shown in figure 28 below. 
 
Figure 25: SMC activity 
The respondents were asked to comment on the decisions they make for activity of SCM they were 
responsible for. From the findings, 48% of the respondents make patient summary reports that 
determine the order quantities, 26% of the respondents determine order quantities and what 
quantities to redistribute to other facilities, 17% of the respondents said they were involved in Both 
product selection and redistribution activities and 9% of the respondents said they ensure ethical 
process is followed during ordering process as shown in figure 29. 
The respondents were asked about their opinions on what needed to change on how SCM was 
handled in the county. From the findings, 30% of the respondents said the lead time should be 
reduced, 26% of the respondents said the push system should be eliminated and 22% of the 
respondents said the procurement process needed to change. 15 of the respondents said the 












and more training on supply chain management should be provided. This is summarized in figure 
30 below. 
 
Figure 26: Decision you normally make for the activity you are responsible for 
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CHAPTER FIVE: DISCUSSIONS 
5.1 Logistic Management Information System (LMIS) 
There is enough evidence from the findings according to table 7 that the LMIS reports and orders 
were always submitted to the relevant departments on time and that the data that was being 
submitted was normally accurate and complete. Emergency orders were rarely placed in the county 
health facilities, hence the buffer stock level were not really affected in Busia County. 
According to table 8, reliable means of transport were used to ferry commodities to the facilities 
hence there was no threat to the delivery of essential supplies to respective SDPs in Busia County. 
However, according to figure 7, most of the facilities had a lead time of more than a quarter and 
experienced long delays in delivery of essential supplies to their respective SDPs.   
According to table 9, most health facilities in Busia County are connected to the electricity and 
some embraced electronic management tools for commodity management. However only 17.8% 
of the facilities were using current commodity management software. This could be due to most 
of the staff not being trained on LMIS use according to table 10 and also because only 22% of the 
facilities were connected to the internet which could be a barrier to effective supply chain 
management. 49% of the respondents according to table 12 said that the LMIS was appropriate for 
them and for their use in their facilities, 70% said they could teach other members of staff how to 
use the LMIS. But only 17.2% of the respondents said that the LMIS was easy to use whereas 94% 
of the respondents said that they still needed more training on the LMIS aspect. 
5.2 Efficient use of funds for procurement of medicines 
 5.2.1 ABC Analysis 
From the ABC analyses of the seven hospitals, class A items consisting of about 10% of the items 
consumed 70% of the ADE while class C consisting of 70% of the items consumed only 10% of 
the ADE. Class A medicines are the “important few” while class C items are the “trivial many”. 
Therefore, class A items are supposed be actively managed while class C items should be passively 
managed if supply chain resources are to be used efficiently. Class B consisting of 18% of the 
number of items consumed 20% of the ADE these should be managed by exception. 
As seen from the analysis of medical expenditure done at Muhimbili National Hospital in Tanzania 
by Tumaini (2013), the analysis produced similar results to the ones for Busia County. In the study, 
class A items consisting 10.5% of the number of items consumed 69.5% ADE. Class B items 
consisting of 18% of the number of items consumed 20.7% of the ADE and class C items 
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consisting of 71.3% of the items consumed 10% of the ADE. The study recommended that class 
A items being few and expensive require close day to day control. While class B and C need 
regular and infrequent reviews respectively. Devnani, Gupta, and Nigar in a study of a tertiary care 
teaching, research and referral institute in India in 2010 also found similar results. In their ABC 
analysis classes, A, B, and C consisting of 14%, 22%, and 64% respectively consumed 70%, 20% 
and 10% of the ADE respectively. Abate (2012) in the analysis of medicines inventory at Black 
Lion Hospital in Ethiopia got different results. In his study, Class A items were found to only 
represent 1.3 % of the items but 79% of the budget. 
ABC analysis helps us to use supply chain management resources efficiently. In this case, by 
controlling only 10% of the items one is able to effectively manage 70% of the budget. But the 
one major limitation of ABC analysis is that it only gives importance to cost and demand attributes 
of the items during grouping. In a hospital setting, there may be low budget essential medicines 
that are either cheap in price or rarely used but are lifesaving. When using ABC analysis these 
items may fall in class B or C items hence they will not be effectively managed. Therefore, ABC 
analysis on its own is not enough for management of medicines in a hospital setting and there is 
therefore need for additional methods of medicines management to be considered or employed. 
5.2.2 VEN Analysis 
In the VEN analysis study of the seven hospitals, about 20% of the items in the essential medicines 
list were considered to be vital and accounted for about 40% of the ADE. Essential items were 
about 40% and Non-essential items were about 40% of the items and consumed about 40% and 
20% of the ADE respectively. Comparison with similar studies shows high variation in the 
percentages of vital essential and non-essential items. Tumaini’s (2012) study at Muhimbili 
National Hospital showed that only 50% of items were vital. 62% and 3% of the items were 
considered to be essential and non-essential respectively. On the other hand Devnani, Gupta, and 
Nigar (2010) in their study of a tertiary care teaching, research and referral institute in India 
showed that only 12% of their medicines were considered to be vital, 59% were essential and 29% 
were non-essential. This is because the VEN classification is subjective and different institution 
have different service profiles for this classification. 
The main purpose of VEN analysis is to make sure critical items are available at all times. The 
vital items are an absolute necessity for the proper functioning of the institution and are therefore 
prioritized in the pharmaceutical supply chain. In this study, if VEN analysis is considered on its 
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own it would enable effective management of all vital items - 60% of the items accounting for 
80% of the budget. This would be better in management in terms of criticality factor as it will help 
manage all vital items but considering the cost factor, it would effectively manage 80% of the 
budget as compared to ABC analysis which would only effectively manage 70% of the budget. A 
combination of both classification methods that take into account both criticality and the cost factor 
would be better to employ in a county hospital setting. 
5.2.3 ABC-VEN Matrix Analysis 
In a combination with both ABC and VEN analysis, both cost and criticality factors are taken into 
account. In a combination of ABC and VEN analysis, the resultant matrix makes it possible for 
health institutions to actively manage about 20% items belonging to category I, because they are 
either expensive or vital. The annual expenditure of these items as per the research was 75% of 
ADE of the pharmacy. 
AV, AE and BV subgroups of category I are considered to be expensive items and their being out 
of stock in a health facility is unacceptable as they are either vital or essential. To prevent locking 
up of capital due to these items, low buffer stock needs to be maintained while keeping a strict 
vigil on the consumption level and the stock on hand. From the total cost analysis, purchasing costs 
are mostly fixed costs and low buffer stocks can be maintained by increasing frequency of ordering 
from the current quarterly orders to bimonthly or monthly orders, but with great consideration of 
the lead times. A two-bin method of ordering needs to be followed for these as this will reduce the 
risk of stock outs. 
CV items are drugs of low cost but are of high criticality. Because this amount is small, these items 
can be procured once or twice a year as opposed to current quarterly procurement. This is because 
the items in this category have relatively low holding cost and would therefore not increase the 
total of inventory holding costs. 
Items of category I, are considered to be both expensive and non-essential. The item in AN 
subgroup should be considered for removal from the essential medicines list so as to save costs 
and if not removed, items in this subgroup should be carefully monitored for rational use to prevent 
wastage. 
The items in category II are those that can be ordered once or twice a year, thereby saving on 
purchasing costs. But since purchasing costs are mostly fixed costs, no saving will really be made. 
All in all, quarterly ordering method for category II items should be maintained. 
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Though the items in category III have low holding cost from the analysis done, the purchasing cost 
is fixed, therefore reducing the frequency of purchases of this category of items will not reduce 
the total pharmaceutical cost but increasing the frequency of ordering will surely reduce the 
holding costs. For these category of items, the current quarterly ordering should be maintained. 
Similar studies showed comparable results. In the Devnani, Gupta, and Nigar (2010) study, 
category II items consisted of 54.63% of items that consumed 74.21% of the budgetary allocation 
of a tertiary teaching research and referral hospital in India. Category II items consisted of 23.38% 
of items that consumed 23.23% of the budget, while category III items consisted of 23.38% of the 
items that consumed 3.56% of the budgetary allocation of that particular hospital. 
5.3 Staff Training on Supply Chain Management and personnel staffing levels 
According to table 55, at least 1 pharmacist, 1 pharmaceutical technologists and 1 nurse were 
trained in inventory management practices, rational drug use, product quantification and 
forecasting and supply chain planning and mapping. This indicated that there was a shortage of 
trained pharmacy personnel in Busia County which could hinder access to medicine (Lubinga et 
al., 2014). According to figure 57, the trainings were not conducted to the satisfaction of the health 
care staff in Busia County. 
There was enough evidence according to figure 25 of inadequate staffing personnel as nurses were 
the ones who were mostly responsible for supply chain management in most of the health facilities. 
MOH HIS Annual Report (2012) pointed out that the number of pharmaceutical personnel in 
Kenya stood at 510 and that of nurses was 20371 respectively. In the same year another report, 
The Economic Survey (2012) stated that for every 100,000 populations there were 20 doctors, 6 
pharmacists, and 155 nurses.  All these cadres are vital as they are involved in the efficient 
management of the supply chain either directly or indirectly. Most of the facilities did not have the 
reference materials needed to perform departmental duties optimally according to table 61, which 









CHAPTER SIX: SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
6.1 Introduction  
This chapter presents a summary of the research project findings, conclusions, and 
recommendations of the study. 
6.2 Summary of the findings 
This research paper aimed at identifying areas for health system performance improvement with 
regards to the pharmaceutical commodity supply chain in Busia County. The research objectives 
formulated were: 
1. To determine the efficiency of the Logistics Management Information System (LMIS) in Busia 
County in serving her needs.  
2. To determine whether the county funds allocated for procurement of medicines are efficiently 
used. 
3. To determine whether the staff  managing the pharmaceutical supply chain system are well 
trained and of the right number. 
The study sites were Busia County health institutions, namely the County Health office, the county 
store, the seven sub-county hospitals, nine health centers, sixteen dispensaries, both government 
sponsored and faith-based ones and also one private hospital that receives pharmaceutical 
commodities from the government, due to the fact that one of the sub counties did not have a faith-
based dispensary or health centre. Staff that participated in this research are the ones who manage 
pharmaceutical commodity supply chain in their respective facilities and also those that make 
decisions at the county level. The respondents were: three personnel from the county level, 24 
pharmacy personnel, 2 clinical officers and 26 nursing personnel. Data was collected from the 
main hospital pharmacies, hospital pharmacy stores, Comprehensive Care Clinic (CCC) 
pharmacies, the county store and the county health office at the county department of health 
headquarters. The data collection methods used were qualitative approach where observation and 
questionnaires were used to record key competency gaps of staff who use LMIS optimally at their 
workstations. In-depth interview using an interviewers guide were administered to county staff 
who make decisions regarding budgetary allocation for health.  Self-administered questionnaires 
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were also administered in order to get information from staff who manage hospital pharmaceutical 
supply chain at different facility levels. For quantitative approach, ABC and VEN analysis were 
done so as to find out if the budgetary allocation for health was efficiently being used or not. 
6.2.1 The Logistics Management Information System 
From the analysis the current LMIS system in Busia County is not adequate and efficient enough 
to manage the needs of the county as seen from the respondents’ reviews. From this study, 60% of 
the respondents stated that the LMIS system aided them in decision making with regard to the 
proper management of the pharmaceutical commodity supply chain. 70% of the respondents 
reported that they were able to teach their fellow staff on LMIS use whereas 72% of the 
respondents reported that they preferred the LMIS since it could make the necessary commodity 
adjustments that the facilities needed from time to time. However only 49% of the respondents 
stated that the software was appropriate for them and for their work and 94 % of the respondents 
further stated that they needed additional training on LMIS use. The county should put this into 
consideration, so as to enable proper functioning of the supply chain system in the county. The 
county should also consider to upgrade lower level facilities to use computerized electronic method 
of inventory management and reporting from the current manual one. This would go a long way 
to ensure timely reporting and proper control of inventory, hence improve supply chain 
management in Busia County. 
There was enough evidence from the findings that the reports and orders were submitted to the 
relevant departments on time and that the LMIS data submitted is normally accurate and complete. 
Reliable means of transport were used to ferry commodities to the facilities hence there is no threat 
to the delivery of essential supplies to their respective SDPs. However, most of the facilities had 
experienced rather long lead time of up to more than a quarter and also experienced delays in 
delivery of essential supplies to their respective SDPs.  
In as much as most of the higher level health facilities in Busia County were connected to 
electricity and embraced electronic management tools for commodity management, most of them 
were not using current commodity management software and also most of the facilities were not 
connected to the internet which could be a barrier to effective supply chain management. 
6.2.2 Efficient use of funds for procurement of medicines 
ABC and VEN analysis that were done in this study proved that category A, B and C items 
consumed 70%, 20% and 10% of the hospitals Annual Drug Expenditure (ADE) respectively. This 
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showed that funds allocated to procurement of medicines were utilized as efficiently as they were 
supposed to be. Despite this, the sub county budgetary allocation with the exception of the Busia 
County Referral Hospital declined in the 2016/2017 FY as compared to 2015/2016 FY. Quantities 
of medicines purchased for the 2016/2017 FY also reduced drastically as compared to 2015/2016 
FY. This showed that the budgetary allocation was reduced, resources were probably scarce and 
therefore the County Referral Hospital had to be given priority over the other facilities in terms of 
resource allocation for procurement of medicines. 
The research showed that use of ABC analysis alone for drug inventory in Busia county would 
help to effectively control about 10% of items that fall in the A category, which consumes about 
70% of ADE of the hospital drug store, but it would also compromise the availability of vital items 
that fall in B and C categories. In the same way, use of VEN analysis alone would be ideal and 
could enable control to be exercised on the identified vital and/or essential items that account for 
80% of the hospitals ADE. However, category A also contains desirable items which cannot be 
ignored completely. The combination of ABC and VEN analysis forms a matrix, which makes it 
possible to focus on about 10% of the items belonging to category I items, which need strict 
managerial control as these items are either expensive or vital. The annual expenditure of these 
items is about 70% of ADE of the hospital budget. 
6.2.3 Personnel staffing levels and training on supply chain management 
This study revealed that 44% of the respondents reported that the nursing officer in-charge was 
solely responsible for SCM of pharmaceutical commodities in their respective facilities. This 
figure is much higher than that of the 42% and 18% of respondents and who reported that the 
pharmacists and pharmaceutical technologists were responsible for supply chain management, a 
task that pharmacy staff should be managing. This is brought about by the inadequate number of 
pharmacy personnel in the county.  
According to the Kenya Human Resource for Health Staffing Norms (Ministry of Health, 2014), 
a county referral hospital should have 21 pharmacy personnel: 11 pharmacists and 10 
pharmaceutical technologists, a sub county hospital should have 6 pharmacists and 8 
pharmaceutical technologists, a health centre should have a pharmacist and 3 pharmaceutical 
technologist and a dispensary a pharmaceutical technologist. This is not so in Busia County as the 
personnel staffing does not meet these norms. For instance, sub-county facilities have 4 pharmacy 
personnel each instead of 14 personnel as per the Human Resource Staffing Norms.  County should 
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consider employing more pharmacy staff so as to minimize or eliminate task shifting by other 
cadres especially the nursing one, which would in turn lead to patients receiving quality care as 
personnel would concentrate on what they were actually trained and equipped to do. When 
calculated from the norms, Busia County needs 225 pharmacy personnel to manage 
pharmaceutical services from level 2 to level 5 health facilities, which when compared to the 53 
staff on head count, both old and newly employed by partners and the county government, the 
number is totally inadequate.  
Staff training on supply chain management in Busia County was reported to be inadequate as the 
training is cadre-specific, so not all health personnel who manage the supply chain in the various 
county health facilities are trained on all aspects of supply chain management. From this study, 
only 44% of pharmacists, 16% of pharmaceutical technologists and only 8% of nurses reported 
that they were satisfied with how the supply chain management trainings were being conducted in 
the county. The county should look into training of staff on supply chain management for 
pharmaceutical commodities and improve the training content so that all personnel involved in 
supply chain management can understand all aspects of it and improve its performance.  
Most of the health facilities reported not having vital reference materials needed to perform 
departmental duties optimally which could compromise quality patient care. Also most of the 
respondents reported that they lacked vital tools, reference materials, lacked basic amenities and 
infrastructure that were needed for them to perform optimally. The long lead times that the health 
facilities experience as reported by 24% of the respondents to be more than a three months more 
often interfered with service delivery of health personnel to the population. The county should 
address the long lead times that county health facilities experience so that health personnel can 
perform their duties to the population optimally.  
6.3 Conclusions  
Availability of an efficient Logistics Management Information System, efficient use of county 
funds for procurement of medicines, adequate staffing levels and adequate training of health 
personnel who manage the supply chain are key to Busia County achieving an efficient and 




6.4 Recommendations  
6.3.1 The Logistics Management Information System (LMIS) 
For organization and effectiveness, supply chain interventions need the active participation of 
stakeholders, an efficient LMIS, good inventory management practices and political goodwill from 
the government. Increasing funding for health care will allow for more research and development 
of a more comprehensible LMIS which will in turn enable sustainability of supply chain 
management system. An efficient LMIS is a necessity for the county to adopt in order to achieve 
an effective supply chain management system which would help minimize waste and inefficiencies 
in the system and by so doing, better health care standards in Busia County.  
In order to achieve efficiency in her hospitals, Busia County should embrace technology and 
upgrade their current drug inventory system. Staff should also be trained on good inventory 
management practices so as to improve their skills, and also on the LMIS so as to enable good 
inventory practices being employed in the facilities, since it is through proper inventory 
management that savings in total inventory cost can be made. 
6.3.2 Effective use of county funds for procurement of medicines 
 On Annual Drug Expenditure, use of ABC analysis alone, which is based on monetary value and 
use, is not a good measure for inventory management as some items that have low monetary value 
are vital and their importance can be disregarded simply because they are not category A items 
(Wandalkar et al., 2013). Criticality of drugs is also important and should be put into consideration 
(Mohamed & Ahmed, 2016). Efficient and effective inventory management is achieved when 
ABC is used in combination with VEN analysis (Anand et al., 2013), as it is more cost-effective 
and minimalizes stock out incidences of vital medicines. 
6.3.3 Personnel staffing levels and training on supply chain management 
Addressing human resource for health shortage currently being experienced in the county will go 
a long way to improve supply chain management processes and inventory management practices 
and will also enhance smooth flow of information within the supply chain, leading to improved 
access to essential medicines by the population and good health outcomes.  
Addressing human resource for health shortage will also improve the flow of logistics information, 
enable good inventory management and efficiency of the supply chain management as a whole. It 
will, in turn, lead to good health outcomes brought about by improved access to medicines. In an 
effort to reduce staff shortage, the county government should employ the unemployed health 
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workers according to the Human Resource for Health staffing norms with an emphasis on the right 
skill mix so as to be able to minimize or eliminate task shifting of health personnel. 
The county should embrace a more efficient supply chain that is being managed by better-trained 
personnel in order to improve access to health care in poor resource settings. This can be achieved 
through more trainings that incorporates all cadres and by employing more pharmacy personnel 
so that supply chain system is effectively managed in the county.  
Training needs gaps on supply chain management should be addressed to enable efficient 
management of commodities in health facilities. This can be made possible through increasing 
funding for health care as that would enable the much-needed capacity building and supply chain 
training for staff in the county. Training content should also be looked into as most staff are 
currently not satisfied with how the trainings are done or with the training content itself  
6.4 Limitations of the study 
The accuracy of the study was dependent on the quality of the data used. The different public 
hospitals use both the manual and electronic systems of documentation putting into question the 
accuracy of some of the data gathered using the manual system. There were also a few comparable 
studies to compare with especially on the Logistic Management Information System (LMIS) and 
Human Resource for Health for Pharmaceutical Supply Chain Management.   
To identify matters affecting the supply chain management and service delivery at county level, 
interviews were conducted with 5 officers. Since only two senior county officers were willing to 
participate in this research, interviews were conducted with three other officers who fill in for 
county officers from time to time to fill that gap. 
A few sub counties did not have a faith-based organization dispensary or personnel in the facility 
had not worked in that particular facility for more than a year. In that situation, the study site was 
moved to a low volume faith-based organization health centre or a nursing home in the same sub 
county. 
6.5 Recommendations for further research 
The study was done in one county in few selected facilities. Further studies should include more 
study sites. Variables such as commodity pricing used by different pre-qualified county suppliers 
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need to be studied in order to give us more understanding of pharmaceutical commodities supply 
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Annex 1: Questionnaire on Logistics Management Information Systems (LMIS)  
The questionnaire will be issued to Pharmacy Personnel and Nurses who help manage the 
Pharmaceutical Supply Chain. The questionnaire will be used to address RQ1: “Is the existing 
Logistics Management Information System sufficiently robust to serve the needs of Busia 
County?” 
Background: The hospitals, health centres and dispensaries in Busia County can be considered 
as microcosm of the larger health system in the county, sharing many of the same problems and 
concerns. The flow, quality and quantity of information available in these facilities are vital 
aspects of a drug management information system, the LMIS, in the county, and they can only be 
as strong as its weakest components. The following tool will be used to evaluate performance of 
the LMIS in this facility.  
No. Questions Response Comments 
01 Cadre of the interviewee 
 
  
02 Number of years you have worked 
in this station 
 
Years:   
03 Who is the officer responsible for 






(iii) Nursing officer 
in-charge 




1. Good Inventory Management Practices  




01 Do you regularly use the following 
documents to manage the supply 
chain? 
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(i) Counter issue and requisition 
forms 
(ii) Stock control cards 
(iii) Daily activities register 
(iv) Antibiotic register 
(v) Insulin register 
(vi) Register for controlled 
substances 
02 What LMIS forms do you use for 
ordering and reporting on 
commodity management? 
(i) Country-specific 
(ii) Others (specify) 
   
03 Are the LMIS forms always 
available for facility use during 
reporting or ordering process? If not, 
state how long your facility has 
operated without LMIS tools 
   
04 Does the tool cover all the key areas 
as it is supposed to? 
 
   
05 How often do you send the 
following document to the County 
and National levels for appropriate 
action? 
(a) Commodity orders:  
(i) Monthly 
(ii)Quarterly 
   
(b) Commodity reports: 
(i) Monthly 
(ii) Quarterly 
   
06 Are your reports and orders 
submitted to the relevant 
departments on time? (counter check 
the reporting tools or order forms) 
   
 
07 Is the data you submit normally 
accurate and complete?(check the 
reporting tools or order forms) 
   
 
08 Have you had to place an emergency 
order recently? If so, how many? 
 
   
 
09 What transportation means is used to 
ferry commodities? 
(a) From the supplier directly to the 
facility: 
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(i) Contracted companies 
(ii) Facility utility vehicle 
(iii) Private vehicle 
(iv) Motor boats 
(v) Animal-driven carts 
(vi) Motorcycle 
(vii) On foot using porters 
 
(b) From the County or Sub County 
store to this facility: 
(i) Contracted companies 
(ii) Facility utility vehicle 
(iii) Facility ambulance 
(iv) Private vehicle 
(v) Motor boats 
(vi) Animal-driven carts 
(vii) Motorcycle 
(viii) On foot using porters 
(ix) Others (specify) 
09 What is your lead-time? 
(i) Two weeks 
(ii) A month 
(iii) Two months  
(iv) A quarter 
(v) More than a quarter 
   
10 Have you had any supervisory visit 
by the county or relevant 
departments on inventory 
management recently? If so, 
specify.( check with the visitors 
book) 
 
   
 
2. Facility Infrastructure 
No. Question Response Comments 
Yes No 
01. Is the facility connected to any form 
of electricity? 
   
02. Does the facility embrace electronic 
management tools for commodity 
management? 
   
03. If yes on question 2 above, is the 
facility using current commodity 
management software? 
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04. Is the facility well connected to the 
internet? 
   
 
3. Staff Training and LMIS use in facilities. 
No. Questions Response Comments 
01. How many staff in this facility 
handle the supply chain? 
(i) Pharmacists 
(ii) Pharmaceutical technologists 
(iii) Nurses 
  
02. How many of the staff above are 
trained on LMIS use? 
(i) Pharmacists 
(ii) Pharmaceutical Technologists 
(iii) Nurses 
  
03. Does the LMIS data collected from 
facilities aid you in decision-
making? Is so, how?(Level 4 and 5 
facilities) 
  
04. Comment on your preference of the 
electronic LMIS use as compared to 
manual system or vice versa. 
  
05. Is the software appropriate to you 
and to your work? 
  
06. Does the current LMIS make the 
necessary adjustments and 
commodity requests when need 
arises? 
  
07. Is the reporting timely?   




09. Do you and your staff need 
additional training on LMIS use? 
  





Annex 2: Questionnaire for County informants on budgetary allocation. 
The questionnaire will be used to address RQ2: “Is the current level of budgetary allocation 
sufficient and are funds efficiently used?” 
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The objective for this survey is: (a) to ensure that Busia as a county gets sufficient drug quantities 
from her budgetary allocation and (b) to enable access to medicines by patients as effectively as 
possible.  
01. Which decisions do you make that are vital in achieving these objectives?  
02. In your opinion who should be tasked with the responsibility of decision-making and 
coordination of activities towards achieving the above objectives 
03. Which categories of information do you need to make such important decisions? 
04. What is the source of the information that aide you in decision-making? 
05. What else can you be in a position to offer in order to help enable more access to medicines 
by patients in this county? 
06. Are you aware of the policy requirements concerning budgetary allocation tor health? 
07. What are your views on the policy requirements concerning budgetary allocations for health? 
08. Are the policies adequate to address the needs of Busia county health department concerning 
budgetary allocation for health? If not, what are the constraints? 
09. Which policies on budgetary allocation in your opinion should be changed? What 
improvements would you make? 
10. Any additional comments 
Annex 3: Questionnaire on Human Resource for Health for Pharmaceutical Supply Chain 
Management 
The questionnaire will be used to address RQ3: “Are the current staff adequately trained, is the 
number sufficient and is the work organization conducive for them to deliver optimally?” 
1. Staffing Norms and Qualifications 
  Pharmacists Pharmaceutical 
Technologists 
Nurses 




 (b) Ideal Staff Numbers  
 
  
02. (a) Staff qualifications Msc Pharmacy: 





epivigilance - 1 
Diploma in 
Pharmacy 








Bsc Pharmacy - 15 









2. Staff Training on Supply Chain Management 




01. Which officer is solely 
responsible for supply chain 
management in this facility?  
 
    
02. How many staff in the facility 
are trained on: 
(i) Inventory management 
practices 
(ii) Rational drug use 
(iii) Quantification 
(iv) Forecasting 
(v) Supply chain planning and 
mapping 
 
    
03. How many of the staff are able 
to report on sub-standard 
commodities as well as patient 
side effects from medicines 
after their administration? 
    
04. Are these reporting forms 
available at the facility? 
(i) Yellow form 
(ii) Pink form 
(iii) Alert card  
 
Yes No Yes No Yes No  
      
05. Are SCM trainings conducted 
in the county done to your 
satisfaction?  
       
06. What in your opinion needs to 
change in SCM training 
aspect? 
    
 
3. Work Environment 




01. Dispensing and storage areas: 
(i) Is it clean and orderly? 
(ii) Is it well ventilated? 
(iii) Is the lighting in the store 
sufficient? 
(iv) Is storage space adequate? 
(v) Are pharmaceuticals stored on 
shelves and floor pallets as required? 
(vi) Is commodity security of 
pharmaceuticals guaranteed in the 
store and pharmacy? 
(vii) Are expired items stored 
separately from other pharmaceutical 
commodities? 
(viii) Is the temperature monitored in 
the store? 
(ix) Are inventory records in the 
dispensing area and store regularly 
updated? 
 
   
02. Cold chain management: 
(i) Does your fridge have a 
thermometer for monitoring its 
temperature? 
(ii) Do you fill in temperature charts 
twice a day like you are supposed to? 
(iii) Is there sufficient room in the 
refrigerator to accommodate all 
medicines that require cold chain 
storage? If not, comment on how you 
store your commodities? 
(iv) What other power source do you 
use in case of electricity failure? 
 
   
03.  Infrastructure: 
(i) Do you have working computers in 
the department? 
(ii) Is the work space adequate to 
enable you perform your duties 
optimally? 
(iii) Do you have the basic amenities 
like water, electricity and internet 
access in the department? 
 
   
 (d) Resources :    
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 Do you have all the reference 
materials you need to perform your 
departmental duties optimally? 
(i) Drug Formulary 
(ii) Essential Medicines List 
(iii) Standard Treatment Guidelines 
(iv) Pharmacovigilance tools 
(v) Pediatric treatment protocols 
 
 (e) Do you have Standard Operating 
Procedures for: 
(i) Good storage practices 
(ii) Good dispensing practices 
(iii) Good inventory management 
practices 
(iv) Good dispensing practices 
 
   
 
4. Inventory Management 
No. Questions Response Comments 








02. Comment on the decisions you 




03. What in your opinion needs to change 
on how SCM is handled? 
 
  







05. What in your opinion can be done to 











06. Comment on who, what and how  
commodity resupply quantities are 
determined in this facility 
 
  
07. What is your lead time (period 
between ordering and receipt of 
commodities): 
(i) One month 
(ii) A quarter 





Annex 4: ABC Analysis Worksheet 
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Annex 5: Consent Form 
PARTICIPANT INFORMATION AND CONSENT FROM 
 
STUDY TITLE: EVALUATING PHARMACEUTICAL SUPPLY CHAIN 
MANAGEMENT CHALLENGES IN BUSIA COUNTY 
 
SECTION 1: INFORMATION SHEET–HEALTH PERSONNEL 
 
Investigator:  Dr. Sharon Apinde 
 
Institutional affiliation:  Strathmore Business School (SBS) 
 
SECTION 2: INFORMATION SHEET–THE STUDY 
2.1: Why is this study being carried out? 
The study is being carried out to assess if the Logistics Management Information System we use in this 
county is robust enough to manage our health needs and to assess if our budgetary allocation for health 
is sufficient and funds efficiently used. The study also aims to address our county staffing norms, assess 
if our work environment as heath care workers enables us to perform our duties that are related to supply 
chain management optimally and our competencies when managing the pharmaceutical supply chain. 
2.2: Do I have to take part? 
No.  Taking part in this study is entirely optional and the decision rests only with you.  If you decide to 
take part, you will be asked to complete a questionnaire to get information on Supply Chain Management 
(SMC). If you are not able to answer all the questions successfully the first time, you may be asked to 
sit through another informational session after which you may be asked to answer the questions a second 
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time.  You are free to decline to take part in the study from this study at any time without giving any 
reasons.   
 
2.3: Who is eligible to take part in this study? 
 
 Pharmacy personnel and nurses who manage the pharmaceutical supply chain in different 
facility levels in the county. 
 Staff at county level involved in decision making concerning the SCM  
 
 
2.4: Who is not eligible to take part in this study?  
 
 Staff who have not worked in their facility for more than a year 
 People not involved in procurement, budgetary allocation and decision making Staff at county 
level who have not held their position for more than a year 
2.5: What will taking part in this study involve for me? 
You will be approached me and requested to take part in the study.  If you are satisfied that you fully 
understand the goals behind this study, you will be asked to sign the informed consent form (this form) 
and then taken through a questionnaire to complete. 
2.6: Are there any risks or dangers in taking part in this study? 
There are no risks in taking part in this study. All the information you provide will be treated as 
confidential and will not be used in any way without your express permission. 
2.7: Are there any benefits of taking part in this study? 
The information will be used to improve access to medicines by patients in the county and by so doing, 
improve hospital pharmaceutical supply chain performance. 
2.8: What will happen to me if I refuse to take part in this study? 
Participation in this study is entirely voluntary.  Even if you decide to take part at first but later change 
your mind, you are free to withdraw at any time without explanation.   
2.9: Who will have access to my information during this research? 
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All research records will be stored in securely locked cabinets.  That information may be transcribed 
into our database but this will be sufficiently encrypted and password protected.  Only the people who 
are closely concerned with this study will have access to your information. All your information will be 
kept confidential.  
2.10: Who can I contact in case I have further questions? 
You can contact me, Sharon Apinde, at SBS, or by e-mail (sapinde21@gmail.com), or by phone 
(0712027598). You can also contact my supervisor, Prof. Gilbert Kokwaro, at the Strathmore Business 
School, Nairobi, or by e-mail (gkokwaro@strathmore.edu) or by phone (0722323651) 
I, __________________________, have had the study explained to me. I have understood all that 
I have read and have had explained to me and had my questions answered satisfactorily. I 
understand that I can change my mind at any stage.  
Please tick the boxes that apply to you; 
Participation in the research study 
 I AGREE to take part in this research  
 
 I DO NOT AGREE to take part in this research 
Storage of information on the completed questionnaire  
 I AGREE to have my completed questionnaire stored for future data analysis 
 





 DD  /       MM  /     YEAR 
Participant’s Name:  
_________________________________________ 
Time: ______ /_______ 
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 (Please print name) HR  /   MN 
I, ________________________ (Name of person taking consent) certify that I have followed the SOP for 
this study and have explained the study information to the study participant named above, and that she has 
understood the nature and the purpose of the study and consents to the participation in the study. She has 





DD  /       MM  /     YEAR 
 
Investigator’s Name:  
_______________________________________ 
Time: ______ /_______ 
 (Please print name) HR  /   MN 
 
Appendix 1: Analysis of Busia County Referral Hospital 2015-2016 
Item Name UOM Value 
%Cumulati














00 19.06% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
TIN OF 
1000S 375,000.00 26.20% A V AV I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 500ML 288,000.00 31.69% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG VIAL 252,000.00 36.49% A N AN I 
CEFTRIAXONE  





LE 207,500.00 45.11% A V AV I 
AMOXYCILLIN 
CAPSULES - 250MG 
TIN OF 
1000S 189,000.00 48.72% A V AV I 
CIPROFLOXACIN 
TABLETS  - 250MG 
TIN OF 












OF 10 125,000.00 60.56% A V AV I 
MORPHINE 
SULPHATE 
INJECTION -  
10MG/ML 
AMPOU




OF 3S 120,000.00 65.23% A V AV I 
ORAL REHYDRATION 
SALTS Co-Pack 105,000.00 67.23% A V AV I 
HYDRALAZINE 
INJECTION  - 
20MG/ML 
AMPOU
LE 95,250.00 69.04% A V AV I 
FOLIC ACID TABLETS  
- 5MG 
TIN OF 
100S 84,000.00 70.64% A E AE I 
METRONIDAZOLE 
TABLETS  - 200MG 
TIN OF 
1000S 80,000.00 72.17% A V AV I 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 
PACK 
OF 20S 75,600.00 73.61% A N AN I 
FLUPHENAZINE 
INJECTION  - 
25MG/ML 
AMPOU








1000S 60,000.00 77.30% B V BV I 
IBUPROFEN TABLETS  
- 200MG 
TIN OF 
1000S 60,000.00 78.45% B V BV I 
PENICILLIN  BENZYL 
INJECTION  - 5MU VIAL 56,000.00 79.51% B N BN II 
ANTI-D (RH) 
INJECTION - 250MCG VIAL 50,000.00 80.47% B N BN II 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 100 ML 50,000.00 81.42% B N BN II 
MORPHINE POWDER 
PKTS X 




BOTTLE 48,840.00 83.30% B V BV I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 100 ML 45,000.00 84.16% B V BV I 
DICLOFENAC 









BOTTLE 40,800.00 85.73% B V BV I 
KETAMINE INJECTION 
- 50MG/ML VIAL 40,000.00 86.49% B V BV I 
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NIFEDIPINE TABLETS  
- 20MG 
TIN OF 
1000S 36,000.00 87.17% B N BN II 
GLIBENCLAMIDE 
TABLETS  - 5MG 
TIN OF 
1000S 35,000.00 87.84% B N BN II 
THIOPENTONE 
SODIUM INJECTION - 
500MG VIAL 33,000.00 88.47% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG VIAL 32,000.00 89.08% B V BV I 
HYDROCORTISONE 
INJECTION  - 100MG VIAL 29,000.00 89.63% B V BV I 
MULTIVITAMIN 
SYRUP 5L 28,200.00 90.17% B N BN II 
HALOPERIDOL 
TABLETS  - 5MG 
TIN OF 
1000S 25,100.00 90.65% B V BV I 
SALBUTAMOL 
NEBULIZING 
SOLUTION  - 5MG/ML 
10ML 
10 ML 





1000S 24,000.00 91.58% C N CN III 
GENTAMICIN 
INJECTION - 80MG- 
40MG/ML 2ML AMP 
AMPOU
LE 22,500.00 92.01% C N CN III 
IBUPROFEN SYRUP 
100MG/5ML 60ML BOTTLE 22,000.00 92.43% C V CV I 
HYDROCORTISONE 
OINTMENT - 1% 
TUBE 
15GM 21,600.00 92.84% C E CE II 
PHENOBARBITONE 
TABLETS - 30MG 
TIN OF 




500S 20,000.00 93.62% C V CV I 
NEOSTIGMINE 
INJECTION  - 
2.5MG/ML VIAL 20,000.00 94.00% C V CV I 
RANITIDINE 
INJECTION  - 
50MG/2ML 
AMPOU




1000S 19,500.00 94.76% C E CE II 
DICLOFENAC GEL, 
1% W/W, 20G TUBE 18,000.00 95.10% C N CN III 
CLOTRIMAZOLE 
CREAM  - 1% 
TUBE 
20GM 17,000.00 95.42% C E CE II 
PANCURONIUM 
INJECTION  - 
4MG/2ML 
AMPOU













cartridge 15,000.00 96.30% C N CN III 
POVIDONE-IODINE 
SOLUTION - 10% 1L 14,500.00 96.58% C N CN III 
HYDROCHLOROTHIA
ZIDE TABLETS - 50MG 
TIN OF 




OF 100S 13,500.00 97.11% C N CN III 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 
AMPOU
LE 13,000.00 97.36% C V CV I 
BENZHEXOL 
TABLETS  - 5MG 
PACK 
OF 




OF 100S 12,000.00 97.82% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 5L 10,800.00 98.02% C N CN III 
CHLORPHENIRAMINE 
INJECTION  - 
10MG/ML 
AMPOU
LE 10,000.00 98.21% C N CN III 
DICLOFENAC 
INJECTION  - 75MG 
AMPOU
LE 10,000.00 98.40% C V CV III 
SILVER 
SULPHADIAZINE 
CREAM - 1% 
250GM 
JAR 10,000.00 98.59% C N CN III 
CHLORPROMAZINE 
TABLETS  - 100MG 
TIN OF 




BTL 9,000.00 98.95% C N CN III 
CHLORAMPHENICAL 
INJECTION  - 1GM VIAL 7,600.00 99.10% C V CV I 
FERROUS SULPHATE 
TABLETS  - 200MG 
TIN OF 
1000S 6,875.00 99.23% C V CV I 
ADRENALINE 
INJECTION  - 1MG/ML 
AMPOU





LE 4,800.00 99.42% C V CV I 
FLUOXETINE 
CAPSULES - 20MG 
PACK 
OF 100S 4,000.00 99.49% C E CE II 
KETOCONAZOLE 
TABLETS - 200MG 
PACK 
OF 30S 4,000.00 99.57% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 
AMPOU
LE 3,600.00 99.64% C V CV I 
METHYLDOPA 
TABLETS  - 250MG 
TIN OF 
1000S 3,550.00 99.70% C V CV I 
BENZYLBENZOATE 
EMULSION - 25% 
APPLICATION 
50ML 










OF 100S 1,900.00 99.85% C N CN III 
CHLORPROMAZINE 
INJECTION  - 
50MG/2ML 
AMPOU
LE 1,800.00 99.88% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 
TIN OF 
1000S 1,750.00 99.92% C N CN III 
HEPARINE INJECTION  




OF 100S 1,000.00 99.96% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  
0.3 % W/V 
5 ML 
BTL 850 99.98% C V CV I 
CHLORPHENIRAMINE 
TABLETS - 4MG 
TIN OF 
1000S 620 99.99% C N CN III 
ACETYLSALICYLIC 
ACID TABLETS - 
300MG 
TIN OF 
1000S 500 100.00% C N CN III 
ATROPINE INJECTION  
- 1MG/ML 
AMPOU
LE 100 100.00% C E CE II 
CALAMINE LOTION  - 
15% 
50ML 




VIAL 4 100.00% C N CN III 
    5247759           
 
Appendix 2: Analysis of Busia County Referral Hospital 2016-2017 















SOLUTION  - 0.9% 
1,250,000.
00 7.75% 7.75% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 875,000.00 5.43% 13.18% A N AN I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 648,000.00 4.02% 17.20% A V AV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 616,000.00 3.82% 21.02% A V AV I 
DEXTROSE - 5% 480,000.00 2.98% 24.00% A V AV I 
ANTI-D (RH) 
INJECTION - 250MCG 450,000.00 2.79% 26.79% A N AN I 
AMOXYCILLIN 




CAPSULES  - 250MG 437,500.00 2.71% 32.28% A N AN I 
METRONIDAZOLE 
INJECTION  - 5MG/ML 437,500.00 2.71% 34.99% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG 385,000.00 2.39% 37.38% A N AN I 
SODIUM 
HYPOCHLORITE 
SOLUTION 372,300.00 2.31% 39.69% A N AN I 
AMOXICILLIN/CLAVULA
NIC ACID ORAL 
SUSPENSION 
312.5MG/5ML 369,000.00 2.29% 41.98% A V AV I 
ORAL REHYDRATION 
SALTS 367,500.00 2.28% 44.26% A V AN I 
INSULIN BIPHASIC 









DIPLOID, 344,850.00 2.14% 50.86% A V AV I 
ERYTHROMYCIN 
TABLETS  - 250MG 275,000.00 1.71% 52.57% A N AN I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 270,000.00 1.67% 54.24% A N AN I 
SODIUM LACTATE 
SOLUTION 268,800.00 1.67% 55.91% A N AN I 
Co-trimoxazole 
suspension, 240 mg/5ml 251,600.00 1.56% 57.47% A N AN I 
POVIDONE-IODINE 
SOLUTION - 10% 243,600.00 1.51% 58.98% A N AN I 
CEFIXIME TABLET 
400MG 225,000.00 1.40% 60.37% A V AV I 
OMEPRAZOLE 
CAPSULES  - 20MG 225,000.00 1.40% 61.77% A V AV I 
FLUPENTHIXOL 
DECANOATE  - 
20MG/ML 202,500.00 1.26% 63.03% A N AN I 
DICLOFENAC 
INJECTION  - 75MG 200,000.00 1.24% 64.27% A N AN I 
ALCOHOL BASED 
HAND RUB 180,000.00 1.12% 65.38% A V AV I 
MORPHINE POWDER 175,000.00 1.09% 66.47% A V AV I 
MORPHINE SULPHATE 
INJECTION -  10MG/ML 175,000.00 1.09% 67.55% A N AN I 
ETHANOL 
(DENATURED) - 94% 170,000.00 1.05% 68.61% A V AV I 
OXYTOCIN INJECTION 




TABLETS  - 250MG 165,000.00 1.02% 70.67% B N BN II 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 
5MG(MARCAINE 
HEAVY) 150,000.00 0.93% 71.60% B N BN II 
IBUPROFEN TABLETS  
- 200MG 150,000.00 0.93% 72.53% B N BN II 
GLUCOSE INJECTION 
50%  50ML  
(DEXTROSE) 138,000.00 0.86% 73.39% B N BN II 
CARBAMAZEPINE 
TABLETS 200MG 135,000.00 0.84% 74.23% B N BN II 
METFORMINE 
TABLETS  - 500MG 134,640.00 0.84% 75.06% B N BN II 
PARACETAMOL 
SUSPENSION - 
120MG/5ML 126,000.00 0.78% 75.84% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG 124,800.00 0.77% 76.62% B N BN II 
PHENOBARBITONE  
INJECTION - 200MG/ML 124,500.00 0.77% 77.39% B N BN II 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 120,000.00 0.74% 78.13% B N BN II 
ETHANOL 
(DENATURED)  - 70% 120,000.00 0.74% 78.88% B V BV I 
PARACETAMOL 
TABLETS  - 500MG 118,125.00 0.73% 79.61% B N BN II 
ATRACURIUM 
INJECTION  - 10MG/ML 117,500.00 0.73% 80.34% B V BV I 
CEFUROXIME 250MG 
TABS 117,000.00 0.73% 81.06% B N BN II 
HYDROCORTISONE 
INJECTION  - 100MG 116,000.00 0.72% 81.78% B N BN II 
ENALAPRIL TABLETS - 
5MG 111,800.00 0.69% 82.48% B N BN II 
FLUCLOXACILLIN  
CAPSULES 500MG 110,000.00 0.68% 83.16% B V BV I 
SILVER 
SULPHADIAZINE 
CREAM - 1% 100,000.00 0.62% 83.78% B N BN II 
HYDRALAZINE 
INJECTION  - 20MG/ML 95,250.00 0.59% 84.37% B N BN II 
WATER FOR 
INJECTION 92,000.00 0.57% 84.94% B V BV I 
GABAPENTIN CAP 
300MG 90,000.00 0.56% 85.50% B N BN II 
OXYTOCIN INJECTION 
- 10 IU/ML 90,000.00 0.56% 86.06% B N BN II 
AZITHROMYCIN 500MG  88,000.00 0.55% 86.60% B N BN II 
DEXTROSE  - 10% 79,560.00 0.49% 87.10% B V BV I 





1% 60,000.00 0.37% 87.90% B N BN II 
PENICILLIN  BENZYL 
INJECTION  - 5MU 56,000.00 0.35% 88.25% B N BN II 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 
TAB 54,000.00 0.33% 88.58% B N BN II 
NIFEDIPINE TABLETS  - 
20MG 54,000.00 0.33% 88.92% B N BN II 
DOXYCYCLINE 
CAPSULES  - 100MG 51,600.00 0.32% 89.24% B N BN II 
VALACYCLOVIR TAB. 
500MG 49,400.00 0.31% 89.55% B N BN II 
Acyclovir 400mg Tabs 49,000.00 0.30% 89.85% B N BN II 
PENICILLIN  BENZYL 
INJECTION  - 1MU 49,000.00 0.30% 90.15% C N CN III 
HALOTHANE 
INHALATION 48,840.00 0.30% 90.46% C V CV I 
REHYDRATION SALTS  
ORAL (ORS) 46,500.00 0.29% 90.74% C N CN III 
FLUPHENAZINE 
INJECTION  - 25MG/ML 43,000.00 0.27% 91.01% C N CN III 
GLIBENCLAMIDE 
TABLETS  - 5MG 42,000.00 0.26% 91.27% C N CN III 
CLOTRIMAZOLE 
CREAM  - 1% 40,120.00 0.25% 91.52% C N CN III 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 40,000.00 0.25% 91.77% C N CN III 
PANCURONIUM 
INJECTION  - 4MG/2ML 40,000.00 0.25% 92.02% C N CN III 
RANITIDINE INJECTION  
- 50MG/2ML 40,000.00 0.25% 92.26% C N CN III 
CHLORPROMAZINE 
TABLETS  - 100MG 39,400.00 0.24% 92.51% C E CE II 
Cotrimoxazole 480mg 
Tabs 38,600.00 0.24% 92.75% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 38,500.00 0.24% 92.99% C N CN III 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 37,800.00 0.23% 93.22% C N CN III 
FUROSEMIDE 
INJECTION  - 
20MG/2ML 35,000.00 0.22% 93.44% C N CN III 
WATER BASED 
LUBRICANT (KY  
JELLY) 33,000.00 0.20% 93.64% C N CN III 
TINIDAZOLE TAB 
500MG 32,500.00 0.20% 93.85% C N CN III 
PREDNISOLONE 
TABLETS  - 5MG 32,400.00 0.20% 94.05% C N CN III 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 32,000.00 0.20% 94.24% C N CN III 
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BENZHEXOL TABLETS  
- 5MG 30,500.00 0.19% 94.43% C V CV III 
KETAMINE INJECTION 
- 50MG/ML 30,000.00 0.19% 94.62% C N CN III 
MAGNESIUM 
SULPHATE INJECTION 
- 50% 30,000.00 0.19% 94.81% C N CN III 
MAGNESIUM 
SULPHATE INJ 4%, 
W/V,100ML BOTTLE 29,000.00 0.18% 94.99% C V CV I 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 28,800.00 0.18% 95.16% C V CV I 
MULTIVITAMIN SYRUP 28,200.00 0.17% 95.34% C N CN III 
HYDROCHLOROTHIAZI
DE TABLETS - 50MG 28,000.00 0.17% 95.51% C N CN III 
DICLOFENAC SODIUM 
TABLETS - 50MG 27,600.00 0.17% 95.68% C N CN III 
GLUTARALDEHYDE 2% 
SOLUTION 27,300.00 0.17% 95.85% C N CN III 
INSULIN SOLUBLE - 
100IU/ML 27,300.00 0.17% 96.02% C N CN III 
ALBENDAZOLE 
TABLETS 400MG 27,000.00 0.17% 96.19% C N CN III 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 27,000.00 0.17% 96.36% C E CE II 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 26,000.00 0.16% 96.52% C E CE II 
SALBUTAMOL 
NEBULIZING 
SOLUTION  - 5MG/ML 
10ML 25,000.00 0.16% 96.67% C V CV I 
THIOPENTONE 
SODIUM INJECTION - 
500MG 24,750.00 0.15% 96.83% C N CN III 
ACETYLSALICYLIC 
ACID TAB 75MG, 
ENTERIC COATED 24,000.00 0.15% 96.98% C N CN III 
HEPARINE INJECTION  
- 5000UNITS/ML  5ML 23,800.00 0.15% 97.12% C V CV III 
VALPROIC 
ACID(SODIUM 
VALPROATE) 200MG  
TABLETS 21,900.00 0.14% 97.26% C N CN III 
FERROUS SULPHATE 
TABLETS  - 200MG 20,625.00 0.13% 97.39% C V CV I 
ATROPINE INJECTION  
- 1MG/ML 20,000.00 0.12% 97.51% C V CV I 
NEOSTIGMINE 
INJECTION  - 2.5MG/ML 20,000.00 0.12% 97.64% C N CN III 
HALOPERIDOL 




INJECTION - 20MG- 
10MG/ML 2ML AMP 18,000.00 0.11% 97.86% C V CV I 
GENTAMICIN 
INJECTION - 80MG- 
40MG/ML 2ML AMP 18,000.00 0.11% 97.98% C N CN III 
HYDROCORTISONE 
OINTMENT - 1% 18,000.00 0.11% 98.09% C N CN III 
QUININE SULPHATE 
TABLETS - 300MG 18,000.00 0.11% 98.20% C E CE II 
TETRACYCLINE EYE 
OINTMENT -1% 18,000.00 0.11% 98.31% C N CN III 
AMITRIPTYLINE 
TABLETS  - 25MG 16,200.00 0.10% 98.41% C V CV I 
SALBUTAMOL 
INHALER - 
100MCG/ACTUATION 15,000.00 0.09% 98.50% C V CV I 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 5MG 14,100.00 0.09% 98.59% C V CV I 
FUROSEMIDE 
TABLETS  - 40MG 14,000.00 0.09% 98.68% C V CV I 
DIGOXIN TABLETS  - 
0.25MG 13,800.00 0.09% 98.76% C V CV I 
IBUPROFEN SYRUP 
100MG/5ML 60ML 13,200.00 0.08% 98.85% C V CV I 
NYSTATIN 
SUSPENSION - 100 
000IU/ML 12,900.00 0.08% 98.93% C V CV I 
AMLODIPINE TABLET 
5MG 12,000.00 0.07% 99.00% C V CV I 
METRONIDAZOLE 
TABLETS  - 200MG 12,000.00 0.07% 99.07% C N CN III 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 10,800.00 0.07% 99.14% C V CV I 
RETINOL (VITAMIN 
A)CAPSULES 50000IU 10,800.00 0.07% 99.21% C N CN III 
METHYLDOPA 
TABLETS  - 250MG 10,650.00 0.07% 99.27% C V CV I 
GRISEOFULVIN TAB 
125MG 9,750.00 0.06% 99.34% C N CN III 
ANTI-RABIES SERUM 
INJ - 200 1U/ML 9,660.00 0.06% 99.40% C V CV I 
PARACETAMOL 
SUPPOSITORIES 
125MG 9,000.00 0.06% 99.45% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 8,100.00 0.05% 99.50% C V CV I 
DIHYDROCODEINE 
PHOSPHATE TAB 
30MG 7,700.00 0.05% 99.55% C V CV I 
COMPOUND 
MAGNESIUM 




INJECTION 10MG/ML  
100ML VIAL 6,000.00 0.04% 99.63% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 5,250.00 0.03% 99.67% C E CE II 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 5,000.00 0.03% 99.70% C V CV I 
PENICILLIN  
BENZATHINE 
INJECTION  - 2.4 MU 5,000.00 0.03% 99.73% C N CN III 
SALBUTAMOL 
TABLETS  - 4MG 5,000.00 0.03% 99.76% C N CN III 
FLUOXETINE 
CAPSULES - 20MG 4,000.00 0.02% 99.78% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 4,000.00 0.02% 99.81% C N CN III 
SALBUTAMOL SYRUP  
- 2MG/5ML 4,000.00 0.02% 99.83% C N CN III 
CALAMINE LOTION  - 
15% 3,750.00 0.02% 99.86% C V CV I 
CHLORPROMAZINE 
INJECTION  - 
50MG/2ML 3,600.00 0.02% 99.88% C E CE II 
SODIUM 
BICARBONATE 
INJECTION - 8.4% 3,200.00 0.02% 99.90% C N CN III 
METOCLOPRAMIDE 
INJECTION  - 5MG/ML 2,800.00 0.02% 99.92% C N CN III 
ADRENALINE 
INJECTION  - 1MG/ML 2,500.00 0.02% 99.93% C V CV I 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 2,400.00 0.01% 99.95% C N CN III 
LOPERAMIDE 
CAPSULES  - 2MG 2,000.00 0.01% 99.96% C V CV I 
CHLORPHENIRAMINE 
TABLETS - 4MG 1,860.00 0.01% 99.97% C V CV I 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  
0.3 % W/V 1,700.00 0.01% 99.98% C N CN III 
LEVOTHYROXINE 
SODIUM 100MCG TAB  1,380.00 0.01% 99.99% C N CN III 
METOCLOPRAMIDE  
TABLETS - 10MG 1,300.00 0.01% 100.00% C N CN III 
ACETYLSALICYLIC 
ACID TABLETS - 
300MG 500 0.00% 100.00% C V CV I 




Appendix 3: KHUNYANGU SCH 2015-2016 
Item Name Value %Total 
%Cumulati














% 12.10% A V AV I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
300,000.0
0 5.82% 17.92% A V AV I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 
230,400.0
0 4.47% 22.39% A V AV I 
AMOXICILLIN/CLAVULA




0 4.38% 26.77% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 
210,000.0










0 3.32% 37.57% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 
168,000.0
0 3.26% 40.83% A N AN I 
OXYTOCIN INJECTION - 
5 IU/ML 
168,000.0
0 3.26% 44.09% A N AN I 
DEXTROSE - 5% 
160,000.0
0 3.11% 47.20% A V AV I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 
160,000.0





0 3.07% 53.37% A N AN I 
ERYTHROMYCIN 
TABLETS  - 250MG 
150,000.0
0 2.91% 56.29% A N AN I 
CIPROFLOXACIN 
TABLETS  - 250MG 
148,500.0
0 2.88% 59.17% A E AE I 
ANTI-D (RH) INJECTION 
- 250MCG 
120,000.0
0 2.33% 61.50% A N AN I 
PARACETAMOL 
TABLETS  - 500MG 97,500.00 1.89% 63.39% A V AV I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 96,000.00 1.86% 65.26% A N AN I 
ETHANOL 
(DENATURED) - 94% 88,400.00 1.72% 66.97% A N AN I 
FLUCLOXACILLIN  




SUSPENSION (PFR)  - 
125MG/5ML 80,000.00 1.55% 70.13% A V AV I 
CEFUROXIME 250MG 
TABS 78,000.00 1.51% 71.64% A N AN I 
DICLOFENAC 
INJECTION  - 75MG 62,500.00 1.21% 72.86% B V BV I 
IBUPROFEN TABLETS  - 
200MG 60,000.00 1.16% 74.02% B N BN II 
FLUCLOXACILLIN 
INJECTION - 250MG 52,500.00 1.02% 75.04% B V BV I 
INSULIN BIPHASIC 
30/70  - 100IU/ML 51,000.00 0.99% 76.03% B N BN II 
Co-trimoxazole 
suspension, 240 mg/5ml 47,600.00 0.92% 76.95% B N BN II 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 44,800.00 0.87% 77.82% B V BV I 
GLUCOSE INJECTION 
50%  50ML  
(DEXTROSE) 42,000.00 0.82% 78.64% B N BN II 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 
TAB 36,000.00 0.70% 79.34% B V BV I 
FLUCONAZOLE  
CAPSULES - 50MG 36,000.00 0.70% 80.04% B N BN II 
GABAPENTIN CAP 
300MG 36,000.00 0.70% 80.74% B V BV I 
HYDROCORTISONE 
INJECTION  - 100MG 34,800.00 0.68% 81.41% B V BV I 
PARACETAMOL 
SUSPENSION - 
120MG/5ML 33,600.00 0.65% 82.06% B N BN II 
CEFTRIAXONE  
INJECTION - 250MG 32,000.00 0.62% 82.69% B V BV I 
DEXTROSE  - 10% 31,110.00 0.60% 83.29% B N BN II 
SODIUM LACTATE 
SOLUTION 30,720.00 0.60% 83.89% B E BE II 
METFORMINE TABLETS  
- 500MG 30,600.00 0.59% 84.48% B N BN II 
ANTI-RABIES SERUM 
INJ - 200 1U/ML 28,980.00 0.56% 85.04% B V BV I 
POVIDONE-IODINE 
SOLUTION - 10% 28,420.00 0.55% 85.60% B V BV I 
GLIBENCLAMIDE 
TABLETS  - 5MG 28,000.00 0.54% 86.14% B N BN II 
PHENOBARBITONE 
TABLETS - 30MG 28,000.00 0.54% 86.68% B N BN II 
METRONIDAZOLE 
INJECTION  - 5MG/ML 25,000.00 0.49% 87.17% B N BN II 
PREDNISOLONE 
TABLETS  - 5MG 23,400.00 0.45% 87.62% B N BN II 
CARBAMAZEPINE 




INJECTION  - 20MG/ML 22,225.00 0.43% 88.49% B N BN II 
CLOTRIMAZOLE 
CREAM  - 1% 22,100.00 0.43% 88.92% B N BN II 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 21,600.00 0.42% 89.34% B N BN II 
CEFTAZIDIME 1G INJ. 21,140.00 0.41% 89.75% B N BN II 
Acyclovir 400mg Tabs 21,000.00 0.41% 90.16% B N BN II 
GRISEOFULVIN TAB 
125MG 19,500.00 0.38% 90.54% C N CN III 
DICLOFENAC SODIUM 
TABLETS - 50MG 19,320.00 0.38% 90.91% C N CN III 
HYDROCHLOROTHIAZI
DE TABLETS - 50MG 18,000.00 0.35% 91.26% C N CN III 
HYDROCORTISONE 
OINTMENT - 1% 18,000.00 0.35% 91.61% C V CV I 
SALBUTAMOL INHALER 
- 100MCG/ACTUATION 18,000.00 0.35% 91.96% C V CV I 
ENALAPRIL TABLETS - 
5MG 16,900.00 0.33% 92.29% C V CV I 
AZITHROMYCIN 500MG  16,800.00 0.33% 92.61% C N CN III 
PENICILLIN  BENZYL 
INJECTION  - 5MU 16,800.00 0.33% 92.94% C N CN III 
LIGNOCAINE 
HYDROCHLORIDE INJ. 
1% 16,000.00 0.31% 93.25% C V CV I 
WATER FOR 
INJECTION 16,000.00 0.31% 93.56% C N CN III 
SALBUTAMOL SYRUP  - 
2MG/5ML 14,000.00 0.27% 93.83% C N CN III 
OMEPRAZOLE 
CAPSULES  - 20MG 13,500.00 0.26% 94.10% C N CN III 
QUININE SULPHATE 
TABLETS - 300MG 13,500.00 0.26% 94.36% C V CV I 
OXYTOCIN INJECTION - 
10 IU/ML 13,200.00 0.26% 94.61% C N CN III 
SODIUM 
STIBOGLUCONATE  - 
100MG/ML 13,000.00 0.25% 94.87% C E CV I 
NYSTATIN 
SUSPENSION - 100 
000IU/ML 12,900.00 0.25% 95.12% C N CN III 
ALCOHOL BASED 
HAND RUB 12,000.00 0.23% 95.35% C V CV I 
METRONIDAZOLE 
TABLETS  - 200MG 12,000.00 0.23% 95.58% C N CN III 
FERROUS SULPHATE 
TABLETS  - 200MG 11,000.00 0.21% 95.80% C V CV I 
Cotrimoxazole 480mg 
Tabs 9,650.00 0.19% 95.98% C N CN III 
REHYDRATION SALTS  





CREAM - 1% 9,000.00 0.17% 96.34% C N CN III 
ACETYLSALICYLIC 
ACID TAB 75MG, 
ENTERIC COATED 8,640.00 0.17% 96.51% C N CN III 
PHENOBARBITONE  
INJECTION - 200MG/ML 8,300.00 0.16% 96.67% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 8,000.00 0.16% 96.82% C N CN III 
PARACETAMOL 
SUPPOSITORIES 
125MG 8,000.00 0.16% 96.98% C N CN III 
MAGNESIUM 
SULPHATE INJECTION - 
50% 7,800.00 0.15% 97.13% C N CN III 
TINIDAZOLE TAB 
500MG 7,800.00 0.15% 97.28% C N CN III 
ETORICOXIB 60MG 
TABLETS 7,590.00 0.15% 97.43% C N CN III 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 7,200.00 0.14% 97.57% C V CV I 
GENTAMICIN 
INJECTION - 80MG- 
40MG/ML 2ML AMP 7,200.00 0.14% 97.71% C V CV I 
METHYLDOPA 
TABLETS  - 250MG 7,100.00 0.14% 97.85% C N CN III 
DOXYCYCLINE 
CAPSULES  - 100MG 6,450.00 0.13% 97.97% C N CN III 
COMPOUND 
MAGNESIUM 
TRISILICATE TABLETS 6,250.00 0.12% 98.09% C V CV I 
PARACETAMOL 
INJECTION 10MG/ML  
100ML VIAL 6,000.00 0.12% 98.21% C V CV I 
MULTIVITAMIN SYRUP 5,640.00 0.11% 98.32% C V CV I 
TETRACYCLINE EYE 
OINTMENT -1% 5,400.00 0.10% 98.42% C V CV I 
FOLIC ACID TABLETS  - 
5MG 5,250.00 0.10% 98.53% C N CN III 
CHLORPROMAZINE 
TABLETS  - 100MG 4,925.00 0.10% 98.62% C E CE II 
FUROSEMIDE 
INJECTION  - 20MG/2ML 4,900.00 0.10% 98.72% C N CN III 
AMLODIPINE TABLET 
5MG 4,500.00 0.09% 98.80% C V CV I 
IBUPROFEN SYRUP 
100MG/5ML 60ML 4,400.00 0.09% 98.89% C N CN III 
FLUPHENAZINE 
INJECTION  - 25MG/ML 4,300.00 0.08% 98.97% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 3,400.00 0.07% 99.04% C N CN III 
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INSULIN SOLUBLE - 
100IU/ML 3,300.00 0.06% 99.10% C E CE II 
RANITIDINE INJECTION  
- 50MG/2ML 3,200.00 0.06% 99.16% C N CN III 
ALBENDAZOLE 
TABLETS 400MG 3,000.00 0.06% 99.22% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 3,000.00 0.06% 99.28% C N CN III 
ATROPINE INJECTION  
- 1MG/ML 3,000.00 0.06% 99.34% C V CV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 3,000.00 0.06% 99.40% C N CN III 
AMITRIPTYLINE 
TABLETS  - 25MG 2,835.00 0.06% 99.45% C V CV I 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 2,700.00 0.05% 99.50% C V CV I 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 2,700.00 0.05% 99.56% C N CN III 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 2,600.00 0.05% 99.61% C V CV I 
PENICILLIN  BENZYL 
INJECTION  - 1MU 2,100.00 0.04% 99.65% C N CN III 
FUROSEMIDE TABLETS  
- 40MG 1,750.00 0.03% 99.68% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 1,750.00 0.03% 99.72% C V CV I 
ETHANOL 
(DENATURED)  - 70% 1,600.00 0.03% 99.75% C N CN III 
CALAMINE LOTION  - 
15% 1,500.00 0.03% 99.78% C V CV I 
FOLIC ACID TABLETS  - 
5MG 1,375.00 0.03% 99.80% C N CN III 
HALOPERIDOL 
TABLETS  - 5MG 1,255.00 0.02% 99.83% C N CN III 
CHLORPHENIRAMINE 
TABLETS - 4MG 1,240.00 0.02% 99.85% C V CV I 
BENZHEXOL TABLETS  
- 5MG 1,220.00 0.02% 99.88% C V CV I 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 1,000.00 0.02% 99.89% C N CN III 
SALBUTAMOL 
NEBULIZING SOLUTION  
- 5MG/ML 10ML 1,000.00 0.02% 99.91% C N CN III 
SALBUTAMOL TABLETS  
- 4MG 1,000.00 0.02% 99.93% C N CN III 
GENTAMICIN 
INJECTION - 20MG- 
10MG/ML 2ML AMP 900 0.02% 99.95% C N CN III 
ATENOLOL TABLETS  - 
50MG 880 0.02% 99.97% C V CV I 
CHLORAMPHENICAL 




INJECTION  - 5MG/ML 350 0.01% 99.98% C N CN III 
METOCLOPRAMIDE  
TABLETS - 10MG 325 0.01% 99.99% C N CN III 
ACETYLSALICYLIC 
ACID TABLETS - 300MG 250 0.00% 99.99% C V CV I 
DIAZEPAM TAB 5MG 225 0.00% 100.00% C V CV I 
ADRENALINE 
INJECTION  - 1MG/ML 100 0.00% 100.00% C V CV I 






Appendix 4: KHUNYANGU SCH 2016-2017 
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% 11.55% A V AV I 
DOXYCYCLINE 
CAPSULES  - 100MG 
129,000.0
0 7.45% 19.00% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 
105,000.0
0 6.06% 25.07% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
100,000.0
0 5.78% 30.84% A V AV I 
CIPROFLOXACIN 
TABLETS  - 250MG 99,000.00 5.72% 36.56% A N AN I 
FLUCLOXACILLIN  
CAPSULES 500MG 82,500.00 4.77% 41.33% A E AE I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 60,000.00 3.47% 44.79% A V AV I 
INSULIN BIPHASIC 
30/70  - 100IU/ML 60,000.00 3.47% 48.26% A V AV I 
AMOXYCILLIN 
CAPSULES - 250MG 56,000.00 3.23% 51.49% A V AV I 
ANTI-D (RH) 
INJECTION - 250MCG 50,000.00 2.89% 54.38% A N AN I 
CEFIXIME TABLET 
400MG 50,000.00 2.89% 57.27% A V AV I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 







NT) 10ML AMPOULE 45,000.00 2.60% 62.76% A V AV I 
PENICILLIN  BENZYL 
INJECTION  - 5MU 42,000.00 2.43% 65.18% A N AN I 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 2.40% 67.58% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG 35,000.00 2.02% 69.60% B E BE II 
ORAL REHYDRATION 
SALTS 35,000.00 2.02% 71.62% B N BN II 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 32,400.00 1.87% 73.50% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG 32,000.00 1.85% 75.34% B N BN II 
DEXTROSE - 5% 32,000.00 1.85% 77.19% B N BN II 
GRISEOFULVIN TAB 
125MG 29,250.00 1.69% 78.88% B V BV I 
Cotrimoxazole 480mg 
Tabs 28,950.00 1.67% 80.55% B V BV I 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 24,000.00 1.39% 81.94% B N BN II 
PHENOBARBITONE 
TABLETS - 30MG 21,000.00 1.21% 83.15% B N BN II 
ALBENDAZOLE 
TABLETS 400MG 20,000.00 1.16% 84.31% B V BV I 
IBUPROFEN TABLETS  
- 200MG 20,000.00 1.16% 85.46% B V BV I 
HYDROCORTISONE 
OINTMENT - 1% 18,000.00 1.04% 86.50% B E BE II 
Co-trimoxazole 
suspension, 240 mg/5ml 17,000.00 0.98% 87.49% B E BE II 
CARBAMAZEPINE 
TABLETS 200MG 15,000.00 0.87% 88.35% B V BV I 
CEFTAZIDIME 1G INJ. 14,000.00 0.81% 89.16% B V BV I 
DICLOFENAC SODIUM 
TABLETS - 50MG 13,800.00 0.80% 89.96% B N BN II 
DEXTROSE  - 10% 12,240.00 0.71% 90.66% B V BV I 
METRONIDAZOLE 
TABLETS  - 200MG 12,000.00 0.69% 91.36% C N CN III 
AZITHROMYCIN 
500MG  10,000.00 0.58% 91.94% C V CV I 
HYDROCHLOROTHIAZI
DE TABLETS - 50MG 10,000.00 0.58% 92.51% C N CN III 
HYDROCORTISONE 
INJECTION  - 100MG 8,700.00 0.50% 93.02% C V CV I 
CLOTRIMAZOLE 
CREAM  - 1% 8,500.00 0.49% 93.51% C V CV I 
CLOTRIMAZOLE 




INJECTION - 80MG- 
40MG/ML 2ML AMP 7,200.00 0.42% 94.34% C E CE II 
NIFEDIPINE TABLETS  
- 20MG 7,200.00 0.42% 94.75% C V CV I 
GLIBENCLAMIDE 
TABLETS  - 5MG 7,000.00 0.40% 95.16% C V CV I 
HYDRALAZINE 
INJECTION  - 20MG/ML 6,350.00 0.37% 95.53% C V CV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 6,000.00 0.35% 95.87% C N CN III 
MULTIVITAMIN SYRUP 5,640.00 0.33% 96.20% C V CV I 
FERROUS SULPHATE 
TABLETS  - 200MG 5,500.00 0.32% 96.52% C N CN III 
DICLOFENAC 
INJECTION  - 75MG 5,000.00 0.29% 96.80% C N CN III 
ATENOLOL TABLETS  - 
50MG 4,400.00 0.25% 97.06% C E CE II 
FLUPHENAZINE 
INJECTION  - 25MG/ML 4,300.00 0.25% 97.31% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 3,600.00 0.21% 97.51% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 3,600.00 0.21% 97.72% C V CV I 
METHYLDOPA 
TABLETS  - 250MG 3,550.00 0.21% 97.93% C V CV I 
BENZHEXOL TABLETS  
- 5MG 3,050.00 0.18% 98.10% C E CE II 
CHLORPROMAZINE 
TABLETS  - 100MG 2,955.00 0.17% 98.27% C N CN III 
POVIDONE-IODINE 
SOLUTION - 10% 2,900.00 0.17% 98.44% C N CN III 
DOMPERIDONE 10MG 
TABLETS 2,850.00 0.16% 98.61% C N CN III 
FOLIC ACID TABLETS  
- 5MG 2,750.00 0.16% 98.77% C V CV I 
KETOCONAZOLE 
TABLETS - 200MG 2,400.00 0.14% 98.90% C N CN III 
ADRENALINE 
INJECTION  - 1MG/ML 2,000.00 0.12% 99.02% C N CN III 
SILVER 
SULPHADIAZINE 
CREAM - 1% 2,000.00 0.12% 99.14% C N CN III 
ENALAPRIL TABLETS - 
5MG 1,950.00 0.11% 99.25% C N CN III 
CHLORPROMAZINE 
INJECTION  - 
50MG/2ML 1,800.00 0.10% 99.35% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 1,750.00 0.10% 99.45% C V CV I 
RANITIDINE 
INJECTION  - 




5MG 1,500.00 0.09% 99.63% C V CV I 
HALOPERIDOL 
TABLETS  - 5MG 1,255.00 0.07% 99.70% C V CV I 
CHLORPHENIRAMINE 
TABLETS - 4MG 1,240.00 0.07% 99.78% C N CN III 
FOLIC ACID TABLETS  
- 5MG 1,050.00 0.06% 99.84% C N CN III 
DIHYDROCODEINE 
PHOSPHATE TAB 
30MG 770 0.04% 99.88% C V CV I 
BENZYLBENZOATE 
EMULSION - 25% 
APPLICATION 750 0.04% 99.92% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 450 0.03% 99.95% C V CV I 
ACETYLSALICYLIC 
ACID TABLETS - 
300MG 250 0.01% 99.97% C N CN III 
BISACODYL 5MG 
TABLETS 250 0.01% 99.98% C E CE II 
DIAZEPAM TAB 5MG 225 0.01% 99.99% C V CV I 
ATROPINE INJECTION  
- 1MG/ML 100 0.01% 100.00% C V CV I 
CALAMINE LOTION  - 
15% 25 0.00% 100.00% C V CV I 
WATER FOR 
INJECTION 4 0.00% 100.00% C N CN III 
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% 12.53% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 
287,000.00 
7.85% 20.38% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
225,000.00 
6.16% 26.54% A N AN I 
ERYTHROMYCIN 
TABLETS  - 250MG 
187,500.00 
5.13% 31.67% A N AN I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 
120,000.00 





3.21% 38.16% A N AN I 
HYDROCORTISONE 
OINTMENT - 1% 
108,000.00 




suspension, 240 mg/5ml 
102,000.00 
2.79% 43.91% A N AN I 
OXYTOCIN INJECTION - 
5 IU/ML 
100,000.00 
2.74% 46.65% A N AN I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 96,000.00 2.63% 49.27% A V AV I 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 





T) 10ML AMPOULE 90,000.00 2.46% 54.36% A N AN I 
PARACETAMOL 
TABLETS  - 500MG 86,250.00 2.36% 56.73% A V AV I 
Cotrimoxazole 480mg 
Tabs 82,990.00 2.27% 59.00% A N AN I 
CIPROFLOXACIN 
TABLETS  - 250MG 79,200.00 2.17% 61.16% A V AV I 
HYDROCORTISONE 
INJECTION  - 100MG 78,300.00 2.14% 63.31% A V AV I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 74,000.00 2.03% 65.33% A N AN I 
CEFTRIAXONE  
INJECTION - 1G 70,000.00 1.92% 67.25% A V AV I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 60,000.00 1.64% 68.89% B N BN II 
ETHANOL (DENATURED) 
- 94% 59,500.00 1.63% 70.52% B V BV I 
PARACETAMOL 
SUSPENSION - 




DIPLOID, 57,000.00 1.56% 73.69% B V BV I 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 56,000.00 1.53% 75.22% B N BN II 
ANTI-D (RH) INJECTION - 
250MCG 50,000.00 1.37% 76.59% B N BN II 
DOXYCYCLINE 
CAPSULES  - 100MG 47,730.00 1.31% 77.89% B V BV I 
NYSTATIN SUSPENSION 
- 100 000IU/ML 43,000.00 1.18% 79.07% B N BN II 
DEXTROSE - 5% 40,000.00 1.09% 80.16% B N BN II 
WATER FOR INJECTION 40,000.00 1.09% 81.26% B N BN II 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 38,400.00 1.05% 82.31% B N BN II 
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CLOTRIMAZOLE CREAM  
- 1% 36,380.00 1.00% 83.31% B N BN II 
IBUPROFEN TABLETS  - 
200MG 34,000.00 0.93% 84.24% B N BN II 
CEFTRIAXONE  
INJECTION - 250MG 32,000.00 0.88% 85.11% B V BV I 
POVIDONE-IODINE 
SOLUTION - 10% 31,900.00 0.87% 85.98% B V BV I 
AMOXICILLIN/CLAVULAN
IC ACID ORAL 
SUSPENSION 
312.5MG/5ML 30,750.00 0.84% 86.83% B N BN II 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 27,000.00 0.74% 87.57% B N BN II 
CEFUROXIME 250MG 
TABS 26,000.00 0.71% 88.28% B N BN II 
FERROUS SULPHATE 
TABLETS  - 200MG 22,000.00 0.60% 88.88% B N BN II 
DICLOFENAC INJECTION  
- 75MG 20,000.00 0.55% 89.43% B N BN II 
GRISEOFULVIN TAB 
125MG 19,500.00 0.53% 89.96% B V BV I 
TETRACYCLINE EYE 
OINTMENT -1% 16,200.00 0.44% 90.40% B V BV I 
METRONIDAZOLE 
TABLETS  - 200MG 16,000.00 0.44% 90.84% C N CN III 
HYDRALAZINE 
INJECTION  - 20MG/ML 15,875.00 0.43% 91.28% C N CN III 
OXYTOCIN INJECTION - 
10 IU/ML 15,600.00 0.43% 91.70% C E CE II 
LIGNOCAINE 
HYDROCHLORIDE INJ. 
1% 12,800.00 0.35% 92.05% C N CN III 
CEFIXIME TABLET 
400MG 12,500.00 0.34% 92.39% C V CV I 
ALBENDAZOLE TABLETS 
400MG 12,000.00 0.33% 92.72% C N CN III 
ALCOHOL BASED HAND 
RUB 12,000.00 0.33% 93.05% C V CV I 
AZITHROMYCIN 500MG  12,000.00 0.33% 93.38% C N CN III 
SALBUTAMOL SYRUP  - 
2MG/5ML 12,000.00 0.33% 93.71% C N CN III 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 10,800.00 0.30% 94.00% C N CN III 
METHYLDOPA TABLETS  
- 250MG 10,650.00 0.29% 94.29% C N CN III 
PENICILLIN  BENZYL 
INJECTION  - 1MU 10,500.00 0.29% 94.58% C V CV I 
PREDNISOLONE 
TABLETS  - 5MG 10,200.00 0.28% 94.86% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 9,000.00 0.25% 95.11% C V CV I 
GENTAMICIN INJECTION 
- 80MG- 40MG/ML 2ML 
AMP 9,000.00 0.25% 95.35% C N CN III 
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CALAMINE LOTION  - 
15% 7,750.00 0.21% 95.57% C N CN III 
PENICILLIN  
BENZATHINE INJECTION  
- 2.4 MU 7,500.00 0.21% 95.77% C V CV I 
RETINOL (VITAMIN 
A)CAPSULES 50000IU 7,200.00 0.20% 95.97% C N CN III 
MULTIVITAMIN SYRUP 7,050.00 0.19% 96.16% C N CN III 
Acyclovir 400mg Tabs 7,000.00 0.19% 96.35% C N CN III 
SALBUTAMOL TABLETS  
- 4MG 7,000.00 0.19% 96.54% C N CN III 
NIFEDIPINE TABLETS  - 
20MG 6,120.00 0.17% 96.71% C V CV I 
DICLOFENAC SODIUM 
TABLETS - 50MG 6,072.00 0.17% 96.88% C N CN III 
HYDROCHLOROTHIAZID
E TABLETS - 50MG 6,000.00 0.16% 97.04% C N CN III 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 6,000.00 0.16% 97.21% C V CV I 
SILVER SULPHADIAZINE 
CREAM - 1% 6,000.00 0.16% 97.37% C N CN III 
SALBUTAMOL INHALER - 
100MCG/ACTUATION 5,250.00 0.14% 97.51% C N CN III 
METRONIDAZOLE 
INJECTION  - 5MG/ML 5,000.00 0.14% 97.65% C V CV I 
DEXTROSE  - 10% 4,896.00 0.13% 97.79% C N CN III 
SODIUM LACTATE 
SOLUTION 4,800.00 0.13% 97.92% C V CV I 
GLUTARALDEHYDE 2% 
SOLUTION 4,550.00 0.12% 98.04% C V CV I 
OMEPRAZOLE 
CAPSULES  - 20MG 4,500.00 0.12% 98.16% C N CN III 
ETHANOL (DENATURED)  
- 70% 4,000.00 0.11% 98.27% C N CN III 
WATER BASED 
LUBRICANT (KY  JELLY) 3,300.00 0.09% 98.36% C N CN III 
TINIDAZOLE TAB 500MG 3,250.00 0.09% 98.45% C N CN III 
SODIUM BICARBONATE 
INJECTION - 8.4% 3,200.00 0.09% 98.54% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 3,000.00 0.08% 98.62% C V CV I 
GLUCOSE INJECTION 
50%  50ML  (DEXTROSE) 3,000.00 0.08% 98.70% C V CV I 
INSULIN BIPHASIC 30/70  
- 100IU/ML 3,000.00 0.08% 98.79% C N CN III 
INSULIN SOLUBLE - 
100IU/ML 3,000.00 0.08% 98.87% C N CN III 
AMITRIPTYLINE 
TABLETS  - 25MG 2,835.00 0.08% 98.95% C N CN III 
FUROSEMIDE 




TABLETS - 4MG 2,604.00 0.07% 99.09% C V CV I 
FUROSEMIDE TABLETS  
- 40MG 2,450.00 0.07% 99.16% C N CN III 
REHYDRATION SALTS  
ORAL (ORS) 2,325.00 0.06% 99.23% C N CN III 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 2,240.00 0.06% 99.29% C N CN III 
IBUPROFEN SYRUP 
100MG/5ML 60ML 2,200.00 0.06% 99.35% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 2,100.00 0.06% 99.40% C N CN III 
ACETYLSALICYLIC ACID 
TABLETS - 300MG 2,000.00 0.05% 99.46% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 1,800.00 0.05% 99.51% C N CN III 
ADRENALINE INJECTION  
- 1MG/ML 1,500.00 0.04% 99.55% C N CN III 
AMLODIPINE TABLET 
5MG 1,500.00 0.04% 99.59% C N CN III 
COMPOUND 
MAGNESIUM 
TRISILICATE TABLETS 1,500.00 0.04% 99.63% C N CN III 
PARACETAMOL 
SUPPOSITORIES 125MG 1,500.00 0.04% 99.67% C N CN III 
METFORMINE TABLETS  
- 500MG 1,360.00 0.04% 99.71% C N CN III 
MAGNESIUM SULPHATE 
INJECTION - 50% 1,200.00 0.03% 99.74% C N CN III 
PARACETAMOL 
INJECTION 10MG/ML  
100ML VIAL 1,200.00 0.03% 99.78% C N CN III 
ATROPINE INJECTION  - 
1MG/ML 1,000.00 0.03% 99.80% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 850 0.02% 99.83% C N CN III 
LOPERAMIDE 
CAPSULES  - 2MG 800 0.02% 99.85% C N CN III 
RANITIDINE INJECTION  
- 50MG/2ML 800 0.02% 99.87% C N CN III 
BISACODYL 5MG 
TABLETS 750 0.02% 99.89% C N CN III 
GLIBENCLAMIDE 
TABLETS  - 5MG 700 0.02% 99.91% C N CN III 
METOCLOPRAMIDE 
INJECTION  - 5MG/ML 700 0.02% 99.93% C V CV I 
ENALAPRIL TABLETS - 
5MG 650 0.02% 99.95% C V CV I 
CHLORPHENIRAMINE 




TAB 75MG, ENTERIC 
COATED 480 0.01% 99.97% C N CN III 
ATENOLOL TABLETS  - 
50MG 440 0.01% 99.98% C E CE II 
METOCLOPRAMIDE  
TABLETS - 10MG 325 0.01% 99.99% C N CN III 
DIAZEPAM TAB 5MG 225 0.01% 100.00% C N CN III 
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Appendix 6: NAMBALE SCH 2016-2017 


















% 15.08% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
125,000.0
0 
9.42% 24.50% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 
105,000.0
0 
7.92% 32.41% A N AN I 
CIPROFLOXACIN 
TABLETS  - 250MG 99,000.00 7.46% 39.88% A V AV I 
DOXYCYCLINE 
CAPSULES  - 100MG 77,400.00 5.83% 45.71% A N AN I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 60,000.00 4.52% 50.23% A V AV I 
GRISEOFULVIN TAB 
125MG 58,500.00 4.41% 54.64% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 56,000.00 4.22% 58.87% A N AN I 
IBUPROFEN TABLETS  - 
200MG 50,000.00 3.77% 62.63% A V AV I 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 3.13% 65.76% A N AN I 
METRONIDAZOLE 
TABLETS  - 200MG 36,000.00 2.71% 68.48% A V AV I 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 32,400.00 2.44% 70.92% A N AN I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 25,000.00 1.88% 72.80% B N BN II 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 24,000.00 1.81% 74.61% B V BV I 
SNAKE VENOM 
ANTISERUM(AFRICAN) 




T) 10ML AMPOULE 
Cotrimoxazole 480mg 
Tabs 19,300.00 1.45% 77.76% B V BV I 
HYDROCORTISONE 
OINTMENT - 1% 18,000.00 1.36% 79.12% B N BN II 
GLIBENCLAMIDE 
TABLETS  - 5MG 17,500.00 1.32% 80.44% B N BN II 
CLOTRIMAZOLE CREAM  
- 1% 17,000.00 1.28% 81.72% B V BV I 
Co-trimoxazole 
suspension, 240 mg/5ml 17,000.00 1.28% 83.00% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG 16,000.00 1.21% 84.21% B V BV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 15,000.00 1.13% 85.34% B V BV I 
HYDROCORTISONE 
INJECTION  - 100MG 14,500.00 1.09% 86.43% B N BN II 
NIFEDIPINE TABLETS  - 
20MG 14,400.00 1.09% 87.52% B N BN II 
DICLOFENAC SODIUM 
TABLETS - 50MG 13,800.00 1.04% 88.56% B V BV I 
FERROUS SULPHATE 
TABLETS  - 200MG 13,750.00 1.04% 89.60% B V BV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 13,000.00 0.98% 90.58% C V CV I 
HYDRALAZINE 
INJECTION  - 20MG/ML 12,700.00 0.96% 91.53% C V CV I 
INSULIN BIPHASIC 30/70  
- 100IU/ML 12,000.00 0.90% 92.44% C N CV I 
ALBENDAZOLE 
TABLETS 400MG 10,000.00 0.75% 93.19% C V CV I 
SILVER SULPHADIAZINE 
CREAM - 1% 10,000.00 0.75% 93.94% C V CV I 
MULTIVITAMIN SYRUP 9,400.00 0.71% 94.65% C N CN III 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 9,000.00 0.68% 95.33% C N CN III 
MAGNESIUM SULPHATE 
INJECTION - 50% 9,000.00 0.68% 96.01% C V CV I 
CARBAMAZEPINE 
TABLETS 200MG 7,500.00 0.57% 96.58% C N CN III 
DICLOFENAC 
INJECTION  - 75MG 5,000.00 0.38% 96.95% C N CN III 
GENTAMICIN INJECTION 
- 80MG- 40MG/ML 2ML 
AMP 4,500.00 0.34% 97.29% C E CE II 
PHENOBARBITONE 
TABLETS - 30MG 4,200.00 0.32% 97.61% C V CV I 
HYDROCHLOROTHIAZID
E TABLETS - 50MG 4,000.00 0.30% 97.91% C N CN III 
KETOCONAZOLE 




INJECTION - 250MG 3,500.00 0.26% 98.48% C V CV I 
ENALAPRIL TABLETS - 
5MG 3,250.00 0.24% 98.72% C N CN III 
POVIDONE-IODINE 
SOLUTION - 10% 2,900.00 0.22% 98.94% C N CN III 
AMLODIPINE TABLET 
5MG 2,250.00 0.17% 99.11% C V CV I 
ATENOLOL TABLETS  - 
50MG 2,200.00 0.17% 99.27% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 1,700.00 0.13% 99.40% C E CE II 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 1,200.00 0.09% 99.49% C N CN III 
AZITHROMYCIN 500MG  1,200.00 0.09% 99.58% C V CV I 
ADRENALINE 
INJECTION  - 1MG/ML 1,000.00 0.08% 99.66% C N CN III 
DOMPERIDONE 10MG 
TABLETS 950 0.07% 99.73% C V CV I 
DEXAMETHASONE 
INJECTION  - 4MG/ML 900 0.07% 99.80% C N CN III 
DIAZEPAM TAB 5MG 900 0.07% 99.87% C V CV I 
RANITIDINE INJECTION  
- 50MG/2ML 800 0.06% 99.93% C V CV I 
BENZYLBENZOATE 
EMULSION - 25% 
APPLICATION 600 0.05% 99.97% C V CV I 
BISACODYL 5MG 
TABLETS 250 0.02% 99.99% C V CV I 
ATROPINE INJECTION  - 
1MG/ML 100 0.01% 100.00% C V CV I 
CALAMINE LOTION  - 
15% 25 0.00% 100.00% C N CN III 
WATER FOR INJECTION 4 0.00% 100.00% C N CN III 
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Appendix 7: PORT VICTORIA SCH 2015-2016 

















9.33% 9.33% A V AV I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
168,000.00 
4.40% 13.73% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 
156,000.00 







T) 10ML AMPOULE 
142,500.00 
3.70% 21.70% A N AN I 
ERYTHROMYCIN 
TABLETS  - 250MG 
124,700.00 
3.52% 25.22% A V AV I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 
120,000.00 




3.23% 31.74% A N AN I 
HYDROCORTISONE 
OINTMENT - 1% 
115,000.00 
2.96% 34.70% A N AN I 
CEFTRIAXONE  
INJECTION - 1G 
114,300.00 
2.88% 37.57% A N AN I 
AMOXICILLIN/CLAVULAN




2.65% 40.22% A V AV I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 
168,000.00 
2.53% 42.75% A V AV I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 
156,000.00 









2.21% 49.79% A N AN I 
DEXTROSE - 5% 
120,000.00 
2.00% 51.79% A V AV I 
OXYTOCIN INJECTION - 
5 IU/ML 
120,000.00 










1.67% 57.26% A N AN I 
HYDROCORTISONE 
INJECTION  - 100MG 
170,000.00 





1.41% 60.13% A N AN I 
INSULIN BIPHASIC 30/70  
- 100IU/ML 
156,000.00 
1.41% 61.54% A N AN I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 
142,500.00 
1.35% 62.89% A N AN I 
HYDRALAZINE 
INJECTION  - 20MG/ML 
124,700.00 
1.34% 64.23% A E AE I 
PARACETAMOL 




SUSPENSION  - 
200MG/5ML 89,600.00 1.05% 66.34% B N BN II 
FLUCLOXACILLIN 
INJECTION - 250MG 87,500.00 1.03% 67.37% B N BN II 
DICLOFENAC 
INJECTION  - 75MG 86,000.00 1.01% 68.38% B N BN II 
METFORMINE TABLETS  
- 500MG 81,600.00 0.96% 69.34% B N BN II 
MORPHINE SULPHATE 
INJECTION -  10MG/ML 81,250.00 0.95% 70.29% B N BN II 
METRONIDAZOLE 
INJECTION  - 5MG/ML 77,500.00 0.91% 71.20% B V BV I 
Cotrimoxazole 480mg 
Tabs 77,200.00 0.91% 72.10% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG 76,800.00 0.90% 73.01% B V BV I 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 
5MG(MARCAINE HEAVY) 76,500.00 0.90% 73.90% B N BN II 
Co-trimoxazole 
suspension, 240 mg/5ml 76,500.00 0.90% 74.80% B V BV I 
ANTI-D (RH) INJECTION - 
250MCG 75,000.00 0.88% 75.68% B N BN II 
PREDNISOLONE 
TABLETS  - 5MG 68,400.00 0.80% 76.48% B E BE II 
CIPROFLOXACIN 
TABLETS  - 250MG 66,000.00 0.77% 77.26% B N BN II 
ETHANOL (DENATURED) 
- 94% 63,750.00 0.75% 78.01% B N BN II 
SODIUM LACTATE 
SOLUTION 60,000.00 0.70% 78.71% B N BN II 
PENICILLIN  BENZYL 
INJECTION  - 5MU 58,800.00 0.69% 79.40% B N BN II 
WATER FOR INJECTION 58,000.00 0.68% 80.08% B N BN II 
ALBENDAZOLE 
TABLETS 400MG 52,000.00 0.61% 80.69% B N BN II 
DEXTROSE  - 10% 51,408.00 0.60% 81.29% B N BN II 
IBUPROFEN TABLETS  - 
200MG 50,000.00 0.59% 81.88% B N BN II 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 48,600.00 0.57% 82.45% B N BN II 
AMLODIPINE TABLET 
5MG 48,000.00 0.56% 83.02% B V BV I 
AZITHROMYCIN 500MG  48,000.00 0.56% 83.58% B V BV I 
CARBAMAZEPINE 
TABLETS 200MG 48,000.00 0.56% 84.14% B V BV I 
DOXYCYCLINE 
CAPSULES  - 100MG 45,150.00 0.53% 84.67% B V BV I 
OMEPRAZOLE 
CAPSULES  - 20MG 45,000.00 0.53% 85.20% B N BN II 
GENTAMICIN INJECTION 
- 80MG- 40MG/ML 2ML 




- 100 000IU/ML 43,000.00 0.50% 86.21% B V BV I 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 0.49% 86.70% B E BE II 
PARACETAMOL 
SUSPENSION - 
120MG/5ML 37,800.00 0.44% 87.14% B N BN II 
Acyclovir 400mg Tabs 36,400.00 0.43% 87.57% B N BN II 
CEPHRADINE 
CAPSULES 500MG  36,000.00 0.42% 87.99% B V BV I 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 
TAB 36,000.00 0.42% 88.41% B N BN II 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 34,500.00 0.40% 88.82% B N BN II 
SILVER SULPHADIAZINE 
CREAM - 1% 34,000.00 0.40% 89.22% B N BN II 
POVIDONE-IODINE 
SOLUTION - 10% 31,900.00 0.37% 89.59% B N BN II 
HYDROCHLOROTHIAZID
E TABLETS - 50MG 30,800.00 0.36% 89.95% B N BN II 
PHENOBARBITONE 
TABLETS - 30MG 29,400.00 0.35% 90.30% C E CE II 
GRISEOFULVIN TAB 
125MG 29,250.00 0.34% 90.64% C N CN III 
ANTI-RABIES SERUM 
INJ - 200 1U/ML 28,980.00 0.34% 90.98% C V CV I 
NIFEDIPINE TABLETS  - 
20MG 28,800.00 0.34% 91.32% C V CV I 
HALOTHANE 
INHALATION 28,490.00 0.33% 91.65% C N CN III 
ENALAPRIL TABLETS - 
5MG 27,950.00 0.33% 91.98% C V CV I 
PENICILLIN  BENZYL 
INJECTION  - 1MU 26,600.00 0.31% 92.29% C N CN III 
OXYTOCIN INJECTION - 
10 IU/ML 26,400.00 0.31% 92.60% C N CN III 
CLOTRIMAZOLE CREAM  
- 1% 25,500.00 0.30% 92.90% C N CN III 
PARACETAMOL 
SUPPOSITORIES 125MG 25,200.00 0.30% 93.20% C N CN III 
KETAMINE INJECTION - 
50MG/ML 23,000.00 0.27% 93.47% C V CV I 
QUININE SULPHATE 
TABLETS - 300MG 22,500.00 0.26% 93.73% C V CV I 
SALBUTAMOL INHALER 
- 100MCG/ACTUATION 22,500.00 0.26% 94.00% C V CV I 
PANCURONIUM 
INJECTION  - 4MG/2ML 18,400.00 0.22% 94.21% C N CN III 
LIGNOCAINE 
HYDROCHLORIDE INJ. 
1% 18,000.00 0.21% 94.42% C N CN III 
METHYLDOPA TABLETS  
- 250MG 17,750.00 0.21% 94.63% C V CV I 
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HEPARINE INJECTION  - 
5000UNITS/ML  5ML 17,680.00 0.21% 94.84% C N CN III 
SALBUTAMOL 
NEBULIZING SOLUTION  
- 5MG/ML 10ML 17,500.00 0.21% 95.05% C V CV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 16,800.00 0.20% 95.24% C N CN III 
THIOPENTONE SODIUM 
INJECTION - 500MG 16,500.00 0.19% 95.44% C N CN III 
MAGNESIUM SULPHATE 
INJECTION - 50% 16,200.00 0.19% 95.63% C N CN III 
ETHANOL (DENATURED)  
- 70% 16,000.00 0.19% 95.81% C V CV I 
RANITIDINE INJECTION  
- 50MG/2ML 16,000.00 0.19% 96.00% C N CN III 
GLIBENCLAMIDE 
TABLETS  - 5MG 14,000.00 0.16% 96.17% C N CN III 
REHYDRATION SALTS  
ORAL (ORS) 13,950.00 0.16% 96.33% C N CN III 
MULTIVITAMIN SYRUP 13,160.00 0.15% 96.48% C N CN III 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 12,600.00 0.15% 96.63% C N CN III 
AMITRIPTYLINE 
TABLETS  - 25MG 12,150.00 0.14% 96.78% C V CV I 
ACETYLSALICYLIC ACID 
TAB 75MG, ENTERIC 
COATED 12,000.00 0.14% 96.92% C N CN III 
ALCOHOL BASED HAND 
RUB 12,000.00 0.14% 97.06% C V CV I 
FLUCONAZOLE  
CAPSULES - 50MG 12,000.00 0.14% 97.20% C V CV I 
GLUCOSE INJECTION 
50%  50ML  (DEXTROSE) 12,000.00 0.14% 97.34% C V CV I 
ATRACURIUM 
INJECTION  - 10MG/ML 11,750.00 0.14% 97.48% C V CV I 
DICLOFENAC SODIUM 
TABLETS - 50MG 11,040.00 0.13% 97.61% C N CN III 
ATROPINE INJECTION  - 
1MG/ML 11,000.00 0.13% 97.73% C N CN III 
NEOSTIGMINE 
INJECTION  - 2.5MG/ML 10,400.00 0.12% 97.86% C V CV I 
SALBUTAMOL SYRUP  - 
2MG/5ML 10,000.00 0.12% 97.97% C N CN III 
FUROSEMIDE 
INJECTION  - 20MG/2ML 9,100.00 0.11% 98.08% C N CN III 
GLUTARALDEHYDE 2% 
SOLUTION 9,100.00 0.11% 98.19% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 9,000.00 0.11% 98.29% C E CE II 
FLUPHENAZINE 
INJECTION  - 25MG/ML 8,600.00 0.10% 98.39% C V CV I 
METOCLOPRAMIDE 




TABLETS  - 200MG 8,000.00 0.09% 98.59% C N CN III 
CALAMINE LOTION  - 
15% 7,500.00 0.09% 98.67% C V CV I 
CHLORPHENIRAMINE 
TABLETS - 4MG 7,440.00 0.09% 98.76% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 7,200.00 0.08% 98.85% C N CN III 
CEFTAZIDIME 1G INJ. 7,000.00 0.08% 98.93% C N CN III 
IBUPROFEN SYRUP 
100MG/5ML 60ML 6,600.00 0.08% 99.01% C N CN III 
TINIDAZOLE TAB 500MG 6,500.00 0.08% 99.08% C N CN III 
INSULIN SOLUBLE - 
100IU/ML 6,300.00 0.07% 99.16% C N CN III 
BENZHEXOL TABLETS  - 
5MG 6,100.00 0.07% 99.23% C V CV I 
ADRENALINE 
INJECTION  - 1MG/ML 6,000.00 0.07% 99.30% C V CV I 
MAGNESIUM SULPHATE 
INJ 4%, W/V,100ML 
BOTTLE 5,800.00 0.07% 99.37% C V CV I 
TETRACYCLINE EYE 
OINTMENT -1% 5,400.00 0.06% 99.43% C N CN III 
FOLIC ACID TABLETS  - 
5MG 5,250.00 0.06% 99.49% C N CN III 
SALBUTAMOL TABLETS  
- 4MG 4,000.00 0.05% 99.54% C N CN III 
FLUPENTHIXOL 
DECANOATE  - 20MG/ML 3,375.00 0.04% 99.58% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 3,000.00 0.04% 99.61% C N CN III 
WATER BASED 
LUBRICANT (KY  JELLY) 2,750.00 0.03% 99.65% C N CN III 
HALOPERIDOL TABLETS  
- 5MG 2,510.00 0.03% 99.68% C N CN III 
PENICILLIN  
BENZATHINE INJECTION  
- 2.4 MU 2,500.00 0.03% 99.70% C N CN III 
PARACETAMOL 
INJECTION 10MG/ML  
100ML VIAL 2,400.00 0.03% 99.73% C V CV I 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 5MG 2,350.00 0.03% 99.76% C V CV I 
DIGOXIN TABLETS  - 
0.25MG 2,300.00 0.03% 99.79% C N CN III 
ATENOLOL TABLETS  - 
50MG 2,200.00 0.03% 99.81% C V CV I 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 2,000.00 0.02% 99.84% C E CE II 
LOPERAMIDE 
CAPSULES  - 2MG 2,000.00 0.02% 99.86% C N CN III 
FUROSEMIDE TABLETS  




TABLETS - 200MG 1,600.00 0.02% 99.90% C V CV I 
FERROUS SULPHATE 
TABLETS  - 200MG 1,375.00 0.02% 99.92% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 1,050.00 0.01% 99.93% C V CV I 
CHLORPROMAZINE 
TABLETS  - 100MG 985 0.01% 99.94% C V CV I 
GENTAMICIN INJECTION 
- 20MG- 10MG/ML 2ML 
AMP 900 0.01% 99.95% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 850 0.01% 99.96% C N CN III 
METOCLOPRAMIDE  
TABLETS - 10MG 780 0.01% 99.97% C N CN III 
DIHYDROCODEINE 
PHOSPHATE TAB 30MG 770 0.01% 99.98% C N CN III 
ACETYLSALICYLIC ACID 
TABLETS - 300MG 500 0.01% 99.98% C V CV I 
COMPOUND 
MAGNESIUM 
TRISILICATE TABLETS 500 0.01% 99.99% C V CV I 
SODIUM BICARBONATE 
INJECTION - 8.4% 320 0.00% 99.99% C N CN III 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 180 0.00% 100.00% C N CN III 
BISACODYL 5MG 
TABLETS 150 0.00% 100.00% C N CN III 
DIAZEPAM TAB 5MG 135 0.00% 100.00% C V CV I 
SUXAMETHONIUM 
CHLORIDE INJECTION 90 0.00% 100.00% C N CN III 
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OXYTOCIN INJECTION - 
5 IU/ML 
300,000.00 13.37
% 13.37% A N AN I 
CEFTRIAXONE  
INJECTION - 1G 
157,500.00 
7.02% 20.39% A E AE I 
CIPROFLOXACIN 
TABLETS  - 250MG 
132,000.00 
5.88% 26.28% A N AN I 
DOXYCYCLINE 
CAPSULES  - 100MG 
129,000.00 
5.75% 32.03% A V AV I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
125,000.00 




INJECTION -  10MG/ML 87,500.00 3.90% 41.50% A V AV I 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 86,400.00 3.85% 45.35% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 70,000.00 3.12% 48.47% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG 70,000.00 3.12% 51.59% A N AN I 
ORAL REHYDRATION 
SALTS 70,000.00 3.12% 54.71% A E AE I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 60,000.00 2.67% 57.39% A V AV I 
FLUCLOXACILLIN  
CAPSULES 500MG 55,000.00 2.45% 59.84% A V AV I 
ANTI-D (RH) INJECTION - 
250MCG 50,000.00 2.23% 62.07% A V AV I 
CEFIXIME TABLET 
400MG 50,000.00 2.23% 64.29% A E AE I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 50,000.00 2.23% 66.52% A N AN I 
IBUPROFEN TABLETS  - 





T) 10ML AMPOULE 45,000.00 2.01% 70.76% A V AV I 
CEFTAZIDIME 1G INJ. 42,000.00 1.87% 72.63% B N BN II 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 1.85% 74.48% B N BN II 
METRONIDAZOLE 
TABLETS  - 200MG 40,000.00 1.78% 76.26% B V BV I 
GRISEOFULVIN TAB 
125MG 39,000.00 1.74% 78.00% B V BV I 
Co-trimoxazole 
suspension, 240 mg/5ml 34,000.00 1.52% 79.52% B N BN II 
CEFTRIAXONE  
INJECTION - 250MG 32,000.00 1.43% 80.94% B V BV I 
HYDRALAZINE 
INJECTION  - 20MG/ML 31,750.00 1.42% 82.36% B N BN II 
INSULIN BIPHASIC 30/70  
- 100IU/ML 30,000.00 1.34% 83.70% B E BE II 
HYDROCORTISONE 
INJECTION  - 100MG 29,000.00 1.29% 84.99% B V BV I 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 24,000.00 1.07% 86.06% B V BV I 
DEXTROSE  - 10% 22,644.00 1.01% 87.07% B N BN II 
AZITHROMYCIN 500MG  20,000.00 0.89% 87.96% B E BE II 
SILVER SULPHADIAZINE 




Tabs 19,300.00 0.86% 89.71% B N BN II 
GENTAMICIN INJECTION 
- 80MG- 40MG/ML 2ML 
AMP 18,000.00 0.80% 90.51% B V BV I 
HYDROCORTISONE 
OINTMENT - 1% 18,000.00 0.80% 91.32% B E BE II 
FLUPHENAZINE 
INJECTION  - 25MG/ML 17,200.00 0.77% 92.08% C V CV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 15,000.00 0.67% 92.75% C N CN III 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 13,000.00 0.58% 93.33% C V CV I 
NEOSTIGMINE 
INJECTION  - 2.5MG/ML 12,000.00 0.53% 93.87% C N CN III 
DICLOFENAC 
INJECTION  - 75MG 10,000.00 0.45% 94.31% C V CV III 
MULTIVITAMIN SYRUP 9,400.00 0.42% 94.73% C V CV I 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 9,000.00 0.40% 95.13% C V CV I 
POVIDONE-IODINE 
SOLUTION - 10% 8,700.00 0.39% 95.52% C N CN III 
CLOTRIMAZOLE CREAM  
- 1% 8,500.00 0.38% 95.90% C N CN III 
DICLOFENAC SODIUM 
TABLETS - 50MG 8,280.00 0.37% 96.27% C N CN III 
ALBENDAZOLE 
TABLETS 400MG 8,000.00 0.36% 96.62% C N CN III 
NIFEDIPINE TABLETS  - 
20MG 7,200.00 0.32% 96.94% C V CV I 
METHYLDOPA TABLETS  
- 250MG 7,100.00 0.32% 97.26% C V CV I 
GLIBENCLAMIDE 
TABLETS  - 5MG 7,000.00 0.31% 97.57% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 7,000.00 0.31% 97.88% C V CV I 
RANITIDINE INJECTION  
- 50MG/2ML 6,400.00 0.29% 98.17% C V CV I 
FOLIC ACID TABLETS  - 
5MG 5,500.00 0.25% 98.42% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 4,500.00 0.20% 98.62% C N CN III 
SUXAMETHONIUM 
CHLORIDE INJECTION 4,500.00 0.20% 98.82% C V CV I 
HYDROCHLOROTHIAZID
E TABLETS - 50MG 4,000.00 0.18% 98.99% C E CE II 
DIHYDROCODEINE 
PHOSPHATE TAB 30MG 3,850.00 0.17% 99.17% C V CV I 
CHLORAMPHENICAL 
INJECTION  - 1GM 3,800.00 0.17% 99.34% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 3,600.00 0.16% 99.50% C V CV I 
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ENALAPRIL TABLETS - 
5MG 3,250.00 0.14% 99.64% C V CV I 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 2,400.00 0.11% 99.75% C V CV I 
DOMPERIDONE 10MG 
TABLETS 1,900.00 0.08% 99.83% C E CE II 
AMLODIPINE TABLET 
5MG 1,500.00 0.07% 99.90% C V CV I 
ADRENALINE 
INJECTION  - 1MG/ML 1,000.00 0.04% 99.94% C N CN III 
CHLORPHENIRAMINE 
TABLETS - 4MG 620 0.03% 99.97% C V CV I 
BISACODYL 5MG 
TABLETS 500 0.02% 99.99% C V CV I 
ATROPINE INJECTION  - 
1MG/ML 100 0.00% 100.00% C N CN III 
CALAMINE LOTION  - 
15% 25 0.00% 100.00% C V CV I 
WATER FOR INJECTION 4 0.00% 100.00% C N CN III 
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T) 10ML AMPOULE 
270,000.0
0 9.87% 23.82% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 
154,000.0
0 5.63% 29.45% A V AV I 
NYSTATIN SUSPENSION 
- 100 000IU/ML 
129,000.0
0 4.72% 34.17% A N AN I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 
105,000.0
0 3.84% 38.01% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
105,000.0
0 3.84% 41.85% A N AN I 
AMOXICILLIN/CLAVULAN




0 3.75% 45.59% A V AV I 
ERYTHROMYCIN 
TABLETS  - 250MG 
100,000.0
0 3.66% 49.25% A V AV I 
OXYTOCIN INJECTION - 
5 IU/ML 
100,000.0




suspension, 240 mg/5ml 88,400.00 3.23% 56.14% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 87,500.00 3.20% 59.34% A V AV I 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 76,800.00 2.81% 62.15% A V AV I 
ETHANOL (DENATURED) 
- 94% 76,500.00 2.80% 64.94% A V AV I 
SODIUM 
HYPOCHLORITE 
SOLUTION 61,200.00 2.24% 67.18% A N AN I 
ANTI-D (RH) INJECTION - 
250MCG 50,000.00 1.83% 69.01% A N AN I 
PARACETAMOL 
SUSPENSION - 
120MG/5ML 46,200.00 1.69% 70.70% A N AN I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 37,200.00 1.36% 72.06% B V BV I 
INSULIN BIPHASIC 30/70  
- 100IU/ML 36,000.00 1.32% 73.37% B N BN II 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 35,000.00 1.28% 74.65% B N BN II 
REHYDRATION SALTS  
ORAL (ORS) 27,900.00 1.02% 75.67% B N BN II 
CEFIXIME TABLET 
400MG 27,500.00 1.01% 76.68% B V BV I 
OMEPRAZOLE 
CAPSULES  - 20MG 27,000.00 0.99% 77.67% B N BN II 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 26,000.00 0.95% 78.62% B N BN II 
DOXYCYCLINE 
CAPSULES  - 100MG 25,800.00 0.94% 79.56% B N BN II 
MAGNESIUM SULPHATE 
INJECTION - 50% 25,200.00 0.92% 80.48% B N BN II 
IBUPROFEN TABLETS  - 
200MG 25,000.00 0.91% 81.40% B N BN II 
OXYTOCIN INJECTION - 
10 IU/ML 22,800.00 0.83% 82.23% B E BE II 
Acyclovir 400mg Tabs 21,000.00 0.77% 83.00% B V BV I 
ANTI-RABIES SERUM INJ 
- 200 1U/ML 19,320.00 0.71% 83.70% B N BN II 
Cotrimoxazole 480mg 
Tabs 19,300.00 0.71% 84.41% B V BV I 
ALCOHOL BASED HAND 
RUB 19,200.00 0.70% 85.11% B N BN II 
PARACETAMOL 
TABLETS  - 500MG 18,750.00 0.69% 85.80% B N BN II 
DEXTROSE - 5% 18,000.00 0.66% 86.46% B E BE II 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 




OINTMENT - 1% 18,000.00 0.66% 87.77% B N BN II 
RETINOL (VITAMIN 
A)CAPSULES 50000IU 18,000.00 0.66% 88.43% B V BV I 
METHYLDOPA TABLETS  
- 250MG 17,750.00 0.65% 89.08% B N BN II 
POVIDONE-IODINE 
SOLUTION - 10% 16,820.00 0.61% 89.69% B V BV I 
DICLOFENAC SODIUM 
TABLETS - 50MG 16,560.00 0.61% 90.30% B V BV I 
CIPROFLOXACIN 
TABLETS  - 250MG 16,500.00 0.60% 90.90% C N CN III 
HYDROCORTISONE 
INJECTION  - 100MG 13,630.00 0.50% 91.40% C N CN III 
QUININE SULPHATE 
TABLETS - 300MG 13,500.00 0.49% 91.89% C N CN III 
DEXTROSE  - 10% 12,240.00 0.45% 92.34% C E CE II 
ALBENDAZOLE 
TABLETS 400MG 10,000.00 0.37% 92.71% C V CV I 
GENTAMICIN INJECTION 
- 80MG- 40MG/ML 2ML 
AMP 9,900.00 0.36% 93.07% C N CN III 
GRISEOFULVIN TAB 
125MG 9,750.00 0.36% 93.43% C V CV I 
SODIUM LACTATE 
SOLUTION 9,600.00 0.35% 93.78% C N CN III 
PREDNISOLONE 
TABLETS  - 5MG 9,000.00 0.33% 94.11% C N CN III 
TETRACYCLINE EYE 




DIPLOID, 8,550.00 0.31% 94.75% C V CV I 
PENICILLIN  BENZYL 
INJECTION  - 5MU 8,400.00 0.31% 95.05% C N CN III 
LIGNOCAINE 
HYDROCHLORIDE INJ. 
1% 8,000.00 0.29% 95.35% C N CN III 
HYDRALAZINE 
INJECTION  - 20MG/ML 6,350.00 0.23% 95.58% C V CV I 
HYDROCHLOROTHIAZID
E TABLETS - 50MG 6,000.00 0.22% 95.80% C N CN III 
PARACETAMOL 
SUPPOSITORIES 125MG 6,000.00 0.22% 96.02% C V CV I 
SILVER SULPHADIAZINE 
CREAM - 1% 6,000.00 0.22% 96.24% C V CV I 
METFORMINE TABLETS  
- 500MG 5,440.00 0.20% 96.44% C N CN III 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 5,400.00 0.20% 96.63% C N CN III 
ENALAPRIL TABLETS - 
5MG 5,200.00 0.19% 96.82% C N CN III 
ATENOLOL TABLETS  - 




INJECTION - 200MG/ML 4,150.00 0.15% 97.14% C N CN III 
AZITHROMYCIN 500MG  4,000.00 0.15% 97.28% C V CV I 
SALBUTAMOL SYRUP  - 
2MG/5ML 4,000.00 0.15% 97.43% C N CN III 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 3,600.00 0.13% 97.56% C N CN III 
MULTIVITAMIN SYRUP 3,290.00 0.12% 97.68% C V CV I 
GLUCOSE INJECTION 
50%  50ML  (DEXTROSE) 3,000.00 0.11% 97.79% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 2,800.00 0.10% 97.89% C N CN III 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 2,700.00 0.10% 97.99% C V CV I 
TINIDAZOLE TAB 500MG 2,600.00 0.10% 98.09% C V CV I 
CALAMINE LOTION  - 
15% 2,500.00 0.09% 98.18% C N CN III 
METRONIDAZOLE 
INJECTION  - 5MG/ML 2,500.00 0.09% 98.27% C N CN III 
GLIBENCLAMIDE 
TABLETS  - 5MG 2,450.00 0.09% 98.36% C V CV I 
WATER FOR INJECTION 2,400.00 0.09% 98.45% C N CN III 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 2,240.00 0.08% 98.53% C V CV I 
WATER BASED 
LUBRICANT (KY  JELLY) 2,200.00 0.08% 98.61% C N CN III 
FOLIC ACID TABLETS  - 
5MG 2,100.00 0.08% 98.69% C V CV I 
FUROSEMIDE TABLETS  
- 40MG 2,100.00 0.08% 98.76% C N CN III 
PENICILLIN  BENZYL 
INJECTION  - 1MU 2,100.00 0.08% 98.84% C N CN III 
AMITRIPTYLINE 
TABLETS  - 25MG 2,025.00 0.07% 98.91% C N CN III 
ADRENALINE INJECTION  
- 1MG/ML 2,000.00 0.07% 98.99% C N CN III 
CHLORPHENIRAMINE 
TABLETS - 4MG 1,922.00 0.07% 99.06% C V CV I 
ACETYLSALICYLIC ACID 
TAB 75MG, ENTERIC 
COATED 1,920.00 0.07% 99.13% C N CN III 
CLOTRIMAZOLE CREAM  
- 1% 1,700.00 0.06% 99.19% C N CN III 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 1,700.00 0.06% 99.25% C V CV I 
METRONIDAZOLE 
TABLETS  - 200MG 1,600.00 0.06% 99.31% C N CN III 
AMLODIPINE TABLET 




INJECTION  - 75MG 1,500.00 0.05% 99.42% C N CN III 
INSULIN SOLUBLE - 
100IU/ML 1,500.00 0.05% 99.47% C V CV I 
SALBUTAMOL INHALER - 
100MCG/ACTUATION 1,500.00 0.05% 99.53% C N CN III 
FERROUS SULPHATE 
TABLETS  - 200MG 1,375.00 0.05% 99.58% C N CN III 
CEFUROXIME 250MG 
TABS 1,300.00 0.05% 99.63% C V CV I 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 1,200.00 0.04% 99.67% C V CV I 
RANITIDINE INJECTION  
- 50MG/2ML 1,200.00 0.04% 99.71% C N CN III 
NIFEDIPINE TABLETS  - 
20MG 1,080.00 0.04% 99.75% C N CN III 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 1,080.00 0.04% 99.79% C V CV I 
ATROPINE INJECTION  - 
1MG/ML 1,000.00 0.04% 99.83% C V CV I 
GENTAMICIN INJECTION 
- 20MG- 10MG/ML 2ML 
AMP 900 0.03% 99.86% C N CN III 
PENICILLIN  
BENZATHINE INJECTION  
- 2.4 MU 750 0.03% 99.89% C N CN III 
CEFTRIAXONE  
INJECTION - 250MG 640 0.02% 99.91% C N CN III 
METOCLOPRAMIDE  
TABLETS - 10MG 390 0.01% 99.93% C N CN III 
FLUCLOXACILLIN 
INJECTION - 250MG 350 0.01% 99.94% C V CV I 
FUROSEMIDE 
INJECTION  - 20MG/2ML 350 0.01% 99.95% C N CN III 
METOCLOPRAMIDE 
INJECTION  - 5MG/ML 350 0.01% 99.97% C N CN III 
LOPERAMIDE 
CAPSULES  - 2MG 300 0.01% 99.98% C V CV I 
DIAZEPAM TAB 5MG 225 0.01% 99.99% C N CN III 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 200 0.01% 99.99% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 180 0.01% 100.00% C V CV I 
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% 29.29% A V AV I 
FLUCLOXACILLIN 




% 47.60% A N AN I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 60,000.00 8.79% 56.39% A N AN I 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 6.08% 62.47% A N AN I 
ORAL REHYDRATION 
SALTS 35,000.00 5.13% 67.59% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 35,000.00 5.13% 72.72% B N BN II 
CIPROFLOXACIN 
TABLETS  - 250MG 33,000.00 4.83% 77.55% B N BN II 
HYOSCINE 
BUTYLBROMIDE TAB 





T) 10ML AMPOULE 22,500.00 3.30% 84.36% B N BN II 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 21,600.00 3.16% 87.53% B N BN II 
Co-trimoxazole 
suspension, 240 mg/5ml 17,000.00 2.49% 90.02% B N BN II 
INSULIN BIPHASIC 
30/70  - 100IU/ML 15,000.00 2.20% 92.21% B V BV I 
CHLORAMPHENICAL 
INJECTION  - 1GM 7,600.00 1.11% 93.33% C N CN  III 
FLUCLOXACILLIN 
INJECTION - 250MG 7,000.00 1.03% 94.35% C N CN  III 
DICLOFENAC SODIUM 
TABLETS - 50MG 5,520.00 0.81% 95.16% C N CN  III 
DICLOFENAC 
INJECTION  - 75MG 5,000.00 0.73% 95.89% C N CN  III 
ALBENDAZOLE 
TABLETS 400MG 5,000.00 0.73% 96.62% C N CN  III 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 3,600.00 0.53% 97.15% C N CN  III 
PHENOBARBITONE 
TABLETS - 30MG 3,500.00 0.51% 97.66% C N CN  III 
POVIDONE-IODINE 
SOLUTION - 10% 2,900.00 0.42% 98.09% C N CN  III 
HALOPERIDOL 
TABLETS  - 5MG 2,510.00 0.37% 98.46% C V CV III 
FOLIC ACID TABLETS  - 
5MG 2,100.00 0.31% 98.76% C V CV I 
PHENYTOIN SODIUM 
TABLETS - 50MG 1,750.00 0.26% 99.02% C N CN  III 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 1,500.00 0.22% 99.24% C N CN  III 
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BENZHEXOL TABLETS  - 
5MG 1,220.00 0.18% 99.42% C V CV I 
GENTAMYCIN 
SULPHATE SOLUTION  
(EYE / EAR DROPS)  0.3 
% W/V 850 0.12% 99.54% C V CV I 
AZITHROMYCIN 500MG  800 0.12% 99.66% C V CV I 
ACETYLSALICYLIC 
ACID TABLETS - 300MG 750 0.11% 99.77% C N CN  III 
AMLODIPINE TABLET 
5MG 750 0.11% 99.88% C N CN  III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 240 0.04% 99.91% C N CN  III 
DIAZEPAM TAB 5MG 225 0.03% 99.95% C E CE II 
DEXAMETHASONE 
INJECTION  - 4MG/ML 180 0.03% 99.97% C N CN  III 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 180 0.03% 100.00% C V CV I 
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SALTS 416,500.00 4.39% 4.39% A N AN I 
AMOXYCILLIN CAPSULES 
- 250MG 378,000.00 3.98% 8.37% A V AV I 
CEFTAZIDIME 1G INJ. 365,820.00 3.85% 12.23% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 364,000.00 3.84% 16.06% A V AV I 
ERYTHROMYCIN TABLETS  
- 250MG 350,000.00 3.69% 19.75% A V AV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 300,000.00 3.16% 22.91% A N AN I 
DEXTROSE - 5% 272,000.00 2.87% 25.77% A N AN I 
FLUCLOXACILLIN 




DIPLOID, 228,000.00 2.40% 30.81% A N AN I 
AMOXICILLIN/CLAVULANIC 
ACID ORAL SUSPENSION 
312.5MG/5ML 225,500.00 2.38% 33.19% A V AV I 
PENICILLIN  BENZYL 
INJECTION  - 5MU 224,000.00 2.36% 35.55% A N AN I 
HYOSCINE 
BUTYLBROMIDE TAB 




SUSPENSION (PFR ) - 
125MG/5ML 210,000.00 2.21% 40.04% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG 210,000.00 2.21% 42.25% A N AN I 
SODIUM HYPOCHLORITE 
SOLUTION 204,000.00 2.15% 44.40% A N AN I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 201,600.00 2.12% 46.52% A N AN I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 196,000.00 2.07% 48.59% A N AN I 
OXYTOCIN INJECTION - 5 
IU/ML 168,000.00 1.77% 50.36% A N AN I 
CIPROFLOXACIN TABLETS  
- 250MG 165,000.00 1.74% 52.09% A V AV I 
INSULIN BIPHASIC 30/70  - 
100IU/ML 165,000.00 1.74% 53.83% A N AN I 
ANTI-D (RH) INJECTION - 
250MCG 150,000.00 1.58% 55.41% A N AN I 
IBUPROFEN TABLETS  - 
200MG 150,000.00 1.58% 56.99% A V AV I 
DEXTROSE  - 10% 146,880.00 1.55% 58.54% A N AN I 
Acyclovir 400mg Tabs 126,000.00 1.33% 59.87% A V AV I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 125,000.00 1.32% 61.19% A V AV I 
HYDROCORTISONE 
INJECTION  - 100MG 121,800.00 1.28% 62.47% B N BN II 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 121,440.00 1.28% 63.75% B V BV I 
FLUCONAZOLE  
CAPSULES - 50MG 120,000.00 1.26% 65.01% B V BV I 
ETHANOL (DENATURED) - 
94% 119,000.00 1.25% 66.27% B N BN II 
PARACETAMOL TABLETS  
- 500MG 112,500.00 1.19% 67.45% B V BV I 
FLUPENTHIXOL 
DECANOATE  - 20MG/ML 101,250.00 1.07% 68.52% B N BN II 
FLUPHENAZINE 
INJECTION  - 25MG/ML 94,600.00 1.00% 69.52% B N BN II 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 
5MG(MARCAINE HEAVY) 90,000.00 0.95% 70.46% B V BV I 
SODIUM LACTATE 
SOLUTION 87,600.00 0.92% 71.39% B N BN II 
METRONIDAZOLE 
INJECTION  - 5MG/ML 87,500.00 0.92% 72.31% B V BV I 
CEFTRIAXONE  
INJECTION - 250MG 86,400.00 0.91% 73.22% B N BN II 
PARACETAMOL 
SUSPENSION - 




CAPSULES 500MG 82,500.00 0.87% 74.97% B N BN II 
PENICILLIN  BENZYL 
INJECTION  - 1MU 77,000.00 0.81% 75.78% B N BN II 
CARBAMAZEPINE 
TABLETS 200MG 75,000.00 0.79% 76.57% B V BV I 
MORPHINE SULPHATE 
INJECTION -  10MG/ML 75,000.00 0.79% 77.36% B V BV I 
OXYTOCIN INJECTION - 10 
IU/ML 72,000.00 0.76% 78.12% B N BN II 
ATRACURIUM INJECTION  
- 10MG/ML 70,500.00 0.74% 78.87% B V BV I 
DICLOFENAC INJECTION  - 
75MG 65,000.00 0.68% 79.55% B V BV I 
WATER FOR INJECTION 60,000.00 0.63% 80.18% B N BN II 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 57,600.00 0.61% 80.79% B V BV I 
POVIDONE-IODINE 
SOLUTION - 10% 57,420.00 0.60% 81.40% B N BN II 
CEFUROXIME 250MG 
TABS 52,000.00 0.55% 81.94% B V BV I 
CEFIXIME TABLET 400MG 50,000.00 0.53% 82.47% B N BN II 
PARACETAMOL 
SUPPOSITORIES 125MG 50,000.00 0.53% 83.00% B E BE II 
FERROUS SULP/FOLIC 
200MG/400MCG ACID TAB 48,000.00 0.51% 83.50% B N BN II 
SILVER SULPHADIAZINE 
CREAM - 1% 46,000.00 0.48% 83.99% B N BN II 
QUININE SULPHATE 
TABLETS - 300MG 45,000.00 0.47% 84.46% B V BV I 
CEFTRIAXONE  
INJECTION - 1G  -IV WITH 
DILUENT 40,000.00 0.42% 84.88% B N BN II 
METRONIDAZOLE 
TABLETS  - 200MG 40,000.00 0.42% 85.30% B V BV I 
CHLORPROMAZINE 
TABLETS  - 100MG 39,400.00 0.42% 85.72% B N BN II 
ETORICOXIB 60MG 
TABLETS 37,950.00 0.40% 86.12% B N BN II 
ATENOLOL TABLETS  - 
50MG 36,080.00 0.38% 86.50% B N BN II 
LIGNOCAINE 
HYDROCHLORIDE INJ. 1% 36,000.00 0.38% 86.88% B V BV I 
METHYLDOPA TABLETS  - 
250MG 35,500.00 0.37% 87.25% B N BN II 
Co-trimoxazole suspension, 
240 mg/5ml 34,000.00 0.36% 87.61% B V BV I 
GENTAMICIN INJECTION - 
80MG- 40MG/ML 2ML AMP 32,400.00 0.34% 87.95% B V BV I 
CLOTRIMAZOLE CREAM  - 
1% 32,300.00 0.34% 88.29% B N BN II 
METFORMINE TABLETS  - 
500MG 30,600.00 0.32% 88.61% B N BN II 
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ALCOHOL BASED HAND 
RUB 30,000.00 0.32% 88.93% B N BN II 
GRISEOFULVIN TAB 
125MG 29,250.00 0.31% 89.24% B E BE II 
ANTI-RABIES SERUM INJ - 
200 1U/ML 28,980.00 0.31% 89.54% B N BN II 
ACETYLSALICYLIC ACID 
TAB 75MG, ENTERIC 
COATED 28,800.00 0.30% 89.85% B N BN II 
MULTIVITAMIN SYRUP 28,200.00 0.30% 90.14% C N CN III 
GLUCOSE INJECTION 50%  
50ML  (DEXTROSE) 27,000.00 0.28% 90.43% C N CN III 
TETRACYCLINE EYE 
OINTMENT -1% 27,000.00 0.28% 90.71% C N CN III 
PREDNISOLONE TABLETS  
- 5MG 26,400.00 0.28% 90.99% C V CV I 
AZITHROMYCIN 500MG  26,000.00 0.27% 91.27% C V CV I 
SALBUTAMOL SYRUP  - 
2MG/5ML 26,000.00 0.27% 91.54% C N CN III 
DOXYCYCLINE CAPSULES  
- 100MG 25,800.00 0.27% 91.81% C V CV I 
HYDRALAZINE INJECTION  
- 20MG/ML 25,400.00 0.27% 92.08% C N CN III 
MORPHINE POWDER 25,000.00 0.26% 92.34% C N CN III 
HALOTHANE INHALATION 24,420.00 0.26% 92.60% C V CV I 
REHYDRATION SALTS  
ORAL (ORS) 23,250.00 0.24% 92.85% C N CN III 
OMEPRAZOLE CAPSULES  
- 20MG 22,500.00 0.24% 93.08% C N CN III 
Cotrimoxazole 480mg Tabs 21,230.00 0.22% 93.31% C V CV I 
FOLIC ACID TABLETS  - 
5MG 21,000.00 0.22% 93.53% C N CN III 
SALBUTAMOL 
NEBULIZING SOLUTION  - 
5MG/ML 10ML 20,000.00 0.21% 93.74% C V CV I 
ENALAPRIL TABLETS - 
5MG 19,500.00 0.21% 93.94% C N CN III 
HALOPERIDOL TABLETS  - 
5MG 18,825.00 0.20% 94.14% C N CN III 
BENZHEXOL TABLETS  - 
5MG 18,300.00 0.19% 94.33% C N CN III 
MAGNESIUM SULPHATE 
INJECTION - 50% 18,000.00 0.19% 94.52% C V CV I 
NIFEDIPINE TABLETS  - 
20MG 18,000.00 0.19% 94.71% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 17,500.00 0.18% 94.90% C E CE II 
MAGNESIUM SULPHATE 
INJ 4%, W/V,100ML 
BOTTLE 17,400.00 0.18% 95.08% C N CN III 
ALBENDAZOLE TABLETS 
400MG 17,000.00 0.18% 95.26% C V CV I 
DICLOFENAC SODIUM 
TABLETS - 50MG 16,560.00 0.17% 95.43% C N CN III 
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DIGOXIN TABLETS  - 
0.25MG 16,100.00 0.17% 95.60% C N CN III 
ETHANOL (DENATURED)  - 
70% 16,000.00 0.17% 95.77% C N CN III 
PANCURONIUM 
INJECTION  - 4MG/2ML 16,000.00 0.17% 95.94% C N CN III 
SALBUTAMOL INHALER - 
100MCG/ACTUATION 15,000.00 0.16% 96.10% C N CN III 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 14,400.00 0.15% 96.25% C E CE II 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 14,400.00 0.15% 96.40% C N CN III 
VITAMIN B COMPLEX (B1, 
B6 AND B12) 14,040.00 0.15% 96.55% C N CN III 
IBUPROFEN SYRUP 
100MG/5ML 60ML 13,200.00 0.14% 96.69% C V CV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 13,000.00 0.14% 96.83% C N CN III 
NYSTATIN SUSPENSION - 
100 000IU/ML 12,900.00 0.14% 96.96% C V CV I 
GENTAMICIN INJECTION - 
20MG- 10MG/ML 2ML AMP 12,600.00 0.13% 97.10% C V CV I 
PHENYTOIN SODIUM 
TABLETS - 50MG 12,250.00 0.13% 97.22% C V CV I 
INSULIN SOLUBLE - 
100IU/ML 12,000.00 0.13% 97.35% C N CN III 
CHLORAMPHENICAL 
INJECTION  - 1GM 11,400.00 0.12% 97.47% C V CV I 
CALAMINE LOTION  - 15% 11,250.00 0.12% 97.59% C N CN III 
GLIBENCLAMIDE TABLETS  
- 5MG 11,200.00 0.12% 97.71% C N CN III 
HYDROCORTISONE 
OINTMENT - 1% 10,800.00 0.11% 97.82% C N CN III 
HYDROCHLOROTHIAZIDE 
TABLETS - 50MG 10,000.00 0.11% 97.93% C N CN III 
KETAMINE INJECTION - 
50MG/ML 10,000.00 0.11% 98.03% C V CV I 
DIGOXIN ELIXIR/ORAL 
SOLUTION - 50MCG/ML 9,850.00 0.10% 98.14% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 9,600.00 0.10% 98.24% C V CV I 
RETINOL (VITAMIN 
A)CAPSULES 50000IU 9,000.00 0.09% 98.33% C N CN III 
THIOPENTONE SODIUM 
INJECTION - 500MG 8,250.00 0.09% 98.42% C V CV I 
AMITRIPTYLINE TABLETS  
- 25MG 8,100.00 0.09% 98.50% C N CN III 
CEFTRIAXONE  
INJECTION - 1G – IM WITH 
DILUENT 8,000.00 0.08% 98.59% C N CN III 
NEOSTIGMINE INJECTION  
- 2.5MG/ML 8,000.00 0.08% 98.67% C N CN III 
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SALBUTAMOL TABLETS  - 
4MG 7,800.00 0.08% 98.76% C N CN III 
FUROSEMIDE INJECTION  
- 20MG/2ML 7,350.00 0.08% 98.83% C N CN III 
GLUTARALDEHYDE 2% 
SOLUTION 7,280.00 0.08% 98.91% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 7,200.00 0.08% 98.99% C V CV I 
BUPIVACAINE HYD IN 
DEXTROSE INJ - 5MG 7,050.00 0.07% 99.06% C V CV I 
TINIDAZOLE TAB 500MG 6,500.00 0.07% 99.13% C V CV I 
ATROPINE INJECTION  - 
1MG/ML 6,000.00 0.06% 99.19% C V CV I 
GABAPENTIN CAP 300MG 6,000.00 0.06% 99.25% C N CN III 
PARACETAMOL 
INJECTION 10MG/ML  
100ML VIAL 6,000.00 0.06% 99.32% C N CN III 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 5,400.00 0.06% 99.37% C N CN III 
FUROSEMIDE TABLETS  - 
40MG 5,250.00 0.06% 99.43% C N CN III 
HEPARINE INJECTION  - 
5000UNITS/ML  5ML 5,100.00 0.05% 99.48% C N CN III 
WATER BASED 
LUBRICANT (KY  JELLY) 4,950.00 0.05% 99.54% C N CN III 
SODIUM BICARBONATE 
INJECTION - 8.4% 4,800.00 0.05% 99.59% C N CN III 
FLUOXETINE CAPSULES - 
20MG 4,000.00 0.04% 99.63% C N CN III 
DIHYDROCODEINE 
PHOSPHATE TAB 30MG 3,850.00 0.04% 99.67% C N CN III 
METOCLOPRAMIDE 
INJECTION  - 5MG/ML 3,500.00 0.04% 99.71% C N CN III 
LEVOTHYROXINE SODIUM 
100MCG TAB  3,450.00 0.04% 99.74% C N CN III 
GENTAMYCIN SULPHATE 
SOLUTION  (EYE / EAR 
DROPS)  0.3 % W/V 3,400.00 0.04% 99.78% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 3,200.00 0.03% 99.81% C N CN III 
ADRENALINE INJECTION  - 
1MG/ML 3,000.00 0.03% 99.84% C N CN III 
DILOXANIDE FUROATE 
TAB 500MG 2,700.00 0.03% 99.87% C V CN III 
LOPERAMIDE CAPSULES  
- 2MG 2,500.00 0.03% 99.90% C N CN III 
RANITIDINE INJECTION  - 
50MG/2ML 2,400.00 0.03% 99.92% C N CN III 
CHLORPHENIRAMINE 
TABLETS - 4MG 1,798.00 0.02% 99.94% C E CE II 
FERROUS SULPHATE 
TABLETS  - 200MG 1,375.00 0.01% 99.96% C N CN III 
METOCLOPRAMIDE  




TRISILICATE TABLETS 1,250.00 0.01% 99.98% C N CN III 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 1,000.00 0.01% 99.99% C V CV I 
DIAZEPAM TAB 5MG 450 0.00% 100.00% C V CV I 
SUXAMETHONIUM 
CHLORIDE INJECTION 90 0.00% 100.00% C N CN III 
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CAPSULES  - 250MG 375,000.00 12.52% 12.52% A V AV I 
OXYTOCIN INJECTION - 5 
IU/ML 300,000.00 10.02% 22.54% A V AV I 
FLUCLOXACILLIN  
CAPSULES 500MG 275,000.00 9.18% 31.73% A V AV I 
CEFTRIAXONE  
INJECTION - 1G 175,000.00 5.84% 37.57% A N AV I 
CIPROFLOXACIN 
TABLETS  - 250MG 132,000.00 4.41% 41.98% A V AV I 
DOXYCYCLINE 
CAPSULES  - 100MG 129,000.00 4.31% 46.29% A V AV I 
MORPHINE POWDER 125,000.00 4.17% 50.46% A N AV I 
GRISEOFULVIN TAB 




10ML AMPOULE 90,000.00 3.01% 56.72% A N AV I 
CARBAMAZEPINE 
TABLETS 200MG 75,000.00 2.50% 59.23% A V AV I 
AMOXYCILLIN CAPSULES 
- 250MG 70,000.00 2.34% 61.56% A V AV I 
FLUCLOXACILLIN 
INJECTION - 250MG 70,000.00 2.34% 63.90% A N AV I 
ORAL REHYDRATION 
SALTS 70,000.00 2.34% 66.24% A V AV I 
VITAMIN B COMPLEX (B1, 
B6 AND B12) 64,800.00 2.16% 68.40% A N AV I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 60,000.00 2.00% 70.41% B V BV I 
INSULIN BIPHASIC 30/70  
- 100IU/ML 60,000.00 2.00% 72.41% B N BN II 
HYDRALAZINE 
INJECTION  - 20MG/ML 50,800.00 1.70% 74.11% B V BV I 
ANTI-D (RH) INJECTION - 
250MCG 50,000.00 1.67% 75.78% B N BN II 




SUSPENSION (PFR)  - 
125MG/5ML 50,000.00 1.67% 79.12% B V BV I 
IBUPROFEN TABLETS  - 
200MG 50,000.00 1.67% 80.79% B V BV I 
PHENOBARBITONE  
INJECTION - 200MG/ML 41,500.00 1.39% 82.17% B N BN II 
PHENOBARBITONE 
TABLETS - 30MG 35,000.00 1.17% 83.34% B E BE II 
Co-trimoxazole suspension, 
240 mg/5ml 34,000.00 1.14% 84.48% B V BV I 
METRONIDAZOLE 
TABLETS  - 200MG 32,000.00 1.07% 85.55% B V BV I 
SODIUM HYPOCHLORITE 
SOLUTION 25,500.00 0.85% 86.40% B N BN II 
HYOSCINE 
BUTYLBROMIDE TAB 
10MG 24,000.00 0.80% 87.20% B N BN II 
DICLOFENAC SODIUM 
TABLETS - 50MG 22,080.00 0.74% 87.94% B N BN II 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 21,600.00 0.72% 88.66% B N BN II 
NIFEDIPINE TABLETS  - 
20MG 21,600.00 0.72% 89.38% B N BN II 
Cotrimoxazole 480mg Tabs 19,300.00 0.64% 90.02% B V BV II 
DOMPERIDONE 10MG 
TABLETS 19,000.00 0.63% 90.66% B N BN II 
GLIBENCLAMIDE 
TABLETS  - 5MG 17,500.00 0.58% 91.24% C V CV I 
CLOTRIMAZOLE CREAM  
- 1% 17,000.00 0.57% 91.81% C E CE II 
AMLODIPINE TABLET 
5MG 15,000.00 0.50% 92.31% C V CV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 13,000.00 0.43% 92.75% C N CN III 
DEXTROSE - 5% 10,000.00 0.33% 93.08% C N CN III 
DICLOFENAC INJECTION  
- 75MG 10,000.00 0.33% 93.41% C N CN III 
MULTIVITAMIN SYRUP 9,400.00 0.31% 93.73% C N CN III 
GENTAMICIN INJECTION - 
80MG- 40MG/ML 2ML AMP 9,000.00 0.30% 94.03% C V CV I 
POVIDONE-IODINE 
SOLUTION - 10% 8,700.00 0.29% 94.32% C N CN III 
AZITHROMYCIN 500MG  8,000.00 0.27% 94.59% C V CV I 
HYDROCHLOROTHIAZIDE 
TABLETS - 50MG 8,000.00 0.27% 94.85% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 8,000.00 0.27% 95.12% C N CN III 
PANCURONIUM 
INJECTION  - 4MG/2ML 8,000.00 0.27% 95.39% C N CN III 
DIHYDROCODEINE 




SYRUP - 2MG/5ML 7,200.00 0.24% 95.88% C E CE II 
METHYLDOPA TABLETS  - 
250MG 7,100.00 0.24% 96.12% C N CN III 
ATENOLOL TABLETS  - 
50MG 6,600.00 0.22% 96.34% C V CV I 
HALOPERIDOL TABLETS  
- 5MG 6,275.00 0.21% 96.55% C V CV I 
MORPHINE SULPHATE 
INJECTION -  10MG/ML 6,250.00 0.21% 96.76% C N CN III 
BENZHEXOL TABLETS  - 
5MG 6,100.00 0.20% 96.96% C N CN III 
BENZYLBENZOATE 
EMULSION - 25% 
APPLICATION 6,000.00 0.20% 97.16% C N CN III 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 6,000.00 0.20% 97.36% C N CN III 
HYDROCORTISONE 
INJECTION  - 100MG 5,800.00 0.19% 97.56% C V CV I 
RANITIDINE INJECTION  - 
50MG/2ML 5,600.00 0.19% 97.75% C E CE II 
FERROUS SULPHATE 
TABLETS  - 200MG 5,500.00 0.18% 97.93% C N CN III 
FOLIC ACID TABLETS  - 
5MG 5,250.00 0.18% 98.10% C N CN III 
KETAMINE INJECTION - 
50MG/ML 5,000.00 0.17% 98.27% C V CV I 
CHLORPROMAZINE 
TABLETS  - 100MG 4,925.00 0.16% 98.44% C V CV I 
DEXTROSE  - 10% 4,896.00 0.16% 98.60% C N CN III 
SUXAMETHONIUM 
CHLORIDE INJECTION 4,500.00 0.15% 98.75% C V CV I 
FLUPHENAZINE 
INJECTION  - 25MG/ML 4,300.00 0.14% 98.89% C N CN III 
FLUOXETINE CAPSULES - 
20MG 4,000.00 0.13% 99.03% C E CE II 
GENTAMYCIN SULPHATE 
SOLUTION  (EYE / EAR 
DROPS)  0.3 % W/V 3,400.00 0.11% 99.14% C V CV I 
THIOPENTONE SODIUM 
INJECTION - 500MG 3,300.00 0.11% 99.25% C N CN III 
ENALAPRIL TABLETS - 
5MG 3,250.00 0.11% 99.36% C V CV I 
MAGNESIUM SULPHATE 
INJ 4%, W/V,100ML 
BOTTLE 2,900.00 0.10% 99.46% C N CN III 
FOLIC ACID TABLETS  - 
5MG 2,750.00 0.09% 99.55% C N CN III 
ADRENALINE INJECTION  
- 1MG/ML 2,500.00 0.08% 99.63% C N CN III 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 2,000.00 0.07% 99.70% C V CV I 
NEOSTIGMINE 




INJECTION  - 1GM 1,900.00 0.06% 99.83% C N CN III 
DEXAMETHASONE 
INJECTION  - 4MG/ML 1,800.00 0.06% 99.89% C V CV I 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 1,200.00 0.04% 99.93% C V CV I 
CHLORPHENIRAMINE 
TABLETS - 4MG 620 0.02% 99.95% C E CE II 
BISACODYL 5MG 
TABLETS 500 0.02% 99.97% C E CE II 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 450 0.02% 99.98% C V CV I 
DIAZEPAM TAB 5MG 450 0.02% 100.00% C V CV I 
ATROPINE INJECTION  - 
1MG/ML 100 0.00% 100.00% C V CV I 
CALAMINE LOTION  - 15% 25 0.00% 100.00% C E CE II 
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0 8.10% 8.10% A N AN I 
SODIUM CHLORIDE 
/NORMAL SALINE 
SOLUTION  - 0.9% 
472,000.0
0 4.77% 12.87% A N AN I 
HYDROCORTISONE 
OINTMENT - 1% 
468,000.0
0 4.73% 17.61% A N AN I 
ERYTHROMYCIN 
TABLETS  - 250MG 
400,000.0




0 3.54% 25.19% A N AN I 
CEFTRIAXONE  
INJECTION - 1G 
315,000.0
0 3.18% 28.37% A V AV I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 
300,000.0




0 2.78% 34.18% A V AV I 
OXYTOCIN INJECTION - 
5 IU/ML 
268,000.0
0 2.71% 36.89% A V AV I 
AMOXICILLIN/CLAVULA









0 2.47% 42.06% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 
238,000.0
0 2.41% 44.47% A N AN I 
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DEXTROSE - 5% 
208,000.0





NT) 10ML AMPOULE 
202,500.0
0 2.05% 48.62% A E AE I 
AMOXYCILLIN 
SUSPENSION (PFR ) - 
125MG/5ML 
201,000.0
0 2.03% 50.65% A N AN I 
ANTI-D (RH) INJECTION 
- 250MCG 
200,000.0
0 2.02% 52.67% A N AN I 
HYDROCORTISONE 
INJECTION  - 100MG 
162,400.0
0 1.64% 54.31% A N AN I 
FLUCLOXACILLIN 
INJECTION - 250MG 
157,500.0






0 1.47% 57.37% A N AN I 
CEFTRIAXONE  
INJECTION - 250MG 
144,000.0




0 1.46% 60.29% A N AN I 
ERYTHROMYCIN 
SUSPENSION (PFR)  - 
125MG/5ML 
140,000.0
0 1.42% 61.70% A N AN I 
AMOXYCILLIN / 
CLAVULANIC ACID 
TABLETS - 625MG 
132,000.0
0 1.33% 63.04% A V AV I 
MORPHINE SULPHATE 
INJECTION -  10MG/ML 
125,000.0
0 1.26% 64.30% B N BN II 
BUPIVACAINE HYD IN 













0 1.18% 67.91% B N BN II 
MAGNESIUM 
SULPHATE INJ 4%, 
W/V,100ML BOTTLE 
116,000.0
0 1.17% 69.08% B N BN II 
METRONIDAZOLE 
INJECTION  - 5MG/ML 
112,500.0
0 1.14% 70.22% B N BN II 
PREDNISOLONE 
TABLETS  - 5MG 
110,400.0
0 1.12% 71.33% B N BN II 
METFORMINE TABLETS  
- 500MG 
108,800.0
0 1.10% 72.43% B V BV I 
INSULIN BIPHASIC 
30/70  - 100IU/ML 
105,000.0
0 1.06% 73.50% B V BV I 
DICLOFENAC 
INJECTION  - 75MG 
102,000.0




(DENATURED)  - 70% 96,000.00 0.97% 75.50% B N BN II 
ETHANOL 
(DENATURED) - 94% 85,000.00 0.86% 76.36% B N BN II 
IBUPROFEN TABLETS  - 
200MG 85,000.00 0.86% 77.22% B N BN II 
METRONIDOZOLE 
SUSPENSION  - 
200MG/5ML 80,000.00 0.81% 78.02% B V BV I 
DEXTROSE  - 10% 75,888.00 0.77% 78.79% B N BN II 
VALACYCLOVIR TAB. 
500MG 74,100.00 0.75% 79.54% B N BN II 
WATER FOR 
INJECTION 74,000.00 0.75% 80.29% B N BN II 
PARACETAMOL 
TABLETS  - 500MG 71,250.00 0.72% 81.01% B V BV I 
Acyclovir 400mg Tabs 70,000.00 0.71% 81.72% B N BN II 
PENICILLIN  BENZYL 
INJECTION  - 5MU 67,200.00 0.68% 82.40% B N BN II 
PARACETAMOL 
SUPPOSITORIES 
125MG 65,000.00 0.66% 83.05% B V BV I 
HYDRALAZINE 
INJECTION  - 20MG/ML 63,500.00 0.64% 83.70% B V BV I 
AMLODIPINE TABLET 
5MG 60,000.00 0.61% 84.30% B V BV I 
HYOSCINE BUTYL 
BROMIDE INJECTION 
20MG/ML 60,000.00 0.61% 84.91% B N BN II 
Co-trimoxazole 
suspension, 240 mg/5ml 59,500.00 0.60% 85.51% B N BN II 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
2MG/0.2ML AMPOULE 58,240.00 0.59% 86.10% B N BN II 
GENTAMICIN 
INJECTION - 80MG- 
40MG/ML 2ML AMP 55,800.00 0.56% 86.66% B N BN II 
ALBENDAZOLE 
TABLETS 400MG 52,000.00 0.53% 87.19% B N BN II 
AZITHROMYCIN 500MG  52,000.00 0.53% 87.71% B V BV I 
CIPROFLOXACIN 
TABLETS  - 250MG 49,500.00 0.50% 88.21% B E BE II 
FERROUS SULP/FOLIC 
200MG/400MCG ACID 
TAB 48,000.00 0.49% 88.70% B V BV I 
POVIDONE-IODINE 
SOLUTION - 10% 46,400.00 0.47% 89.17% B N BN II 
NYSTATIN 
SUSPENSION - 100 
000IU/ML 43,000.00 0.43% 89.60% B N BN II 
GLUCOSE INJECTION 
50%  50ML  




CAPSULES  - 20MG 36,000.00 0.36% 90.36% C N CN III 
OXYTOCIN INJECTION - 
10 IU/ML 36,000.00 0.36% 90.73% C N CN III 
VITAMIN B COMPLEX 
(B1, B6 AND B12) 32,400.00 0.33% 91.05% C N CN III 
METRONIDAZOLE 
TABLETS  - 200MG 32,000.00 0.32% 91.38% C N CN III 
SILVER 
SULPHADIAZINE 
CREAM - 1% 30,000.00 0.30% 91.68% C N CN III 
GRISEOFULVIN TAB 
125MG 29,250.00 0.30% 91.98% C N CN III 
ANTI-RABIES SERUM 
INJ - 200 1U/ML 28,980.00 0.29% 92.27% C V CV I 
ALCOHOL BASED 
HAND RUB 28,800.00 0.29% 92.56% C V CV I 
LIGNOCAINE 
HYDROCHLORIDE INJ. 
1% 28,000.00 0.28% 92.84% C N CN III 
NIFEDIPINE TABLETS  - 
20MG 25,200.00 0.25% 93.10% C V CV I 
METHYLDOPA 
TABLETS  - 250MG 24,850.00 0.25% 93.35% C V CV I 
Cotrimoxazole 480mg 
Tabs 24,125.00 0.24% 93.59% C V CV I 
MAGNESIUM 
SULPHATE INJECTION - 
50% 24,000.00 0.24% 93.84% C N CN III 
CLOTRIMAZOLE 
CREAM  - 1% 22,100.00 0.22% 94.06% C N CN III 
PENICILLIN  BENZYL 
INJECTION  - 1MU 21,000.00 0.21% 94.27% C N CN III 
SALBUTAMOL INHALER 
- 100MCG/ACTUATION 21,000.00 0.21% 94.48% C E CE II 
PHENOBARBITONE  
INJECTION - 200MG/ML 20,750.00 0.21% 94.69% C N CN III 
DOXYCYCLINE 
CAPSULES  - 100MG 20,640.00 0.21% 94.90% C V CV I 
HEPARINE INJECTION  
- 5000UNITS/ML  5ML 20,400.00 0.21% 95.11% C N CN III 
CLOTRIMAZOLE 
PESSARIES 3S- 200GM 19,800.00 0.20% 95.31% C N CN III 
WATER BASED 
LUBRICANT (KY  JELLY) 19,800.00 0.20% 95.51% C N CN III 
CHLORPROMAZINE 
TABLETS  - 100MG 19,700.00 0.20% 95.71% C E CE II 
DICLOFENAC SODIUM 
TABLETS - 50MG 19,320.00 0.20% 95.90% C V CV I 
ETORICOXIB 60MG 
TABLETS 18,975.00 0.19% 96.09% C V CV I 
ACETYLSALICYLIC 
ACID TAB 75MG, 
ENTERIC COATED 16,800.00 0.17% 96.26% C N CN III 
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BUPIVACAINE HYD IN 
DEXTROSE INJ - 5MG 16,450.00 0.17% 96.43% C V CV I 
RANITIDINE INJECTION  
- 50MG/2ML 16,000.00 0.16% 96.59% C E CE II 
SALBUTAMOL 
NEBULIZING SOLUTION  
- 5MG/ML 10ML 15,000.00 0.15% 96.74% C V CV III 
FUROSEMIDE 
INJECTION  - 20MG/2ML 14,000.00 0.14% 96.89% C V CV I 
GLIBENCLAMIDE 
TABLETS  - 5MG 14,000.00 0.14% 97.03% C N CN III 
METOLAZONE TABLET 
5MG 13,080.00 0.13% 97.16% C V CV I 
PHYTOMENADIONE 
INJECTION (VIT K1) - 
10MG/ML AMPUOLE 13,000.00 0.13% 97.29% C N CN III 
PARACETAMOL 
SUSPENSION - 
120MG/5ML 12,600.00 0.13% 97.42% C N CN III 
FLUCONAZOLE  
CAPSULES - 50MG 12,000.00 0.12% 97.54% C N CN III 
GABAPENTIN CAP 
300MG 12,000.00 0.12% 97.66% C N CN III 
DIGOXIN TABLETS  - 
0.25MG 11,500.00 0.12% 97.78% C N CN III 
MULTIVITAMIN SYRUP 11,280.00 0.11% 97.89% C N CN III 
IBUPROFEN SYRUP 
100MG/5ML 60ML 11,000.00 0.11% 98.00% C E CE II 
GLUTARALDEHYDE 2% 
SOLUTION 9,100.00 0.09% 98.09% C N CN III 
ATROPINE INJECTION  
- 1MG/ML 9,000.00 0.09% 98.19% C V CV I 
CHLORPHENIRAMINE 
SYRUP - 2MG/5ML 9,000.00 0.09% 98.28% C V CV I 
DEXAMETHASONE 
INJECTION  - 4MG/ML 9,000.00 0.09% 98.37% C N CN III 
GENTAMICIN 
INJECTION - 20MG- 
10MG/ML 2ML AMP 9,000.00 0.09% 98.46% C V CV I 
VALPROIC 
ACID(SODIUM 
VALPROATE) 200MG  
TABLETS 8,760.00 0.09% 98.55% C N CN III 
METOCLOPRAMIDE 
INJECTION  - 5MG/ML 8,400.00 0.08% 98.63% C N CN III 
FERROUS SULPHATE 
TABLETS  - 200MG 8,250.00 0.08% 98.71% C N CN III 
THIOPENTONE 
SODIUM INJECTION - 
500MG 8,250.00 0.08% 98.80% C V CV I 
FLUPHENAZINE 
INJECTION  - 25MG/ML 7,740.00 0.08% 98.88% C N CN III 
CEFTAZIDIME 1G INJ. 7,000.00 0.07% 98.95% C V CV I 
HYDROCHLOROTHIAZI




DECANOATE  - 
20MG/ML 6,750.00 0.07% 99.08% C N CN III 
HALOPERIDOL 
TABLETS  - 5MG 6,275.00 0.06% 99.15% C N CN III 
CHLORPHENIRAMINE 
TABLETS - 4MG 6,200.00 0.06% 99.21% C V CV I 
BENZHEXOL TABLETS  
- 5MG 6,100.00 0.06% 99.27% C N CN III 
ADRENALINE 
INJECTION  - 1MG/ML 6,000.00 0.06% 99.33% C V CV I 
CARBAMAZEPINE 
TABLETS 200MG 6,000.00 0.06% 99.39% C V CV I 
TETRACYCLINE EYE 
OINTMENT -1% 5,400.00 0.05% 99.45% C V CV I 
FOLIC ACID TABLETS  - 
5MG 5,250.00 0.05% 99.50% C N CN III 
CALAMINE LOTION  - 
15% 5,000.00 0.05% 99.55% C N CN III 
ENALAPRIL TABLETS - 
5MG 4,875.00 0.05% 99.60% C V CV I 
PHENOBARBITONE 
TABLETS - 30MG 4,340.00 0.04% 99.64% C V CV I 
AMITRIPTYLINE 
TABLETS  - 25MG 4,050.00 0.04% 99.69% C V CV I 
FLUOXETINE 
CAPSULES - 20MG 4,000.00 0.04% 99.73% C N CN III 
PANCURONIUM 
INJECTION  - 4MG/2ML 4,000.00 0.04% 99.77% C V CV I 
DIGOXIN ELIXIR/ORAL 
SOLUTION - 50MCG/ML 3,940.00 0.04% 99.81% C N CN III 
CHLORPHENIRAMINE 
INJECTION  - 10MG/ML 3,000.00 0.03% 99.84% C N CN III 
PHENYTOIN SODIUM 
TABLETS - 50MG 2,800.00 0.03% 99.87% C N CN III 
SALBUTAMOL TABLETS  
- 4MG 2,400.00 0.02% 99.89% C N CN III 
KETAMINE INJECTION - 
50MG/ML 2,000.00 0.02% 99.91% C N CN III 
AMINOPHYLLINE 
INJECTION 25MG/ML- 
10ML 1,800.00 0.02% 99.93% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 1,600.00 0.02% 99.94% C N CN III 
LOPERAMIDE 
CAPSULES  - 2MG 1,500.00 0.02% 99.96% C N CN III 
METOCLOPRAMIDE  
TABLETS - 10MG 1,300.00 0.01% 99.97% C N CN III 
CHLORPROMAZINE 
INJECTION  - 50MG/2ML 990 0.01% 99.98% C V CV I 
SODIUM BICARBONATE 
INJECTION - 8.4% 960 0.01% 99.99% C V CV I 
ACETYLSALICYLIC 
ACID TABLETS - 300MG 500 0.01% 100.00% C V CV I 
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INSULIN SOLUBLE - 
100IU/ML 300 0.00% 100.00% C N CN III 
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% 27.29% A N AN I 
CEFTRIAXONE  
INJECTION - 1G 80 
105,000.
00 9.55% 36.84% A V AV I 
CIPROFLOXACIN 
TABLETS  - 250MG 57 
94,050.0





0 6.37% 51.76% A N AN I 
AMOXYCILLIN 
CAPSULES - 250MG 32 
44,800.0





0 3.77% 59.61% A N AN I 
VITAMIN B 
COMPLEX (B1, B6 
AND B12) 330 
35,640.0
0 3.24% 62.85% A N AN I 
FLUCLOXACILLIN 
CAPSULES  - 250MG 14 
35,000.0




0 2.84% 68.87% A V AV I 
HYDRALAZINE 
INJECTION  - 
20MG/ML 40 
25,400.0
0 2.31% 71.18% B V BV I 
ALBENDAZOLE 
TABLETS 400MG 24 
24,000.0
0 2.18% 73.37% B N BN II 
HYOSCINE 
BUTYLBROMIDE 
TAB 10MG 3 
24,000.0
0 2.18% 75.55% B N BN II 
DOXYCYCLINE 
CAPSULES  - 100MG 18 
23,220.0





0 1.86% 79.52% B N BN II 
ERYTHROMYCIN 
SUSPENSION (PFR)  
- 125MG/5ML 400 
20,000.0





0 1.82% 83.15% B V BV I 
IBUPROFEN 
TABLETS  - 200MG 38 
19,000.0
0 1.73% 84.88% B N BN II 
AZITHROMYCIN 
500MG  450 
18,000.0




INJECTION - 250MG 480 
16,800.0
0 1.53% 88.05% B V BV I 
MORPHINE 
SULPHATE 
INJECTION -  
10MG/ML 100 
12,500.0
0 1.14% 89.18% B E BE II 
DICLOFENAC 
SODIUM TABLETS - 
50MG 41 
11,316.0




0 1.02% 91.23% C N CN III 
BENZYLBENZOATE 
EMULSION - 25% 
APPLICATION 2,000 
10,500.0
0 0.96% 92.19% C N CN III 
DICLOFENAC 
INJECTION  - 75MG 2,000 
10,000.0
0 0.91% 93.10% C V CV I 
POVIDONE-IODINE 
SOLUTION - 10% 30 8,700.00 0.79% 93.89% C N CN III 
CLOTRIMAZOLE 
CREAM  - 1% 3,000 7,820.00 0.71% 94.60% C N CN III 
CARBAMAZEPINE 
TABLETS 200MG 5 7,500.00 0.68% 95.28% C V CV I 
Cotrimoxazole 480mg 
Tabs 7 6,755.00 0.61% 95.90% C N CN III 
PHENOBARBITONE 
TABLETS - 30MG 96 6,720.00 0.61% 96.51% C N CN III 
MAGNESIUM 
SULPHATE 
INJECTION - 50% 50 6,000.00 0.55% 97.05% C V CV I 
HYDROCHLOROTHI
AZIDE TABLETS - 
50MG 13 5,200.00 0.47% 97.53% C N CN III 
KETOCONAZOLE 
TABLETS - 200MG 55 4,400.00 0.40% 97.93% C V CV I 
PANCURONIUM 
INJECTION  - 
4MG/2ML 50 4,000.00 0.36% 98.29% C V CV I 
RANITIDINE 
INJECTION  - 
50MG/2ML 500 4,000.00 0.36% 98.65% C V CV I 
DEXAMETHASONE 
INJECTION  - 
4MG/ML 400 3,600.00 0.33% 98.98% C V CV I 
GENTAMYCIN 
SULPHATE 
SOLUTION  (EYE / 
EAR DROPS)  0.3 % 
W/V 200 3,400.00 0.31% 99.29% C N CN III 
SUXAMETHONIUM 
CHLORIDE 
INJECTION 50 2,250.00 0.20% 99.50% C V CV I 
AMINOPHYLLINE 
INJECTION 




10MG TABLETS 8 1,520.00 0.14% 99.80% C N CN III 
CHLORPHENIRAMIN
E SYRUP - 2MG/5ML 8 1,440.00 0.13% 99.93% C V CV I 
NEOSTIGMINE 
INJECTION  - 
2.5MG/ML 10 400 0.04% 99.97% C E CE II 
CHLORAMPHENICAL 
INJECTION  - 1GM 10 380 0.03% 100.00% C V CV I 
WATER FOR 
INJECTION 1 4 0.00% 100.00% C N CN III 
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